Multispecific polypeptides and methods of use thereof

Abstract

Provided herein are designs of multi-specific polypeptides for binding target cells and engaging T cells. In some embodiments, the multi-specific polypeptide comprises a first binding domain that specifically binds to a T cell receptor beta variable region (TCRβV), or a T cell receptor alpha variable region (TCRαV) expressed on the T cell, and a second binding domain that specifically binds to an antigen (e.g., CD19) on the target cell, and a Fc region. In some embodiments, both the first and the second binding domains are located on the same polypeptide chain of the Fc region (e.g., a Fc region polypeptide chain comprising a Knob mutation). These multi-specific polypeptides are not only effective in killing the target cells, but also expands early memory populations that maintains and / or replenishes effector populations over time.

Description

Attorney Docket No. JANX-004 / 05WO 339516-2027 MULTISPECIFIC POLYPEPTIDES AND METHODS OF USE THEREOFCROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of and the priority from U. S. Provisional Application No. 63 / 754,282, filed February 5, 2025; U.S. Provisional Application No. 63 / 754,238, filed February 5, 2025; U.S. Provisional Application No. 63 / 781,651, filed April 1, 2025; and U. S. Provisional Application No. 63 / 849,701, filed July 23, 2025, the disclosure of each of which is incorporated by reference in its entirety.FIELD

[0002] The present disclosure relates to designs of multi-specific polypeptides for binding CD19 and engaging T cells. The present disclosure also relates to methods of expanding and activating T cells and methods of treating a disease or disorder (e.g., a cancer or an autoimmune disease) using the same.DESCRIPTION OF THE TEXT FILE SUBMITTED ELECTRONICALLY

[0003] The contents of the electronic sequence listing (JANX 004 05WO SeqList ST26.xml; Size: 1,224,006 bytes; and Date of Creation: February 2, 2026) are herein incorporated by reference in their entirety.BACKGROUND

[0004] T cell engagers are a class of immunotherapeutic molecules that redirect the patient’s immune response to recognize and kill target cells (e.g., B cells expressing CD19). While T cell engagers have shown to elicit potent immune activity, these therapeutics have faced challenges due to overactivation of the immune system leading to cytokine release syndrome (CRS), on-target, healthy tissue toxicities, T cell exhaustion, as well as depletion of effector T cell populations with minimal expansion of memory T cell populations that can limit duration of immune activity. Thus, there is a need in the art to improve the design of T cell engagers to improve the duration of immune activity as well as to reduce the toxicity and side effects associated with T cell engagers.SUMMARY

[0005] Provided herein is a multi -specific polypeptide comprising: a first binding domain that specifically binds T cell receptor alpha variable region (TCRαV), or T cell receptor beta variableAttorney Docket No. JANX-004 / 05WO 339516-2027 region (TCRβV); and a second binding domain that specifically binds CD19. Also provided herein is a multi-specific polypeptide comprising: a first binding domain that specifically binds CD3; and a second binding domain that specifically binds CD19.

[0006] In some embodiments, the multi-specific polypeptide further comprises a half-life extension moiety.

[0007] In some embodiments, the CD19 comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 151.

[0008] In some embodiments, the second binding domain comprises: an immunoglobulin heavy chain variable (VH) region comprising a heavy chain CDR1 (HCDR1), a heavy chain CDR2 (HCDR2), and a heavy chain CDR3 (HCDR3), and an immunoglobulin light chain variable (VL) region comprising a light chain CDR1 (LCDR1), a light chain CDR2 (LCDR2), and a light chain CDR3 (LCDR3).

[0009] In some embodiments, the second binding domain is a single chain variable fragment (scFv), Fab, CrossFab, Fab’, or F(ab’)2.

[0010] In some embodiments, the second binding domain is a Fab comprising the VH region, the VL region, a first heavy chain constant region (CHI), and a light chain constant region (CL), wherein the C-terminus of the VH region is connected to the N-terminus of the CHI region, and the C-terminus of the VL region is connected to the N-terminus of the CL region. In some embodiments, the second binding domain is a CrossFab comprising the VH region, the VL region, a first CHI region, and a CL region, wherein the C-terminus of the VH region is connected to the N-terminus of the CL region, and the C-terminus of the VL region is connected to the N-terminus of the CHI region. In some embodiments, the CHI region and the CL region are connected by a disulfide bond. In some embodiments, the second binding domain is a charge steering Fab or charge steering CrossFab. In some embodiments, a CHI region of the charge steering Fab or charge steering CrossFab comprises mutations K147E / K213E according to EU numbering, and a CL region of the charge steering Fab or charge steering CrossFab comprises mutations E123R / Q124K according to EU numbering.

[0011] In some embodiments, the second binding domain is an scFv comprising a VH region and a VL region. In some embodiments, the C-terminus of the VH region is linked to the N -terminus of the VL region. In some embodiments, the C-terminus of the VL region is linked to the N-terminus of the VH region. In some embodiments, the VH region and the VL region are linked by a peptideAttorney Docket No. JANX-004 / 05WO 339516-2027 linker (PL2). In some embodiments, the peptide linker (PL2) comprises the formula of (Gly4Ser)n, wherein n = 1-5. In some embodiments, the peptide linker (PL2) is (Gly4Ser)3. In some embodiments, the peptide linker (PL2) is (Gly4Ser)1.

[0012] In some embodiments, the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2, and the LCDR3 of the second binding domain are according to one of the combinations of complementarity determining regions (CDRs) of Table 14 or Table 15. In some embodiments, the HCDR1 comprises an amino acid sequence of SEQ ID NO: 303, the HCDR2 comprises an ammo acid sequence of SEQ ID NO: 311, the HCDR3 comprises an amino acid sequence of SEQ ID NO: 317, the LCDR1 comprises an amino acid sequence of SEQ ID NO: 323, the LCDR2 comprises an amino acid sequence of SEQ ID NO: 329, and the LCDR3 comprises an amino acid sequence of SEQ ID NO: 334, wherein the CDRs correspond to the second binding domain and are numbered with reference to the Kabat numbering scheme. In some embodiments, the HCDR1 comprises an ammo acid sequence of SEQ ID NO: 304, the HCDR2 comprises an ammo acid sequence of SEQ ID NO: 312, the HCDR3 comprises an amino acid sequence of SEQ ID NO: 318, the LCDR1 comprises an amino acid sequence of SEQ ID NO: 324, the LCDR2 comprises an amino acid sequence of SEQ ID NO: 328, and the LCDR3 comprises an amino acid sequence of SEQ ID NO: 335, wherein the CDRs correspond to the second binding domain and are numbered with reference to the Kabat numbering scheme. In some embodiments, the HCDR1 comprises an amino acid sequence of SEQ ID NO: 306, the HCDR2 comprises an ammo acid sequence of SEQ ID NO: 314, the HCDR3 comprises an amino acid sequence of SEQ ID NO: 318, the LCDR1 comprises an amino acid sequence of SEQ ID NO: 326, the LCDR2 comprises an amino acid sequence of SEQ ID NO: 328, and the LCDR3 comprises an amino acid sequence of SEQ ID NO: 335, wherein the CDRs correspond to the second binding domain and are numbered with reference to the Kabat numbering scheme. In some embodiments, the HCDR1 comprises an amino acid sequence of SEQ ID NO: 306, the HCDR2 comprises an amino acid sequence of SEQ ID NO: 314, the HCDR3 comprises an ammo acid sequence of SEQ ID NO: 320, the LCDR1 comprises an amino acid sequence of SEQ ID NO: 326, the LCDR2 comprises an amino acid sequence of SEQ ID NO: 331, and the LCDR3 comprises an amino acid sequence of SEQ ID NO: 335, wherein the CDRs correspond to the second binding domain and are numbered with reference to the Kabat numbering scheme.

[0013] In some embodiments, the VH region of the second binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at leastAttorney Docket No. JANX-004 / 05WO 339516-2027 98%, at least 99%, or 100% identical to any one of SEQ ID NOs: 365, 367, 369, 371, 373, 375, 377, 379, 381, and 383, and wherein the VL region of the second binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 366, 368, 370, 372, 374, 376, 378, 380, 382, and 384.

[0014] In some embodiments, the second binding domain comprises an scFv comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to any one of SEQ ID NOs: 385-386.

[0015] In some embodiments, the second binding domain comprises a Fab or CrossFab comprising (i) a heavy chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to any one of SEQ ID NOs: 387, 389, 391, 393, 395, 397, 399, 401, 403, and 405; and (ii) a light chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to any one of SEQ ID NOs: 388, 390, 392, 394, 396, 398, 400, 402, 404, and 406.

[0016] In some embodiments, the first binding domain specifically binds TCRβV. In some embodiments, the TCRβV is selected from the group consisting of: TCRβV-5-5, TCRβV-5-6, TCRβV6-5, TCRβV-12-3, TCRβV-12-4, and TCRβV-20-1. In some embodiments, the TCRβV comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to any one of SEQ ID NOs: 100-116. In some embodiments, the first binding domain comprises complementarity determining regions (CDRs) from a binding molecule selected from the group consisting of: IMMU 546, FIN9, AMKB1-2, ZOE, 3G5, ZIZOU4, IMMU 157, LC4, 3D11, 1C1, W112, MH3-2, 4H11, 36213, BAM13, H131, A. H-53, H132, IMMU 222, JU-74, JU74.3, OT145, BL37.2, S511, VER2.32.1, IG125, 56C5, 56C5.2, 16G8, MX-6, JR2, AF-23, AF23, AHUT7, TAMAYA1.2, BA62, BA62.6, Cl, E17.5F3, E17.5F3.15.13, MPB2D5, C21, CAS1.1.3, CH92, 8F10, JOVI-3, WJF24, ELL1.4, JOVI-1, SP305, LG.3A10, 5A8AI0, 5D9F1, andKFN, wherein the CDRs from a binding molecule are each determined according to the Kabat numbering scheme, the Chothia numbering scheme, or the ImMunoGeneTics Information System (IMGT).

[0017] In some embodiments, the first binding domain specifically binds TCRaV. In some embodiments, the TCRaV is TCRaV 1-2. In some embodiments, the TCRaV comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at leastAttorney Docket No. JANX-004 / 05WO 339516-2027 98%, at least 99%, or 100% identical to SEQ ID NO: 149. In some embodiments, the first binding domain comprises CDRs from a binding molecule selected from the group consisting of: Cl 5, 6B11, SFB280, 3C10, Fl, 6D6.6, and clone 34, wherein the CDRs are each determined according to the Kabat numbering scheme, the Chothia numbering scheme, or the ImMunoGeneTics Information System (IMGT).

[0018] In some embodiments, the first binding domain comprises: a VH region comprising an HCDR1, an HCDR2, and an HCDR3, and a VL region comprising an LCDR1, an LCDR2, and an LCDR3.

[0019] In some embodiments, the first binding domain is a single chain variable fragment (scFv), Fab, CrossFab, Fab’, or F(ab’)2.

[0020] In some embodiments, the first binding domain is a Fab comprising the VH region, the VL region, a CHI region, and a CL region, wherein the C-terminus of the VH region is connected to the N-terminus of the CHI region, and the C-terminus of the VL region is connected to the N-terminus of the CL region. In some embodiments, the first binding domain is a CrossFab comprising the VH region, the VL region, a CHI region, and a CL region, wherein the C-terminus of the VH region is connected to the N-terminus of the CL region, and the C-terminus of the VL region is connected to the N-terminus of the CHI region. In some embodiments, the CHI region and the CL region are connected by a disulfide bond. In some embodiments, the first binding domain is a charge steering Fab or charge steering CrossFab. In some embodiments, a CHI region of the charge steering Fab or charge steering CrossFab comprises mutations K147E / K213E according to EU numbering, and a CL region of the charge steering Fab or charge steering CrossFab comprises mutations E123R / Q124K according to EU numbering.

[0021] In some embodiments, the first binding domain is an scFv, In some embodiments, the C-terminus of the VH region is linked to the N-terminus of the VL region. In some embodiments, the C-terminus of the VL region is linked to the N-terminus of the VH region.

[0022] In some embodiments, the VH region and the VL region is linked by one or more engineered disulfide bond(s). In some embodiments, one cysteine that forms the engineered disulfide bond is located in the VH region, and wherein the other cysteine that forms the engineered disulfide bond is located in the VL region. In some embodiments, the positions of the one or more engineered disulfide bond(s) are selected from the group consisting of VH44-VL100, VH100B-VL49, VH100-VL50, VH101-VL46, and VH105-VL43. In some embodiments, the VH region and the VL region are linked by a peptide linker (PL1). In some embodiments, the peptide linker (PL1)Attorney Docket No. JANX-004 / 05WO 339516-2027 comprises the formula of (Gly4Ser)n, wherein n = 1-5. In some embodiments, the peptide linker (PL1) is (Gly4Ser)3. In some embodiments, the peptide linker (PL1) is (Gly4Ser)1.

[0023] In some embodiments, the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2, and the LCDR3 of the first binding domain are according to one of the combinations of complementarity determining regions (CDRs) of Table 1, Table 2, Table 6, or Table 7. In some embodiments, the HCDR1 comprises an amino acid sequence of SEQ ID NO: 1138, the HCDR2 comprises an amino acid sequence of SEQ ID NO: 2, the HCDR3 comprises an amino acid sequence of SEQ ID NO: 1139, the LCDR1 comprises an ammo acid sequence of SEQ ID NO: 1140, the LCDR2 comprises an ammo acid sequence of SEQ ID NO: 5, and the LCDR3 comprises an amino acid sequence of SEQ ID NO: 1141, wherein the CDRs correspond to the first binding domain and are numbered with reference to the Kabat numbering scheme. In some embodiments, the HCDR1 comprises an ammo acid sequence of SEQ ID NO: 1, the HCDR2 comprises an amino acid sequence of SEQ ID NO: 1142, the HCDR3 comprises an ammo acid sequence of SEQ ID NO: 1139, the LCDR1 comprises an ammo acid sequence of SEQ ID NO: 1140, the LCDR2 comprises an amino acid sequence of SEQ ID NO: 5, and the LCDR3 comprises an amino acid sequence of SEQ ID NO: 1141, wherein the CDRs correspond to the first binding domain and are numbered with reference to the Kabat numbering scheme. In some embodiments, the HCDR1 comprises an amino acid sequence of SEQ ID NO: 1143, the HCDR2 comprises an ammo acid sequence of SEQ ID NO: 18, the HCDR3 comprises an amino acid sequence of SEQ ID NO: 1144, the LCDR1 comprises an amino acid sequence of SEQ ID NO: 1145, the LCDR2 comprises an ammo acid sequence of SSS, and the LCDR3 comprises an amino acid sequence of SEQ ID NO: 1146, wherein the CDRs correspond to the first binding domain and are numbered with reference to the IMGT numbering scheme. In some embodiments, the HCDR1 comprises an ammo acid sequence of SEQ ID NO: 17, the HCDR2 comprises an amino acid sequence of SEQ ID NO: 1147, the HCDR3 comprises an amino acid sequence of SEQ ID NO: 1144, the LCDR1 comprises an amino acid sequence of SEQ ID NO: 1145, the LCDR2 comprises an amino acid sequence of SSS, and the LCDR3 comprises an amino acid sequence of SEQ ID NO: 1146, wherein the CDRs correspond to the first binding domain and are numbered with reference to the IMGT numbering scheme. In some embodiments, the VH region of the first binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to one of SEQ ID NOs listed in the VH column of Table 3 or Table 8, and wherein the VL region of the first binding domain comprises an amino acid sequence that is at least 80%, atAttorney Docket No. JANX-004 / 05WO 339516-2027 least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to the corresponding VL SEQ ID NO listed in the same row of Table 3 or Table 8. In some embodiments, the VH region of the first binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1148, and wherein the VL region of the first binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1149. In some embodiments, the VH region of the first binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1150, and wherein the VL region of the first binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1149.

[0024] In some embodiments, the HCDR1 comprises an amino acid sequence of SEQ ID NO: 201, the HCDR2 comprises an ammo acid sequence of SEQ ID NO: 202, the HCDR3 comprises an amino acid sequence of SEQ ID NO: 203, the LCDR1 comprises an amino acid sequence of SEQ ID NO: 204, the LCDR2 comprises an amino acid sequence of SEQ ID NO: 205, and the LCDR3 comprises an amino acid sequence of SEQ ID NO: 206, wherein the CDRs correspond to the first binding domain and are numbered with reference to the Kabat numbering scheme. In some embodiments, the VH region of the first binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to one of SEQ ID NO: 213, and wherein the VL region of the first binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to the corresponding VL SEQ ID NO: 214.

[0025] In some embodiments, the first binding domain comprises an scFv comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to any one of SEQ ID NOs in Table 4 or Table 9. In some embodiments, the first binding domain comprises an scFv comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1151. In some embodiments, the first binding domain comprises an scFv comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1152. In some embodiments, the first binding domain comprises an scFv comprising an amino acid sequence thatAttorney Docket No. JANX-004 / 05WO 339516-2027 is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1153. In some embodiments, the first binding domain comprises an scFv comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1154.

[0026] In some embodiments, the first binding domain comprises a Fab or CrossFab comprising (i) a heavy chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to any one of SEQ ID NOs: 243, 245, 1071-1086, 1112-1123, 1129, 1130, 1155, and 1157; and (ii) a light chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to any one of SEQ ID NOs: 244, 246, 1055-1070, 1100-1111, 1127, 1128, 1156, and 1158.

[0027] In some embodiments, the half-life extension moiety is selected from the group consisting of a fragment crystallizable (Fc) region (e.g., a single chain Fc), an albumin (e.g., human serum albumin), transferrin, a binding domain that specifically binds to transferrin or albumin (e.g., an albumin binding domain (ABD)), an unstructured biodegradable proteins (XTEN), a polyethylene glycol (PEG), a glycine-rich homo-amino-acid polymer (HAP), a hydroxyethyl starch (HES), a polysialic acid (PSA), an immunoglobulin binding polypeptide, and a conformationally disordered polypeptide comprising Proline, Alanine and Serine (PAS), or a derivative or functional fragment thereof.

[0028] In some embodiments, the half-life extension moiety is a fragment crystallizable (Fc) region. In some embodiments, the Fc region comprises two polypeptides. In some embodiments, the Fc region has a knobs-into-holes format, wherein the first polypeptide of the Fc region comprises a hole mutation, and wherein second polypeptide of the Fc region comprises a knob mutation. In some embodiments, the first polypeptide of the Fc region comprises mutations T366S, L368A and Y407V according to EU numbering, and wherein the second polypeptide of the Fc region comprises a mutation T366W according to EU numbering. In some embodiments, the first polypeptide of the Fc region comprising the hole mutation further comprises a mutation Y349C according to EU numbering, wherein the second polypeptide of the Fc region comprising the knob mutation further comprises a mutation S354C according to EU numbering, and wherein the Fc region comprises an engineered disulfide bond formed between these two cysteines. In some embodiments, one or both of the polypeptides of the Fc region comprise mutations L234A, L235 A, and P329G according to EU numbering. In some embodiments, one or both of the polypeptides ofAttorney Docket No. JANX-004 / 05WO 339516-2027 the Fc region comprise the mutation N297G according to EU numbering. In some embodiments, one or both of the polypeptides of the Fc region comprise mutations H435R and Y436F according to EU numbering. In some embodiments, the Fc region lacks one or more effector functions and / or lacks glycosylation. In some embodiments, the effector function is selected from the group consisting of antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), binding to a Fey receptor (FcyR), or any combination thereof. In some embodiments, the first polypeptide of the Fc region with a peptide linker PLE of DKTHTCPPCP (SEQ ID NO: 161) comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 154, and wherein the second polypeptide of the Fc region with a peptide linker PLE of DKTHTCPPCP (SEQ ID NO: 161) comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 155. In some embodiments, the first polypeptide of the Fc region with a peptide linker PLE of DKTHTCPPCP (SEQ ID NO: 161) comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 156, and wherein the second polypeptide of the Fc region with a peptide linker PLE of DKTHTCPPCP (SEQ ID NO: 161) comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 157.

[0029] In some embodiments, the C-terminus of the VH region of the first binding domain is connected to the N-terminus of the VH region of the second binding domain. In some embodiments, the C-terminus of the VH region of the first binding domain is connected to the N-terminus of the VL region of the second binding domain. In some embodiments, the C-terminus of the VL region of the first binding domain is connected to the N-terminus of the VH region of the second binding domain. In some embodiments, the C-terminus of the VL region of the first binding domain is connected to the N-terminus of the VL region of the second binding domain. In some embodiments, the C-terminus of the CH1 region of the first binding domain is connected to the N-terminus of the VH region of the second binding domain. In some embodiments, the C-terminus of the CHI region of the first binding domain is connected to the N-terminus of the VL region of the second binding domain. In some embodiments, the C-terminus of the CL region of the first binding domain is connected to the N-terminus of the VH region of the second binding domain. In some embodiments, the C-terminus of the CL region of the first binding domain is connected to the N-terminus of theAttorney Docket No. JANX-004 / 05WO 339516-2027 VL region of the second binding domain. In some embodiments, the C-terminus of the VH region of the second binding domain is connected to the N-terminus of either the first polypeptide or the second polypeptide of the Fc region. In some embodiments, the C-terminus of the VL region of the second binding domain is connected to the N-termmus of either the first polypeptide or the second polypeptide of the Fc region. In some embodiments, the C-terminus of the CH 1 region of the second binding domain is connected to the N-terminus of either the first polypeptide or the second polypeptide of the Fc region. In some embodiments, the C-terminus of the CL region of the second binding domain is connected to the N-terminus of either the first polypeptide or the second polypeptide of the Fc region.

[0030] In some embodiments, the C -terminus of the VH region of the second binding domain is connected to the N-terminus of the VH region of the first binding domain. In some embodiments, the C-terminus of the VH region of the second binding domain is connected to the N-terminus of the VL region of the first binding domain. In some embodiments, the C-terminus of the VL region of the second binding domain is connected to the N-terminus of the VH region of the first binding domain. In some embodiments, the C-terminus of the VL region of the second binding domain is connected to the N-terminus of the VL region of the first binding domain. In some embodiments, the C-terminus of the CHI region of the second binding domain is connected to the N-terminus of the VH region of the first binding domain. In some embodiments, the C-terminus of the CHI region of the second binding domain is connected to the N-terminus of the VL region of the first binding domain. In some embodiments, the C-terminus of the CL region of the second binding domain is connected to the N-terminus of the VH region of the first binding domain. In some embodiments, the C-terminus of the CL region of the second binding domain is connected to the N-terminus of the VL region of the first binding domain. In some embodiments, the C-terminus of the VH region of the first binding domain is connected to the N-terminus of either the first polypeptide or the second polypeptide of the Fc region. In some embodiments, the C-terminus of the VL region of the first binding domain is connected to the N-terminus of either the first polypeptide or the second polypeptide of the Fc region. In some embodiments, the C-terminus of the CH1 region of the first binding domain is connected to the N-terminus of either the first polypeptide or the second polypeptide of the Fc region. In some embodiments, the C-terminus of the CL region of the first binding domain is connected to the N-terminus of either the first polypeptide or the second polypeptide of the Fc region.Attorney Docket No. JANX-004 / 05WO 339516-2027

[0031] In some embodiments, the second binding domain is connected to the second polypeptide of the Fc region comprising the knob mutation. In some embodiments, the second binding domain is connected to the first polypeptide of the Fc region comprising the hole mutation. In some embodiments, the first binding domain is connected to the second polypeptide of the Fc region comprising the knob mutation. In some embodiments, the first binding domain is connected to the first polypeptide of the Fc region comprising the hole mutation. In some embodiments, the other polypeptide of the Fc region is not connected to any binding domain.

[0032] In some embodiments, the first binding domain is an scFv, wherein the second binding domain is a Fab, wherein the C -terminus of the first binding domain is connected to the N-terminus of the VH region of the second binding domain via a peptide linker (PLB), and wherein the C-terminus of the CHI region of the second binding domain is connected to the N-terminus of the second polypeptide of the Fc region comprising a knob mutation via a peptide linker (PLE).

[0033] In some embodiments, the first binding domain is an scFv, wherein the second binding domain is a Fab, wherein the C -terminus of the first binding domain is connected to the N-terminus of the VL region of the second binding domain via a peptide linker (PLB), and wherein the C-terminus of the CHI region of the second binding domain is connected to the N-terminus of the second polypeptide of the Fc region comprising a knob mutation via a peptide linker (PLE).

[0034] In some embodiments, the first binding domain is an scFv, wherein the second binding domain is a Fab, wherein the N-terminus of the first binding domain is connected to the C-terminus of the CHI region of the second binding domain via a peptide linker (PLB), and wherein the ( -terminus of the first binding domain is connected to the N-terminus of the second polypeptide of the Fc region comprising a knob mutation via a peptide linker (PLE).

[0035] In some embodiments, the first binding domain is a Fab, wherein the second binding domain is an scFv, wherein the C-terminus of the CHI region of the first binding domain is connected to the N-terminus of the second binding domain via a peptide linker (PLB), and wherein the C-terminus of the second binding domain is connected to the N-terminus of the second polypeptide of the Fc region comprising a knob mutation via a peptide linker (PLE).

[0036] In some embodiments, the first binding domain is a Fab, wherein the second binding domain is an scFv, wherein the N-terminus of the VH region of the first binding domain is connected to the C-terminus of the second binding domain via a peptide linker (PLB), and wherein the C-terminus of the CH1 region of the first binding domain is connected to the N-terminus of the second polypeptide of the Fc region comprising a knob mutation via a peptide linker (PLE).Attorney Docket No. JANX-004 / 05WO 339516-2027

[0037] In some embodiments, the first binding domain is a Fab, wherein the second binding domain is an scFv, wherein the N-terminus of the VL region of the first binding domain is connected to the C -terminus of the second binding domain via a peptide linker (PLB), and wherein the C-terminus of the CHI region of the first binding domain is connected to the N-terminus of the second polypeptide of the Fc region comprising a knob mutation via a peptide linker (PLE).

[0038] In some embodiments, the first binding domain is a CrossFab, wherein the second binding domain is a charge steering Fab, wherein the N-terminus of the VL region of the first binding domain is connected to the C -terminus of the CHI region of the second binding domain via a peptide linker (PLB), and wherein the C-terminus of the CHI region of the first binding domain is connected to the N-terminus of the second polypeptide of the Fc region comprising a knob mutation via a peptide linker (PLE).

[0039] In some embodiments, the first binding domain is a CrossFab, wherein the second binding domain is a charge steering Fab, wherein the C-terminus of the CHI region of the first binding domain is connected to the N-terminus of the VL region of the second binding domain via a peptide linker (PLB), and wherein the C-terminus of the CHI region of the second binding domain is connected to the N-terminus of the second polypeptide of the Fc region comprising a knob mutation via a peptide linker (PLE).

[0040] In some embodiments, the first binding domain and the second binding domain are connected via a peptide linker (PLB). In some embodiments, the peptide linker (PLB) is at least 5 amino acids in length. In some embodiments, the peptide linker (PLB) comprises the formula of (Gly4Ser)n, wherein n = 1-5. In some embodiments, the peptide linker (PLB) is (Gly4Ser)3. In some embodiments, the peptide linker (PLB) is (Gly4Ser)2. In some embodiments, the peptide linker (PLB) is (Gly4Ser)1.

[0041] In some embodiments, the first binding domain is linked to either the first polypeptide or the second polypeptide of the Fc region, and wherein the second binding domain is linked to the other polypeptide of the Fc region. In some embodiments, the first binding domain is linked to the second polypeptide of the Fc region comprising a knob mutation, and wherein the second binding domain is linked to the first polypeptide of the Fc region comprising a hole mutation. In some embodiments, the first binding domain is a Fab or CrossFab, and wherein the second binding domain is an scFv. In some embodiments, the first binding domain is a CrossFab connecting to the Fc region via the C -terminus of its CHI region, and wherein the second binding domain is a Fab connecting to the Fc region via the C-terminus of its CHI region. In some embodiments, the firstAttorney Docket No. JANX-004 / 05WO 339516-2027 binding domain is a CrossFab connecting to the Fc region via the C-terminus of its CHI region, and wherein the second binding domain is a charge steering Fab connecting to the Fc region via the C -terminus of its CHI region. In some embodiments, the first binding domain is a CrossFab connecting to the Fc region via the C-terminus of its CL region, and wherein the second binding domain is a Fab connecting to the Fc region via the C-terminus of its CHI region. In some embodiments, the C-terminus of the scFv or the CHI region of the binding domain is linked to the N-terminus of the first or the second polypeptide of the Fc region. In some embodiments, the CL region of the binding domain is linked to the N-terminus of the first or the second polypeptide of the Fc region.

[0042] In some embodiments, the binding domain and the half-life extension moiety are connected via a peptide linker (PLE). In some embodiments, the peptide linker (PLE) is at least 5 amino acids in length. In some embodiments, the peptide linker (PLE) is between 5-10 amino acids, between 11-15 amino acids, between 16-20 amino acids, between 21-25 amino acids, or between 26-30 amino acids, in length. In some embodiments, the peptide linker (PLE) comprises an amino acid sequence having the formula of (Gly4Ser)n, wherein n = 1-5. In some embodiments, the peptide linker (PLE) comprises (Gly4Ser)2. In some embodiments, the peptide linker (PLE) comprises or consists of the amino acid sequence KTHTCP (SEQ ID NO: 158). In some embodiments, the peptide linker (PLE) comprises or consists of the amino acid sequence DKTHTCP (SEQ ID NO: 160). In some embodiments, the peptide linker (PLE) comprises or consists of the amino acid sequence GGGGSGGGGSKTHTCP (SEQ ID NO: 159).

[0043] In some embodiments, the multi-specific polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to any one of SEQ ID NOs: 407-991 and 1159-1179.

[0044] In some embodiments, the multi-specific polypeptide comprises three non-identical polypeptides. In some embodiments, the first polypeptide comprises: (i) a PLE linker; and (ii) an Fc heavy chain comprising a hole mutation; the second polypeptide comprises: (i) an anti-TCRβ scFv; (ii) a PLB linker; (iii) an anti-CD19 Fab light chain; and the third polypeptide comprises: (i) an anti-CD19 Fab heavy chain; (ii) a PLE linker; and (v) an Fc heavy chain comprising a knob mutation. In some embodiments, the first polypeptide comprises: (i) a PLE linker; and (ii) an Fc heavy chain comprising a hole mutation; the second polypeptide comprises: (i) an anti-CD19 Fab light chain; and the third polypeptide comprises: (i) an anti-TCRβ scFv; (ii) a PLB linker; (iii) an anti-CD19 Fab heavy chain; (iv) a PLE linker; and (iii) an Fc heavy chain comprising a knobAttorney Docket No. JANX-004 / 05WO 339516-2027 mutation. In some embodiments, the first polypeptide comprises: (i) a PLE linker; and (ii) an Fc heavy chain comprising a hole mutation; the second polypeptide comprises: (i) an anti-CD19 Fab heavy chain; (ii) a PLE linker; and (iii) an Fc heavy chain comprising a knob mutation; and the third polypeptide comprises: (i) an anti-TCRβ scFv; (ii) a PLB linker; (iii) an anti-CD19 Fab light chain. In some embodiments, the first polypeptide comprises: (i) a PLE linker; and (ii) an Fc heavy chain comprising a hole mutation; the second polypeptide comprises: (i) an anti-TCRβ scFv; (ii) a PLB linker; (iii) an anti-CD19 Fab heavy chain; (iv) a PLE linker; and (v) an Fc heavy chain comprising a knob mutation; and the third polypeptide comprises an anti-CD19 Fab light chain. In some embodiments, the first polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1159; the second polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1166; and the third polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1173. In some embodiments, the first polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1160; the second polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1167; and the third polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1174. In some embodiments, the first polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1161; the second polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1168; and the third polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1175. In some embodiments, the first polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1162; the second polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1169; and the third polypeptide comprises an amino acid sequence that isAttorney Docket No. JANX-004 / 05WO 339516-2027 at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1176. In some embodiments, the first polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1163; the second polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1170; and the third polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1177. In some embodiments, the first polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1164; the second polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1171; and the third polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1178. In some embodiments, the first polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1165; the second polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1172; and the third polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1179.

[0045] In some embodiments, the VH and VL regions are numbered with reference to the Kabat numbering scheme.

[0046] Also provided herein is a recombinant nucleic acid molecule encoding the multi-specific polypeptide disclosed herein.

[0047] Also provided herein is a vector comprising the recombinant nucleic acid molecule disclosed herein.

[0048] Also provided herein is a pharmaceutical composition comprising (i) the multi-specific polypeptide disclosed herein, the recombinant nucleic acid molecule disclosed herein, or the vector disclosed herein, and (ii) a pharmaceutically acceptable carrier, diluent, or excipient.

[0049] Also provided herein is a method of producing a multi-specific polypeptide, comprising introducing the recombinant nucleic acid molecule disclosed herein, or the vector disclosed hereinAttorney Docket No. JANX-004 / 05WO 339516-2027 into a host cell under conditions to express the multi -specific polypeptide complex in the cell, wherein the method is ex vivo.

[0050] Also provided herein is a method of expanding a T cell population, wherein the method comprises contacting an initial T cell population with the multi -specific polypeptide disclosed herein or the pharmaceutical composition disclosed herein, thereby producing an expanded population of T cells; wherein the initial T cell population expresses TCRpV or TCRaV on the cell surface, and wherein the first binding domain of the multi-specific polypeptide specifically binds the TCRPV or TCRaV. In some embodiments, the method depletes B cells.

[0051] In some embodiments, the method expands T cells in vitro or ex vivo. In some embodiments, the method expands T cells in vivo in a subject.

[0052] In some embodiments, the initial population of T cells comprises a plurality of effector T cells and / or memory T cells.

[0053] In some embodiments, the expanded population of T cells has an increased expansion of the effector T cells and / or memory T cells compared to that of a control T cell population contacted with a control multi- specific polypeptide comprising a first binding domain that specifically binds to CDS instead of TCRPV or TCRaV. In some embodiments, the effector T cells are selected from the group consisting of effector memory T cells (TEM), T effector cells (TEFF), T effector cells re¬ expressing CD45RA (TEMRA), and a combination thereof. In some embodiments, the memory T cells are selected from the group consisting of central memory T cells (Tcm), T memory stem cells (Tscm), and a combination thereof.

[0054] In some embodiments, the expanded population of T cells has an increased percentage of effector T cells and / or memory T cells compared to that of a control T cell population contacted with a control multi-specific polypeptide comprising a first binding domain that specifically binds to CD3 instead of TCR[3V or TCRaV. In some embodiments, the effector T cells are effector memory T cells (TEM). In some embodiments, the memory T cells are central memory T cells (Tcm).

[0055] In some embodiments, the expanded population of T cells has an increased and / or prolonged cytotoxicity compared to that of a control T cell population contacted with a control multi-specific polypeptide comprising a first binding domain that specifically binds to CD3 instead of TCRPV or TCRaV.

[0056] In some embodiments, the comparison between the expanded population of T cells expanded by the multi -specific polypeptide and control T cell population contacted with the controlAttorney Docket No. JANX-004 / 05WO 339516-2027multi-specific polypeptide is performed 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 days after an initial contact of the T cells.

[0057] Also provided herein is a method of depleting B cells in a subject having a disease or disorder related to the B cells, comprising administering to the subject an effective amount of the multi-specific polypeptide disclosed herein or the pharmaceutical composition disclosed herein. In some embodiments, the method decreases the number of B cells by at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, at least 99.5%, at least 99.8%, at least 99.9%, or 100%, in the subject. In some embodiments, the B cells are autoreactive B cells. In some embodiments, the B cells are autoreactive memory B cells. In some embodiments, the method reduces autoantibodies.

[0058] Also provided herein is a method of repopulating naive B cells in a subject, comprising administering to the subject an effective amount of the multi-specific polypeptide disclosed herein or the pharmaceutical composition disclosed herein. In some embodiments, the subject has a disease or disorder related to B cells. In some embodiments, the method increases the number of naive B cells by at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100%, in the subject.

[0059] Also provided herein is a method of treating a disease or disorder in a subject in need thereof, comprising administering to the subject an effective amount of the multi-specific polypeptide disclosed herein or the pharmaceutical composition disclosed herein.

[0060] In some embodiments, the disease or disorder is a cancer. In some embodiments, the cancer is a blood cancer. In some embodiments, the blood cancer is chronic lymphocytic leukemia or non-Hodgkin lymphoma. In some embodiments, the disease or disorder is an autoimmune disease. In some embodiments, the autoimmune disease is rheumatoid arthritis or Systemic lupus erythematosus. In some embodiments, the subject has previously been treated with a multi-specific polypeptide comprising a first binding domain specifically binds to CD3 instead of TCRβV or TCRαV. In some embodiments, the subject is relapsing or refractory to a treatment comprising a multi-specific polypeptide comprising a first binding domain specifically binds to CD3 instead of TCRβV or TCRαV.BRIEF DESCRIPTION OF THE FIGURES

[0061] FIG. 1A illustrates non-limiting examples of T-cell engager molecules comprising (i) an anti-CD19 Fab and (ii) an anti-TCR (e.g., TRBV or TRAV) or anti-CD3 scFv. The scFv may haveAttorney Docket No. JANX-004 / 05WO 339516-2027 the format of N’-VH-VL-C’, or N’-VL-VH-C’, and optionally contain an engineered disulfide bond.FIG. 1B illustrates the binding domain format of Blincyto / Blinatumomab, as a non-limiting example of T-cell engager molecules comprising (i) an anti-CD19 scFv and (ii) an anti-CD3 scFv.

[0062] FIG. 2A illustrates non-limiting examples of T-cell engager molecules comprising (i) an anti-TCR (e.g., TRBV or TRAV) or anti-CD3 scFv; (ii) an anti-CD19 Fab; and (iii) an Fc region of knob-into-hole format. The scFv may have the format of N’-VH-VL-C’, or N’-VL-VH-C’, and optionally contain an engineered disulfide bond. The C -terminus of anti-CD19 Fab CHI region is connected to the Fc chain comprising the knob mutation. (Molecule on the Left) the C -terminus of anti-TCR scFv is connected to the VH region of the anti-CD19 Fab; (Molecule on the Right) the C-terminus of anti-TCR scFv is connected to the VL region of the anti-CD19 Fab. FIG.2B illustrate a non-limiting example of T-cell engager molecules comprising (i) an anti-CD19 Fab; (ii) an anti-TCR (e.g., TRBV or TRAV) or anti-CD3 scFv; and (iii) an Fc region of knob-into-hole format. The scFv may have the format of N’-VH-VL-C’, or N’-VL-VH-C’, and optionally contain an engineered disulfide bond. The C-termmus of anti-CD19 Fab CHI region is connected to the N-terminus of scFv. FIG. 2C illustrate a non-limiting example of T-cell engager molecules comprising (i) a T cell binding Fab (e.g., with specific binding to CD3, TRBV or TRAV); (ii) an anti-CD19 scFv; and (iii) an Fc region of knob-into-hole format. The C-terminus of T cell binding Fab CHI region may be connected to the N-terminus of the anti-CD19 scFv via a peptide linker.FIG. 2D illustrates non-limiting examples of T-cell engager molecules comprising (i) an anti-CD19 scFv; (ii) a T cell binding Fab (e.g., with specific binding to CD3, TRBV or TRAV); and (iii) an Fc region of knob-into-hole format. The C-terminus of T cell binding Fab CH1 region is connected to the Fc chain comprising the knob mutation. (Molecule on the Left) The C-terminus of the anti-CD19 scFv is connected to the VH region of the T cell binding Fab. (Molecule on the Right) The C-terminus of the anti-CD19 scFv is connected to the VL region of the T cell binding Fab. FIG.2E illustrates non-limiting examples of T-cell engager molecules comprising (i) an anti-CD19 Fab with charge steering to enrich desired light chain pairing; (ii) a T cell binding CrossFab (e.g., with specific binding to CD3, TRBV or TRAV) to enrich desired light chain pairing; and (iii) an Fc region of knob-into-hole format. The Fab is connected to the Fc chain comprising the knob mutation via the C-terminus of the CH1 region. (Molecule on the Left) The C-terminus of the CHI region of the anti-CD19 Fab with charge steering is connected to the N-terminus of the VL of the T cell binding CrossFab. (Molecule on the Right) The C-terminus of the CHI region of the T cell binding CrossFab is connected to the N-terminus of the VH of the anti-CD19 Fab with charge steering.Attorney Docket No. JANX-004 / 05WO 339516-2027

[0063] FIG.3A illustrates a non-limiting example of T-cell engager molecules comprising (i) an anti-CDl 9 scFv connected to the Fc chain comprising the hole mutation and (li) a T cell binding Fab or CrossFab (e.g., with specific binding to CD3, TRBV or TRAV) connected to the Fc chain comprising the knob mutation. FIG. 3B illustrates non-limiting examples of T-cell engager molecules comprising (i) an anti-CD19 Fab connected to the Fc chain comprising the hole mutation via its CH1 region and (ii) a T cell binding CrossFab (e.g., with specific binding to CD3, TRBV or TRAV) connected to the Fc chain comprising the knob mutation. The anti-CDl 9 Fab may be a regular Fab or a charge steering Fab, and the T cell binding CrossFab may be connected to Fc chain via its CHI region or its CL region.

[0064] FIG.4 A contains charts showing the results of B cell depletion and T cell expansion using TCE-94 or TCE-52, after 7-day culture in healthy donor PBMCs. FIG.4B contains charts showing the results of B cell depletion and T cell expansion using TCE-9, TCE-26, or TCE-11, after 7-day culture in healthy donor PBMCs

[0065] FIG. 5A-5B contain charts showing the results of B cell depletion and T cell expansion using TCE-9, TCE-10, TCE-11, or TCE-12, after 7-day culture in healthy donor PBMCs. FIG. 5C-5D contain charts showing the results of B cell depletion and T cell expansion using TCE-17, TCE-18, TCE-19, or TCE-20, after 7-day culture in healthy donor PBMCs.

[0066] FIG.6 contains charts showing the results of B cell depletion and T cell expansion using TCE-52, after 7-day culture in healthy donor PBMCs.

[0067] FIG. 7A-7B contain charts showing the results of B cell depletion and T cell expansion using TCE-13 or TCE-14, after 7-day culture in healthy donor PBMCs. FIG. 7C-7D contain charts showing the results of B cell depletion and T cell expansion using TCE-21 or TCE-22, after 7-day culture in healthy donor PBMCs.

[0068] FIG. 8A-8B contain charts showing the results of B cell depletion and T cell expansion using TCE-26 or TCE-27, after 7-day culture in healthy donor PBMCs.

[0069] FIG. 9 is a chart summarizing the results of B cell depletion and T cell expansion studies using the indicated T cell engagers.

[0070] FIG. 10A-10E contain charts showing the results of B cell depletion and T cell expansion using the indicated T cell engagers, after 7-day culture in healthy donor PBMCs.

[0071] FIG. 11 is a chart summarizing the results of B cell depletion and T cell expansion studies using the indicated T cell engagers.Attorney Docket No. JANX-004 / 05WO 339516-2027

[0072] FIG. 12A-12B contain charts showing the results of B cell depletion and T cell expansion using TCE-98 or TCE-99, after 7-day culture in healthy donor PBMCs.

[0073] FIG. 13A-13C contain charts showing the results of B cell depletion and T cell expansion using TCE-100 or TCE-101, after 7-day culture in healthy donor PBMCs.

[0074] FIG. 14A-14F contain charts showing the results of B cell depletion and T cell expansion using TCE-92, TCE-93, TCE-94, or TCE-95, after 7-day culture in healthy donor PBMCs.

[0075] FIG. 15 contains charts showing the results of B cell depletion and T cell expansion using TCE-167 or TCE-168, after 7-day culture in healthy donor PBMCs.

[0076] FIG. 16 contains charts showing the results of B cell depletion and T cell expansion using TCE-116 or TCE-118, after 7-day culture in healthy donor PBMCs.

[0077] FIG. 17A-17B contain charts showing the results of B cell depletion and T cell expansion using TCE-93, TCE-95, TCE-117, or TCE-119, after 7-day culture in healthy donor PBMCs.

[0078] FIG. 18A-18B contain charts showing the results of B cell depletion and T cell expansion using TCE-102 or TCE-103, after 7-day culture in healthy donor PBMCs.

[0079] FIG. 19A-19D contain charts showing the results of B cell depletion and T cell expansion using TCE-80, TCE-81, TCE-84, TCE-85, TCE-88, or TCE-89, after 7-day culture in healthy donor PBMCs.

[0080] FIG. 20A-20D contain charts showing the results of B cell depletion and T cell expansion using TCE-96, TCE-97, TCE-82, TCE-86, or TCE-90, after 7-day culture in healthy donor PBMCs.

[0081] FIG.21A-21B contain charts showing the results of B cell depletion and T cell expansion using TCE-83, TCE-87, or TCE-91, after 7-day culture in healthy donor PBMCs.

[0082] FIG.22A-22C are charts summarizing the results of B cell depletion and T cell expansion studies using the indicated T cell engagers,

[0083] FIG. 23A-23B contain charts showing the changes of B cells, CD8+ T cells, CD4+ T cells, and Treg cells in SLE PBMCs over time in the presence of TCE-9 or TCE-11. FIG. 23C-23H contain charts showing the change of TRBV- or TRBV+ cells in different T cell populations over time in the presence of different concentrations of TCE-9 or TCE-11.

[0084] FIG. 24A-24F contain plots showing the changes over time of different naïve, memory, and effector T cell populations from PBMCs of SLE patients in the presence of different concentrations of TCE-9 or TCE-11.Attorney Docket No. JANX-004 / 05WO 339516-2027

[0085] FIG. 25A are charts summarizing B-cell depletion in SLE patient PBMCs using TCE-9 or TCE-11. FIG.25B is a chart summarizing the maximum fold change expansion of T cell subsets in SLE donor PBMCs using TCE-9 or TCE-11.

[0086] FIG. 26 contains charts showing B cell depletion in CLL patient PBMCs in the presence of different concentrations of TCE-9 or TCE-11,

[0087] FIG. 27 contains charts showing the changes of CD8+ and CD4+ T cell populations in CLL patient PBMCs over time in the presence of different concentrations of TCE-9 or TCE-11.

[0088] FIGs. 28A-28H show ELISA binding results for exemplary anti-CD19 and anti-TRBV bispecific T cell engagers CLY-018 to CLY-024. FIG. 28A shows a summary of binding results for CLY-018 to CLY-024 against human CD19 (5 ug / mL) at concentrations from 0-5 μM. FIG.28B summarizes the results of FIG.28A. FIG.28C shows a summary of binding results for CLY-018 to CLY-024 against cyno CD 19 (5 ug / mL) at concentrations from 0-5 μM. FIG. 28D summarizes the results of FIG. 28C. FIG. 28E shows a summary of binding results for CLY-018 to CLY-024 against human TRB V6-5 at 5 ug / mL. FIG. 28F summarizes the results of FIG. 28E.FIG. 28G shows a summary of binding results for CLY-018 to CLY-024 against cyno TRBV6-2 at 5 ug / mL. FIG.28H summarizes the results of FIG.28G.

[0089] FIGs. 29A-29D show results of human cell binding of exemplary anti-CD19 and anti- TRBV bispecific T cell engagers CLY-018 to CLY-024 by flow cytometry. FIG. 29A shows the human B cell binding results. FIG. 29B summarizes the results of FIG.29A. FIG.29C shows the human T cell binding results. FIG.29D summarizes the results of FIG.29C.

[0090] FIGs.30A-30D show results of cyno cell binding of exemplary anti-CD19 and anti-TRBV bispecific T cell engagers CLY-018 to CLY-024 by flow cytometry. FIG. 30A shows the cyno B cell binding results, FIG. 30B summarizes the results of FIG. 30A. FIG. 30C shows the cyno T cell binding results. FIG. 30D summarizes the results of FIG. 30C.

[0091] FIGs. 31A-FIG. 31U show results of functionality assays for exemplary anti-CD19 and anti-TRBV bispecific T cell engagers CLY-018 to CLY-024. FIG. 31A shows normalized B cell count for human PBMC sample and the exemplary T cell engagers. FIG.31 B summarizes the EC50 values for human B cell killing shown in FIG. 31A. FIG. 31C shows results for CD8+TRBV+ for human PBMC sample and the exemplary T cell engagers. FIG. 31D shows results for non-Treg CD4+ TRBV+ for human PBMC sample and the exemplary T cell engagers. FIG. 31E shows results for T regs for human PBMC sample and the exemplary T cell engagers. FIG. 31F shows expansion of CD8+TRBV+ for the CLY-023 T cell engager from human PBMCs. FIG.31 G showsAttorney Docket No. JANX-004 / 05WO 339516-2027 expansion of CD8+TRBV+ for the CLY-018 T cell engager from human PBMCs FIG.31 II shows expansion of CD8 + TRBV+ for the CLY-019 T cell engager from human PBMCs. FIG. 31I shows expansion of CD8+TRBV+ for the CLY-020 T cell engager from human PBMCs. FIG. 31 J shows expansion of CD8+TRBV+ for the CLY-021 T cell engager from human PBMCs. FIG.31K shows expansion of CD8+TRBV+ for the CLY-022 T cell engager from human PBMCs. FIG. 31 L shows B cell count after treatment of cyno PBMCs (donor “326”) with CLY-020, CLY-021, or CLY-024. FIG. 31M summarizes the results of FIG. 31L. FIG. 31 N shows B cell count after treatment of cyno PBMCs (donor “1611”) with CLY-020, CLY-021, or CLY-024. FIG. 310 summarizes the results of FIG. 31N. FIG. 31P shows CD8+TRBV+ T cell fold change for cyno PBMCs (donor “326”) treated with CLY-020, CLY-021, or CLY-024. FIG. 31Q shows CD8+TRBV+ T cell fold change for cyno PBMCs (donor “1611”) treated with CLY-020, CLY-021, or CLY-024. FIG. 31R shows CD4+TRBV+ T cell fold change for cyno PBMCs (donor “326”) treated with CLY-020, CLY-021, or CLY-024. FIG. 31S shows CD4+TRBV+ T cell fold change for cyno PBMCs (donor “1611”) treated with CLY-020, CLY-021, or CLY-024. FIG. 31T shows CD8+TRBV+ T cell fold change for cyno PBMCs (donor “326”) treated with CLY-020. FIG. 31U shows CD8+TRBV+ T cell fold change for cyno PBMC (donor “1611”) treated with CLY-020. FIG. 31V shows B cell fold change at Days 1-4 and 7 following treatment of healthy PBMCs (donor “1”) with various doses of CLY-018 (left panel) or CLY-019 (right panel). FIG. 31W shows B cell fold change at Days 1-4 and 7 following treatment of healthy PBMCs (donor “2”) with various doses of CLY-018 (left panel) or CLY-019 (right panel), FIG. 31X shows CD8+TRBV+ T cell count at Day 4 (left panel) and Day 7 (right panel) following treatment of healthy PBMCs (donor “1”) with various doses of CLY-018 or CLY-019. FIG. 31Y shows CD8+TRBV+ T cell count at Day 4 (left panel) and Day 7 (right panel) following treatment of healthy PBMCs (donor “2”) with various doses of CLY-018 or CLY-019. FIG. 31Z shows B cell fold change at Days 1-3 and 7 following treatment of healthy bone marrow aspirates from donor “1” (left panel) and donor “2” (right panel) with various doses of CLY-018. FIG. 31AA shows B cell fold change at Days 1, 3, 4 and 7 following treatment of healthy splenocytes from donor “1” (left panel), donor “2” (middle panel), or donor “3” (right panel) with various doses of CLY-018.

[0092] FIGs. 32A-32F show functionality results for assays utilizing exemplary anti-CD19 and anti-TRBV bispecific T cell engagers CLY-023, CLY-018, CLY-019, and CLY-022. FIG. 32A shows average TRBV+CD8+ T cell count for 3 donors treated with CLY-023, CLY-018, CLY-019, or CLY-022 in a 7-day culture. FIG. 32B shows average TRBV+CD4+ T cell count for 3 donorsAttorney Docket No. JANX-004 / 05WO 339516-2027 treated with CLY-023, CLY-018, CLY-019, or CLY-022 in a 7-day culture. FIG. 32C shows expansion of TRBV+CD8+ T cells after a 7-day culture with CLY-022, CLY-019, CLY-018, or CLY-023 enriched for TRBV6-1, 6-2, 6-5, and 6-9 (n=3 donor CD8+ T cells). Note that CLY-022 also expanded TRBV 10-3 T cells. FIG. 32D shows expansion of TRBV+CD4+ T cells after a 7-day culture with CLY-022, CLY-019, CLY-018, or CLY-023 enriched for TRBV6-1, 6-2, 6-5, and 6-9 (n=2-3 donor CD4+ T cells). Note that CLY-022 also expanded TRBV10-3 T cells. FIG.32E shows expansion of TRAV+CD8+ T cells after a 7-day culture with CLY-022, CLY-019, CLY- 018, or CLY-023 indicating no change in relative abundance of TRAVs with TRBV stimulation (n=2-3 donor CD4+ T cells). FIG. 32F shows expansion of TRAV+ CD4+ T cells after a 7-day culture with CLY-022, CLY-019, CLY-018, or CLY-023 indicating no change in relative abundance of TRAVs with TRB V stimulation (n=2-3 donor CD4+ T cells).

[0093] FIGs. 33A-33R show results of in vivo activity of exemplary anti-CD19 and anti-TRBV bispecific T cell engagers in a cynomolgus monkey model. FIG. 33A shows the plasma concentration of CLY-023 for monkeys treated with CLY-023. FIG. 33B shows CD20+ B cell count in the blood of monkeys treated with CLY-023. Note that minimal B cell depletion was observed in monkeys dosed up to Img / kg IV. FIG. 33C shows cytokine induction results for monkeys treated with CLY-023 at 0.1 mg / kg IV. FIG. 33D shows cytokine induction results for monkeys treated with CLY-023 at 1 mg / kg IV. Of note is that no in life observations or signs of cytokine release syndrome in monkeys dosed up to 1 mg / kg IV were detected. FIG.33E shows the plasma concentration of CLY-024 for monkeys treated with CLY-024 at various concentrations, FIG. 33F shows CD 20+ B cell count in the blood of monkeys treated with CLY-024, Of note is that moderate B cell depletion observed in monkey dosed at Img / kg IV. Minimal B cell depletion observed at lower doses (< Img / kg IV). FIG. 33G shows cytokine induction results for monkeys treated with CLY-024 at 0,01 mg / kg, iv. FIG. 33H shows cytokine induction results for monkeys treated with CLY-024 at 0,1 mg / kg, iv. FIG. 331 shows cytokine induction results for monkeys treated with CLY-024 at 1 mg / kg, iv. No in life observations or signs of cytokine release syndrome in cynomolgus monkeys dosed up to Img / kg IV. FIG. 33J shows plasma concentration of CLY- 020 in monkeys treated with CLY-020. FIG. 33K shows CD20+ B cell count in the blood of monkeys treated with CLY-020 over 28 days. FIG. 33L shows cytokine induction in CLY-020-treated monkeys for IL-2, IFN gamma, IL-6 and TNF. FIG. 33M shows plasma concentration of CLY-018 in monkeys treated with CLY-018. FIG. 33N shows CD20+ B cell count in monkeys treated with CLY-018. FIG. 330 shows cytokine induction for monkeys treated with CLY-018 atAttorney Docket No. JANX-004 / 05WO 339516-2027 a concentration of 0.1 mg / kg IV. FIG. 33P shows cytokine induction for monkeys treated with CLY-018 at 1 mg / kg IV. FIG. 33Q shows cytokine induction for monkeys treated with CLY-018 at 2.5 mg / kg IV. FIG. 33R shows cytokine induction for monkeys treated with CLY-018 at 9 mg / kg. No in life observations or signs of cytokine release syndrome in cynomolgus monkeys dosed up to 9mg / kg IV was observed. FIG. 33S shows CD20+ B cell count in the blood of monkeys over time with various dosing regimens of CLY-018. FIG. 33T shows plasma concentration of CLY-018 in monkeys over time following treatment with various dosing regimens of CLY-018. FIG. 33U shows peak IL-6 cytokine induction in monkeys following treatment with various dosing regimens of CLY-018. FIG. 33V shows percent change in B cells in the blood of monkeys with various dosing regimens of CLY-018. Percent change was calculated by determining B cell count before treatment compared to Day 7 after treatment with CLY-018. FIG. 33W shows peak IL-6 cytokine induction in monkeys following treatment with various dosing regimens of CLY-018. FIG. 33X shows percentage of CD20+ B cells in the blood, bone marrow, spleen, and lymph node before (Day 0) and after (Day 17) treatment with various dosing regimens of CLY-018. The data shown are for animals that maintained PK exposure through Day 17 with no impact from potential anti¬ drug antibodies. FIG.33Y shows the number of switched memory, unswitched memory, naive, and immature / transitional / double negative B cells in the blood before and after treatment with various dosing regimens of CLY-018. Data is consistent with an immune reset. FIG. 33Z show’s a schematic of a B cell depletion phase and a B cell recovery phase following administration of a CD19xTRBV T cell engager (TCE), Treatment with the TCE results in rapid and complete B cell depletion within several days (B cell depletion phase) followed by an immune reset characterized by B cell repopulation of predominantly naive B cells, sustained depletion of autoreactive memory cells, and reduction of autoantibodies (B cell recovery phase). IV, intravenous; SC, subcutaneous; QW, once weekly,

[0094] FIGs. 34A-34T show activity of the CLY-018 T cell engager in healthy human PBMCs and PBMCs of autoimmune subjects (e.g., RA, SLE, and MG). FIG. 34A shows average B-cell fold change / killing of healthy human PBMC treated with CLY-018 over the course of 7 days. FIG.34B shows average non-Treg CD4+ T cell fold change of healthy human PBMCs treated with CLY- 018 over the course of 7 days. FIG. 34C shows average CD8+ T cell fold change of healthy human PBMC treated with CLY-018 over the course of 7 days. FIG.34D shows average T reg fold change of healthy human PBMC treated with CLY-018 over the course of 7 days. FIG. 34E shows results of CD8+ T cell expansion for the Tn, Tscm, Ttm, Tcm, Tern, Teff, and Temra subsets of healthyAttorney Docket No. JANX-004 / 05WO 339516-2027 human PBMCs treated with CLY-018. FIG. 34F shows average B-cell fold change / killing of PBMCs from subjects with RA treated with CLY-018 over 7 days. FIG. 34G shows average non-Treg CD4+ T cell fold change of PBMCs from subjects with RA treated with CLY-018 over 7 days. FIG. 34H shows average CD8+ T cell fold change of PBMCs from subjects with RA treated with CLY-018. FIG. 34I shows average T reg fold change of PBMCs from subjects with RA treated with CLY-018. FIG. 34J shows results of CD8+ T cell expansion for the Tn, Tscm, Ttm, Tcm, Tern, Teff, and Temra subsets from PBMCs of RA subjects incubated with CLY-018. FIG. 34K shows average B-cell fold change / killing of PBMCs from 3 SLE subjects treated with CLY-018 over 7 days. FIG. 34L shows average non-Treg CD4+ T cell fold change of PBMCs from 3 SLE subjects treated with CLY-018 over 7 days. FIG. 34M shows average CD8+ T cell fold change of PBMCs from 3 SLE subjects treated with CLY-018. FIG. 34N shows average T reg fold change of PBMCs from 3 SLE subjects treated with CLY-018. FIG. 340 shows results of CD 8+ T cell expansion for the Tn, Tscm, Ttm, Tcm, Tem, Teff, and Temra subsets from PBMCs of SLE subjects incubated with CLY-018. FIG. 34P shows average B-cell fold change of PBMCs from 3 MG subjects treated with CLY-018 over 7 days. FIG. 34Q shows average non-Treg CD4+ T cell fold change of PBMCs from 3 MG subjects treated with CLY-018 over 7 days. FIG.34R shows average CD8+ T cell fold change of PBMCs from 3 MG subjects treated with CLY-018. FIG. 34S shows average T reg fold change of PBMCs from 3 MG subjects treated with CLY-018. FIG. 34T shows results of CD8+ T cell expansion for the Tn, Tscm, Ttm, Tcm, Tem, Teff, and Temra subsets of the PBMCs from MG subjects incubated with CLY-018. FIG. 34U shows relative abundance of TRBV+ T cell subsets (Tn, Tscm, Ttm, Tcm, Tem, Teff, and Temra) in human PBMCs from healthy donors, SLE donors, RA donors, and MG donors before (Day 0) and after (Day 7) treatment with 1 nM of CLY-018. FIG.34V shows B cell counts (left y-axis) and CD8+TRBV+ T cell fold change (right y-axis) of human PBMCs from healthy donors, RA donors, SLE donors, and MG donors treated with various doses of CLY-018 or TCE-52. RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; MG, myasthenia gravis.

[0095] FIG. 35 shows percent lysis of Raji B cells over time in T cell co-culture upon treatment with CLY-018 or TCE-160.

[0096] FIGs. 36A-36B depict relative B cell depletion and IL-6 cytokine release of the CD19- TCRBV bispecifics of the present disclosure (Tx 1) compared to other B cell therapeutics (CLN-978 (Tx 2), Blincyto (Tx 3), Epcoritamab (Tx 4), Glofitamab (Tx 5), and Mosunetuzumab (Tx 6)). those of other B-cell therapeutics by Cullinan, Amgen, Genmab, Roche and Genentech. FIG 36AAttorney Docket No. JANX-004 / 05WO 339516-2027 depicts B cell depletion as percent change of measured B cell population 1 week prior to dose with either CD19-TCRBV bispecifics of the present disclosure or other competing therapeutics. FIG 36B depicts B cell depletion as percent change of measured B cell population 1 week prior to dose with either CD19-TCRBV bispecifics of the present disclosure (Tx 1) or other B cell therapeutics (Tx 2 to Tx 6).

[0097] FIGs. 37A-37E depict potency of B cell depletion by CD19-TCRBV bispecifics of the present disclosure. FIG. 37A shows EC50 of B cell depletion of different cell populations from disease patients. FIG. 37B shows percentage of B cell killing within cell populations from disease patients. FIGs. 37C, 37D, and 37E depict B cell depletion and T cell expansion after treatment with CD19-TCRBV bispecifics of the present disclosure. SLE-systemic lupus; RA- rheumatoid arthritis; MG- myasthenia gravis (MG); IIM- idiopathic inflammatory myopathy.

[0098] FIG.38 shows the design of a clinical trial designed to further validate human treatments using CD19-TCRBV bispecifics of the present disclosure.DETAILED DESCRIPTION

[0099] In some embodiments, the present disclosure provides designs of multi-specific polypeptides for binding target cells and engaging T cells with improved efficacy. In some embodiments, such multi-specific polypeptides not only are effective in killing the target cells, but also induce larger increases in early memory’ populations that maintains and / or replenishes effector populations over time. In some embodiments, the multi-specific polypeptide comprises a first binding domain that specifically binds to a T cell receptor beta variable region (TCRpV) or a T cell receptor alpha variable region (TCRαV) expressed on the T cell. In some embodiments, the multispecific polypeptide comprises a first binding domain that specifically binds to CD3. In some embodiments, the multi-specific polypeptide comprises a second binding domain that specifically binds to an antigen (e.g., CD19) on the target cell. In some embodiments, the multi-specific polypeptide comprises a Fc region, and both the first and the second binding domains are located on the same polypeptide chain of the Fc region (e.g., a Fc region polypeptide chain comprising a Knob mutation). In some embodiments, the multi-specific polypeptide comprises the first binding domain (e.g., an scFv) linked to the second binding domain (e.g., a Fab), and the second binding domain in turn linked to a polypeptide chain of the Fc region. In some embodiments, the multi¬ specific polypeptide does not comprise a cytokine.Attorney Docket No. JANX-004 / 05WO 339516-2027

[0100] In some embodiments, the present disclosure provides methods of expanding T cells, comprising contacting a T cell with a multi-specific polypeptide, thereby inducing a production of a population of T cells comprising a plurality of memory T cells and effector T cells. In some embodiments, the methods disclosed herein are advantageous because the resulting population of T cells has an increased durability than that of a CD3 binder-expanded population of T cells. Specifically, the methods effectively expands both effector T cells (such as effector memory T cells (TEM), T effector cells (TEFF), and / or T effector cells re-expressing CD45RA (TEMRA)) and memory T cells (such as central memory T cells (TCM) and / or T memory stem cells (TSCM)). It is noteworthy that the methods bias the expanded T cell composition towards both towards TCM and TEM. In the meantime, the methods bias the expanded T cell composition towards CD8+ and CD4+ (non-Treg) T cells and away from regulatory T cells. The resulting population of T cells thus has an increased and / or prolonged cytotoxicity than that of a CD3 binder-expanded population of T cells.

[0101] In some embodiments, the methods disclosed herein can reduce the toxicity and side effects associated with cytokine release syndrome (CRS) because the resulting population of T cells has reduced cytokine release than that of a CD3 binder-expanded population of T cells.

[0102] Given the advantageous features of the methods of expanding T cells disclosed herein, the present disclosure also provided methods of treating a disease or disorder in a subject in need thereof, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a multi- specific polypeptide to the subject, wherein the multi-specific polypeptide contacts a T cell of the subject, thereby inducing a production of a population of T cells, wherein the multi-specific polypeptide comprises a first binding domain that specifically binds to a T cell receptor beta variable region (TCRpV) or a T cell receptor alpha variable region (TCRαV) expressed on the T cell, and wherein the population of T cells comprises a plurality of memory T cells and effector T cells. The disease or disorder can be a cancer (e.g., chronic lymphocytic leukemia) or an autoimmune disease (e.g,, rheumatoid arthritis, and Systemic lupus erythematosus).7.1. Definitions

[0103] Unless otherwise defined herein, technical and scientific terms used in the present description have the meanings that are commonly understood by those of ordinary skill in the art. For purposes of interpreting this specification, the following description of terms will apply and whenever appropriate, terms used in the singular will also include the plural and vice versa unless the content clearly dictates otherwise. In the event that any description of a term set forth conflictsAttorney Docket No. JANX-004 / 05WO 339516-2027 with any document incorporated herein by reference, the description of the term set forth below shall control.

[0104] The terms “a”, “an”, and “the”, as used herein, include plural references unless the context clearly dictates otherwise.

[0105] The term “about” or “approximately”, as used herein, in reference to a number or range of numbers, is understood to mean the stated number and numbers + / - 10% thereof, or 10% below the lower listed limit and 10% above the higher listed limit for the values listed for a range (except where such number would exceed 100% of a possible value or go below 0%). It is used to indicate that a value includes the inherent variation of error for the device or the method being employed to determine the value, or the variation that exists among the samples being measured.

[0106] The term “between”, as used in a phrase as such “between A and B” or “between A-B” refers to a range including both A and B.

[0107] The terms “comprise” and its grammatical equivalents, as used herein, specify the presence of stated features, integers, steps, operations, elements, and / or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and / or groups thereof.

[0108] The terms “including”, “includes”, “included”, and other forms, as used herein, are not limiting.

[0109] The terms “or” and “and / or”, as used herein, include any, and all, combinations of one or more of the associated listed items,

[0110] In the present description, any concentration range, percentage range, ratio range, or integer range is to be understood to include the value of any integer within the recited range and, when appropriate, fractions thereof (such as one tenth and one hundredth of an integer), unless otherwise indicated.

[0111] The phrase “any range or subrange therebetween” or equivalents, are used herein to denote the intention that disclosure of any range or series of possible values, inherently also discloses all ranges and subranges encompassed by the highest and lowest values disclosed. This term includes the entire range from highest to lowest disclosed values, as well as subranges from any two or more disclosed points. This term is also intended to disclose any subranges encompassed anywhere within the highest and lowest disclosed values, including between two points that are explicitly recited in the document, up to one decimal point. Thus, disclosure of values 0, 5, 10, 15, 20, including all ranges and subranges therebetween, should be interpreted as also encompassing aAttorney Docket No. JANX-004 / 05WO 339516-2027 range from 0-20, a range from 0-5 or 5-15, as well as a range from 2-16, or 3.1 to 19.8, etc. Unless otherwise indicated, it is to be understood that all numbers expressing quantities, ratios, and numerical properties of ingredients, reaction conditions, and so forth, used in the specification are contemplated to be able to be modified in all instances by the term “including all ranges and subranges therebetween”.

[0112] The term “administer”, “administration”, or “administering”, as used herein refers to the act of injecting or otherwise physically delivering a substance (e.g., a pharmaceutical composition provided herein) to a subject (e.g., human), such as by oral, mucosal, topical, intradermal, parenteral, intravenous, intravitreal, intraarticular, subretinal, intramuscular, intrathecal delivery and / or any other method of physical delivery described herein or known in the art. The delivery can be systemic or to a specific tissue.

[0113] The terms “amino-terminal” and “carboxyl-terminal” are used herein to denote positions within polypeptides. Where the context allows, these terms are used with reference to a particular sequence or portion of a polypeptide to denote proximity or relative position.

[0114] The term “antibody,” “immunoglobulin,” or “Ig” is used interchangeably herein, and is used in the broadest sense and specifically covers, for example, monoclonal antibodies (including agonist, antagonist, neutralizing antibodies, full length or intact monoclonal antibodies), antibody compositions with poly epitopic or monoepitopic specificity, polyclonal or monovalent antibodies, multivalent antibodies, and multi-specific antibodies (e.g., bispecific antibodies so long as they exhibit the desired biological activity). A conventional antibody is composed of two identical pairs of polypepti de chains, wherein each pair has one heavy chain (about 50-70 kDa) and one light chain (about 25 kDa), each amino-terminal portion of each chain includes a variable region of about 100 to about 130 or more amino acids, and each carboxy -terminal portion of each chain includes a constant region. See, e.g,, Antibody Engineering (Borrebaeck, ed., 2d ed. 1995); and Kuby, Immunology (3d ed. 1997), An antibody can be human, humanized, chimeric and / or affinity matured, as well as an antibody from other species, for example, mouse and rabbit, etc. Antibodies also include, but are not limited to, synthetic antibodies, recombinantly produced antibodies, camelized antibodies or their humanized variants, and intrabodies. An antibody can be selected from any class of immunoglobulins, including IgM, IgG, IgD, IgA and IgE, and any isotype, including IgGl, IgG2, IgG3 and IgG4 (e.g., variants of IgG4 and IgG4 nullbody). An antibody can comprise kappa or lambda light chain constant sequences.Attorney Docket No. JANX-004 / 05WO 339516-2027

[0115] The term “antigen”, as used herein, refers to a structure to which an antibody or an antibody fragment can specifically bind. An antigen may be a polypeptide, carbohydrate, nucleic acid, lipid, hapten, or other naturally occurring or synthetic compound.

[0116] The term “antigen-binding domain”, (e.g., a CD3 or TCRpV-binding domain) as used herein, refers to a portion of a binding molecule that specifically binds a target antigen or target epitope. Antigen-binding domains may comprise antibodies or antigen-binding fragments thereof. The term “antigen-binding fragment”, as used herein, refers to a portion of an antibody heavy and / or light chain polypeptide that retains some or all of the binding activity of the antibody from which the fragment was derived. An antigen-binding fragment may comprise 1, 2, 3, 4, 5, or all 6 CDRs of a variable heavy chain (VH) and / or variable light chain (VL) sequence. Non-limiting examples of functional fragments include single-chain Fvs (scFv), Fab fragments, CrossFab fragments, F(ab’) fragments, F(ab)2 fragments, F(ab’)2 fragments, disulfide-linked Fvs (dsFv), Fd fragments, Fv fragments, diabody, triabody, tetrabody, and minibody. Such functional antigen-binding fragment can be found in, for example, Harlow and Lane, Antibodies: A Laboratory Manual (1989); Mol. Biology and Biotechnology: A Comprehensive Desk Reference (Myers, ed., 1995); Huston, et al, 1993, Ceil Biophysics 22:189-224; Pliickthun and Skerra, 1989, Meth. Enzymol. 178:497-515; and Day, Advanced Immunochemistry (2d ed. 1990).

[0117] The term “binds” or “binding”, as used herein, refers to a covalent or non-covalent interaction between molecules (e.g., forming a complex by interactions). Exemplary non-covalent interactions include hydrogen bonds, ionic bonds, hydrophobic interactions, and / or van der Waals interactions. Terms such as “specific binding,” “specifically binds to,” or “is specific for” means that a binding domain or a binding molecule comprising a binding domain binds the target with an affinity or Ka(z.e., an equilibrium association constant of a particular binding interaction with units of 1 / M) equal to or greater than 105M’1, while not significantly binding other components present in a test sample.

[0118] The term “binding affinity”, as used herein, refers to the strength of the sum total of noncovalent interactions between a binding domain X and its binding partner Y. Unless indicated otherwise, as used herein, “binding affinity” refers to intrinsic binding affinity which reflects a 1:1 interaction between members of a binding pair (e.g., antibody and antigen). Binding domains can be classified as “high affinity” binding domains and “low affinity” binding domains. “High affinity” binding domains refer to those binding domains with a Ka of at least 107M-1, at least 108M’1, at least 109M'1, at least 1010M'1, at least 1011M'1, at least 1012M'1, or at least 1013M-1. “Low affinity”Attorney Docket No. JANX-004 / 05WO 339516-2027 binding domains refer to those binding domains with a Kaof up to 107M-1, up to 106M-1, up to 105M-1. High-affinity binding domains generally bind the binding partners faster and tend to remain bound longer, whereas low-affinity binding domains generally bind the binding partners slowly and tend to dissociate readily. / Affinity can also be defined as an equilibrium dissociation constant (Kd) of a particular binding interaction with units of M e.g., 10-5M to 10-13, or about 1000 nM, about 900 nM, about 800 nM, about 700 nM, about 600 nM, about 500 nM, about 300 nM, about 250 nM, about 200 nM, about 150 nM, about 100 nM, about 50 nM, about 25 nM, about 10 nM, or about 5 nM, including any ranges or subranges therebetween). Affinities of binding domains according to the present disclosure can be readily determined using conventional techniques (see, e.g., Scatchard et al. (1949) Ann. N. Y. Acad. Sci. 51:660; and U. S. Patent Nos. 5,283,173, 5,468,614, or the equivalent).

[0119] The term “binding molecule”, as used herein, refers to a polypeptide or complex of polypeptides comprising at least one binding domain that specifically binds to a target. In some embodiments, the binding molecule is a multi-specific polypeptide. As used herein, a “multi¬ specific polypeptide” refers to a polypeptide comprising two or more binding domains each capable of specifically binding to a target. For example, the polypeptides described herein may comprise 2, 3, 4, or more binding domains and may be able to bind 2, 3, 4, or more targets. In some embodiments, the multi-specific polypeptide comprises a first binding domain that specifically binds to a T cell receptor beta variable region (TCRβV) or a T cell receptor alpha variable region (TCRαV) expressed on the T cell. In some embodiments, the multi-specific polypeptide comprises a first binding domain that specifically binds to CD3. In some embodiments, the multi-specific polypeptide further comprises a second binding domain specifically binding to a protein expressed on a B cell (e.g,, CD 19).

[0120] The term “CD3 binder-expanded population of T cells”, as used herein, refers to a population of T cells expanded from a T cell after a polypeptide specifically binding to CD3 expressed on the T cell.

[0121] The term “coding sequence” or a polynucleotide which “encodes” a polypeptide, as used herein, is a nucleic acid molecule which is transcribed (in the case of DNA) and translated (in the case of mRNA) into a polypeptide when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5’ (ammo) terminus and a translation stop codon at the 3’ (carboxy) terminus. A transcription termination sequence may be located 3’ to the coding sequence.Attorney Docket No. JANX-004 / 05WO 339516-2027

[0122] The term “constant region” or “constant domain”, as used herein, refers to a carboxy terminal portion of the light and heavy chain which is not directly involved in binding of the antibody to antigen but exhibits various effector function, such as interaction with the Fc receptor. This portion has a more conserved amino acid sequence relative to the variable region. The constant region may contain the CHI, CH2, and CH3 regions of the heavy chain and the CL region of the light chain.

[0123] The term “contact”, as used in the context of contacting a target cell with a compound (e.g., a multi-specific polypeptide), is intended to include incubating the target cell and the compound together.

[0124] The term “cytokine”, as used herein, refers to small proteins, a functional fragment therefore, a functional variant thereof, and a combination thereof that act as signaling molecules to regulate immunity, inflammation, and hematopoiesis. Cytokines include chemokines, interferons, interleukins, lymphokmes, and tumor necrosis factors. Specific examples of cytokines include interleukin-2 (IL-2), interleukin-7 (IL-7), interleukin- 10 (IL- 10), interleukin- 12 (IL- 12), interleukin- 15 (IL- 15), interleukin- 18 (IL- 18), interleukin-21 (IL-21), interferon gamma, a functional fragment therefore, a functional variant thereof, and a combination thereof.

[0125] The term “cytotoxicity”, as used herein, refers to an ability of an effector cell to kill a target cell. In some embodiments, the effector cell is a TCRPV+ T cell. In some embodiments, the effector cell is a TCRaV+ T cell. In some embodiments, the target cell is a B cell, such as a CD 19-positive B cell.

[0126] The term “disulfide bond”, as used herein, refers to the covalent linkage between the thiol groups of two cysteine residues. The specific position / location of the disulfide bond can be defined using the location of the two cysteine residues within a protein or polypeptide. For instance, a VH44-VI / 100 disulfide bond of the TCRpV-binding domain refers to a disulfide bond formed between the cysteine residue at amino acid position 44 of the VH region of the TCRpV-binding domain and the cysteine residue at amino acid position 100 of the VL region of the TCRPV -binding domain. Similarly, a VH100B-VL49 disulfide bond of the TCRpV-binding domain refers to a disulfide bond formed between the cysteine residue at amino acid position 100B of the VI I region of the TCRpV-binding domain and the cysteine residue at amino acid position 49 of the VL region of the TCRpV-binding domain. It is well known to a skilled artisan that antibodies have different HCDR3 lengths and additional residues may occur between positions VH100 and VH101 that canAttorney Docket No. JANX-004 / 05WO 339516-2027 be numbered with a letter from A to K according to the Kabat numbering scheme (e.g., VH100A, VH100B, VH100C... H100K).

[0127] The term “durability”, as used herein, refers to the ability of a population of T cells to maintain their effector function (i.e., ability to kill a target cell) and the capacity to expand and differentiate.

[0128] The term “effective amount”, as used herein, refers to an amount of a therapeutic (e.g., a pharmaceutical composition provided herein) which is sufficient to prevent, diagnose, treat, delay the onset of, reduce and / or ameliorate the severity, duration, advancement, and / or recurrence of a given condition, disorder or disease and / or a symptom related thereto. The term also encompasses an amount necessary to improve or enhance the prophylactic or therapeutic effect (s) of another therapy or to serve as a bridge to another therapy.

[0129] The term “effector T cell”, as used herein, refers to active form of T cells that have relatively short lifespans and carry out the functions of an immune response. Effector T cells can be cytotoxic (CD8+), helper (CD4+, non-reg), and regulatory T cells. Specific types of effector T cells include effector memory T ceils (TEM), T effector cells (TEFF), and T effector cells re¬ expressing CD45RA (TEMRA). In some embodiments, the effector T cell is TCRPV+. In some embodiments, the effector T cell is TCRaV+.

[0130] The term “Fab” or “Fab region”, as used herein, refers to an antibody region that binds to antigens. A conventional IgG usually comprises two Fab regions, each residing on one of the two arms of the Y-shaped IgG structure. Each Fab region is typically composed of one variable region and one constant region of each of the heavy and the light chain. More specifically, the variable region and the constant region of the heavy chain in a Fab region are VH and CHI regions, and the variable region and the constant region of the light chain in a Fab region are VL and CL regions. The VH, CHI, VL, and Cl. in a Fab region can be arranged in various ways to confer an antigen binding capability. For example, VH and CHI regions can be on one polypeptide, and VL and Cl. regions can be on a separate polypeptide, similarly to a Fab region of a conventional IgG, Alternatively, VH, CHI, VL and CL regions can all be on the same polypeptide and oriented in different orders,

[0131] The term “heavy chain”, when used in reference to an antibody, refers to a polypeptide chain of about 50-70 kDa, wherein the amino-termmal portion includes a variable region of about 120 to 130 or more amino acids, and a carboxy -terminal portion includes a constant region. The constant region can be one of five distinct types, (e.g., isotypes) referred to as alpha, delta, epsilon.Attorney Docket No. JANX-004 / 05WO 339516-2027 gamma, and mu, based on the amino acid sequence of the heavy chain constant region. The distinct heavy chains differ in size: alpha, delta, and gamma contain approximately 450 amino acids, while epsilon and mu contain approximately 550 amino acids. When combined with a light chain, these distinct types of heavy chains give rise to five well known classes (e.g., isotypes) of antibodies, IgA, IgD, IgE, IgG, and IgM, respectively, including four subclasses of IgG, namely IgGl, IgG2, IgG3, and IgG4.

[0132] The term “light chain”, when used in reference to an antibody, refers to a polypeptide chain of about 25 kDa, wherein the amino-terminal portion includes a variable region of about 100 to about 110 or more amino acids, and a carboxy -terminal portion includes a constant region. The approximate length of a light chain is 211 to 217 amino acids. There are two distinct types, referred to as kappa or lambda based on the amino acid sequence of the constant domains.

[0133] The term “peptide linker”, as used herein, generally refers to a short polypeptide sequence connecting two sub-domains of a polypeptide. Non-limiting examples of peptide linkers include flexible linkers comprising glycine-serine repeats, and peptide linkers derived from (a) an interdomain region of a transmembrane protein (e.g., a type I transmembrane protein); (b) a stalk region of a type II C-lectin; or (c) an immunoglobulin hinge. In some embodiments, a linker provides a spacer function compatible with interaction of the two sub-binding domains so that the resulting polypeptide retains a specific binding affinity to the same target molecule as an antibody that comprises the same light and heavy chain variable regions. In some embodiments, the linker connects two or more binding domains (e.g., the TCRpV-binding domain and the CD19-binding domain) and is referred to herein as a peptide linker “PLB” (a peptide linker for binding domains). In some embodiments, the linker connects a binding domain with a half-life extension moiety and is referred to herein as a peptide linker “PLE” (a peptide linker to an extension moiety). In some embodiments, the linker connects a VH region of an scFv and a VL region of an scFv and is referred to herein as a “scFv linker”.

[0134] The term “memory T cell”, as used herein, refers to long-lived T cells that remain in the body after a pathogen has been cleared. Memory T cells are highly capable of responding to antigens upon reintroduction. Specific types of effector T cells include central memory T cells (TCM), T memory stem cells (TSCM), and transitional memory T cells (TTM).

[0135] The term “operatively linked” and similar phrases (e.g., operably linked, genetically fused), as used herein, refer to the operational linkage of nucleic acid sequences or amino acid sequences placed in functional relationships with each other. For example, a promoter operativelyAttorney Docket No. JANX-004 / 05WO 339516-2027 linked to a polynucleotide encoding a polypeptide result in the transcription of the polynucleotide and ultimately the expression of the polypeptide. As another example, an operatively linked peptide is one in which the functional domains are placed with appropriate distance from each other to impart the intended function of each domain.

[0136] The term “pharmaceutically acceptable excipient, carrier or diluent”, as used herein, refers to any substance formulated alongside the active ingredient of a pharmaceutical composition that allows the active ingredient to retain biological activity and is non-reactive with the subject’s immune system. Such a substance can be included for the purpose of long-term stabilization, bulking up solid formulations that contain potent active ingredients in small amounts, or to confer a therapeutic enhancement on the active ingredient in the final dosage form, such as facilitating absorption, reducing viscosity, or enhancing solubility. The selection of appropriate substance can depend upon the route of administration and the dosage form, as well as the active ingredient and other factors. Compositions having such substances can be formulated by well-known conventional methods (see, e.g., Remington, The Science and Practice of Pharmacy, 23rd edition, A. Adejare, ed., Academic Press, 2020).

[0137] The term “pharmaceutical composition” or “therapeutic composition”, as used herein, refers to a composition capable of being administered to a subject for the treatment of a particular disease or disorder.

[0138] The term “polynucleotide” or “nucleic acid”, as used herein, refers to deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and DNA / RNA hybrids. Polynucleotides may be singlestranded or double-stranded and either recombinant, synthetic, or isolated. Polynucleotides include, but are not limited to: pre-messenger RNA (pre-mRNA), messenger RNA (mRNA), RNA, genomic DNA (gDNA), PCR amplified DNA, complementary DNA (cDNA), synthetic DNA, or recombinant DNA. Polynucleotides can comprise modified nucleotides or bases, and / or their analogs, or any substrate that can be incorporated into a polymer by DNA or RNA polymerase or by a synthetic reaction. Unless specified otherwise, the left-hand end of any single-stranded polynucleotide sequence disclosed herein is the 5’ end; the left-hand direction of double-stranded polynucleotide sequences is referred to as the 5’ direction. The direction of 5’ to 3’ addition of nascent RNA transcripts is referred to as the transcription direction.

[0139] The terms “polypeptide” and “peptide” and “protein”, as used herein, refer to polymers of amino acids of any length. The polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non-amino acids. The terms also encompass an aminoAttorney Docket No. JANX-004 / 05WO 339516-2027 acid polymer that has been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification. Also included within the definition are, for example, polypeptides containing one or more analogs of an amino acid, including but not limited to, unnatural amino acids, as well as other modifications known in the art.

[0140] The term “population” of cells, as used herein, refers to any number of cells greater than 1, for example, at least about 1x10’ cells, at least about IxlO4cells, at least about IxlO5cells, at least about IxlO6cells, at least about IxlO7cells, at least about IxlO8cells, at least about IxlO9cells, at least about IxlO10cells, at least about IxlO11or more cells. A population of cells may refer to an in vitro population (e.g., a population of cells in culture) or an in vivo population (e.g., a population of cells residing in a particular tissue).

[0141] The term “prevent”, as used herein, refers to a pharmaceutical or other intervention regimen for reducing the likelihood of the onset (or recurrence) of a disease, disorder, condition, or associated symptom(s).

[0142] The term “single-chain variable fragment (scFv)”, as used herein, refers to a fusion protein of the variable heavy chain (VH) and the variable light chain (VL) of an antibody, connected with a short scFv linker peptide. In some embodiments, the scFv linker is about 5 amino acids to about 30 amino acids in length. In some embodiments, the scFv linker is rich in glycine for flexibility, as well as serine or threonine for solubility, and can either connect the N-terminus of the VH region with the C-terminus of the VL region, or vice versa. scFvs retain the specificity of the original antibody, despite removal of the constant regions and the introduction of the scFv linker. scFvs are, described in e.g., Houston, J, S., Methods in Enzymol. 203 (1991) 46-96).

[0143] The term “sequence identity”, as used herein, refers to the percentage of bases or amino acids between two polynucleotide or polypeptide sequences that are the same, when compared and aligned for maximum correspondence over a comparison window or designated region. As such one polynucleotide or polypeptide sequence has a certain percentage of sequence identity compared to another polynucleotide or polypeptide sequence. For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. The term “reference sequence” refers to a molecule to which a test sequence is compared. Methods of sequence alignment for comparison and determination of percent sequence identity and percent complementarity are well known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the homology alignment algorithm of Needleman and Wunsch, (1970) J. Mol.Attorney Docket No. JANX-004 / 05WO 339516-2027 Biol. 48:443, by the search for similarity method of Pearson and Lipman, (1988) Proc. Nat’ 1. Acad. Sci. USA 85:2444, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), by manual alignment and visual inspection (see, e.g., Brent et al., (2003) Current Protocols in Molecular Biology), by use of algorithms know in the art including the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., (1977) Nuc. Acids Res. 25:3389-3402; and Altschul et al., (1990) J. Mol. Biol. 215:403-410, respectively. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information. BLAST nucleotide searches can be performed with the NBLAST nucleotide program parameters set, e.g., for score 100, word length-2 to obtain nucleotide sequences homologous to a nucleic acid molecule described herein. BLAST protein searches can be performed with the XBLAST program parameters set, e.g., to score 50, word length-3 to obtain amino acid sequences homologous to a protein molecule described herein. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al., Nucleic Acids Res., 1997, 25:3389-402. Alternatively, PSI BLAST can be used to perform an iterated search which detects distant relationships between molecules (Id.). When utilizing BLAST, Gapped BLAST, and PSI BLAST programs, the default parameters of the respective programs (e.g., of XBLAST and NBLAST) can be used (see, e.g., National Center for Biotechnology Information (NCBI) on the worldwide web, ncbi.nlm.nih.gov). Another non-limiting example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Myers and Miller, 1988, CABIOS 4:11-17. Such an algorithm is incorporated in the ALIGN program (version 2.0) which is part of the GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used. Unless noted otherwise, the term “sequence identity” refers to sequence identity as calculated by Clustal Omega® using default parameters.

[0144] The term “subject”, as used herein, refers to an “animal” and in particular a “mammal” such as a non-primate (e.g., mice, rats, bovines, horses, household cats, tigers and other large cats, dogs, pigs, rabbits, goats, deer, sheep, ferrets, gerbils, guinea pigs, hamsters, bats, and birds (e.g., chickens, turkeys, and ducks)) or a primate (e.g., monkeys, baboons, chimpanzees, and human). The term may be used interchangeably with the term “patient” or “individual”. In some embodiments, the subject is a mammal, e.g., a human, diagnosed with a disease or disorder provided herein. In some embodiments, the subject is a mammal, e.g., a human, at risk of developing a diseaseAttorney Docket No. JANX-004 / 05WO 339516-2027 or disorder provided herein. In some embodiments, the subject is human. The term does not denote a particular age or sex. Thus, individuals of all ages, from newborn to adult, whether male or female, are intended to be covered.

[0145] The term “substantially similar,” as used herein, denotes at least about 40% similar, at least about 50% similar, at least about 60% similar, at least about 70% similar, at least about 80% similar, at least about 90% similar, at least about 95% similar, at least about 96% similar, at least about 97% similar, at least about 98% similar or at least about 99% similar.

[0146] The term “variable region”, “variable domain”, “V region”, or “V domain”, as used herein, refers to a portion of the light or heavy chains of an antibody that is generally located at the amino-terminal of the light or heavy chain and has a length of about 120 to 130 amino acids in the heavy chain and about 100 to 110 amino acids in the light chain, and are used in the binding and specificity of each particular antibody for its particular antigen. The variable region of the heavy chain may be referred to as “VH.” The variable region of the light chain may be referred to as “ VL.” The term “variable” refers to the fact that certain segments of the variable regions differ extensively in sequence among antibodies. The V region mediates antigen binding and defines specificity of a particular antibody for its particular antigen. However, the variability is not evenly distributed across the 110-amino acid span of the variable regions. Instead, the V regions consist of less variable (e.g., relatively invariant) stretches called framework regions (FRs) of about 15-30 amino acids separated by shorter regions of greater variability (e.g., extreme variability) called “hypervariable regions” or “complementarity determining regions” that are each about 9-12 amino acids long. The variable regions of heavy and light chains each comprise four FRs, largely adopting a β sheet configuration, connected by three hypervariable regions, which form loops connecting, and in some cases form part of, the β sheet structure. The hypervariable regions in each chain are held together in close proximity by the FRs and, with the hypervariable regions from the other chain, contribute to the formation of the antigen-binding site of antibodies (see, e.g., Kabat et al, Sequences of Proteins of Immunologi cal Interest (5th ed. 1991)),

[0147] The complementarity determining regions (CDRs) have been defined by well-known numbering systems. For example, the Kabat Complementarity Determining Regions (CDRs) are based on sequence variability and are the most commonly used (see, e.g., Kabat, et al., supra). Chothia refers instead to the location of the structural loops (see, e.g., Chothia and Lesk, J. Mol. Biol., 1987, 196:901-17). The end of the Chothia CDR-H1 loop when numbered using the Kabat numbering convention varies between 1132 and H34 depending on the length of the loop (this isAttorney Docket No. JANX-004 / 05WO 339516-2027 because the Kabat numbering scheme places insertions at H35A and H35B; if neither 35A nor 35B is present, the loop ends at 32; if only 35A is present, the loop ends at 33; if both 35A and 35B are present, the loop ends at 34). The AbM hypervariable regions represent a compromise between the Kabat CDRs and Chothia structural loops, and are used by Oxford Molecular’s AbM antibody modeling software (see, e.g., Antibody Engineering Vol. 2 (Rontermann and Diibel, eds., 2d ed.2010)). The “contact” CDRs are based on an analysis of the available complex crystal structures. Another universal numbering system that has been developed and widely adopted is ImMunoGeneTics (IMGT) Information System® (Lafranc, et al, Dev. Comp. Immunol., 2003, 27(l):55-77). IMGT is an integrated information system specializing in immunoglobulins (IG), T-cell receptors (TCR), and major histocompatibility complex (MHC) of human and other vertebrates. An additional numbering system (AHon) has been developed by Honegger and Pluckthun, J. Mol. Biol., 2001, 309: 657-70. Correspondence between the numbering system, including, for example, the Kabat numbering and the IMGT unique numbering system, is well known to one skilled in the art (see, e.g., Kabat, supra, Chothia and Lesk, supra; Martin, supra, Lefranc, et al., supra).

[0148] The boundaries of a given CDR may vary depending on the scheme used for identification. Thus, unless otherwise specified, the CDRs of a given antibody or region thereof, such as a variable region, should be understood to encompass the complementary determining region as defined by any of the known schemes described herein. In some instances, the scheme for identification of a particular CDR or CDRs is specified, such as the CDR as defined by the Kabat, Chothia, or Contact method. In other cases, the particular amino acid sequence of a CDR is given. In some embodiments, a combination of CDR numbering systems may be used. In such embodiments, CDR sequences of a given binding molecule as determined by multiple numbering systems (e.g,, a CDR1 sequence as determined by the Kabat, IMGT, and Chothia numbering systems) are compiled into a single sequence that encompasses the entirety of each of the CDR amino acid ranges in the variable region.

[0149] As the “location” of the CDRs within the structure of the immunoglobulin variable domain is conserved between species and present in structures called loops, by using numbering systems that align variable domain sequences according to structural features, CDR and framework residues are readily identified. This information can be used in grafting and replacement of CDR residues from immunoglobulins of one species into an acceptor framework from, typically, a human antibody.Attorney Docket No. JANX-004 / 05WO 339516-2027

[0150] The term “variant”, when used in relation to polypeptide, refers to a polypeptide comprising one or more (such as, for example, about 1 to about 25, about 1 to about 20, about 1 to about 15, about 1 to about 10, or about I to about 5, including any ranges or subranges therebetween) amino acid sequence substitutions, deletions, and / or additions as compared to a native or unmodified sequence. Variants may be naturally occurring, such as allelic or splice variants, or may be artificially constructed. Polypeptide variants may be prepared from the corresponding nucleic acid molecules encoding the variants.

[0151] The term “vector”, as used herein, refers to a substance that is used to carry or introduce a nucleic acid sequence (e.g., a nucleic acid sequence encoding an antibody as described herein) into a host cell. Vectors applicable for use include, for example, plasmids, phage vectors, viral vectors, episomes, and artificial chromosomes. A vector may include sequences that direct autonomous replication in a cell, or may include sequences sufficient to allow integration into host cell DNA. Additionally, the vectors can include one or more selectable marker genes and appropriate expression control sequences. Selectable marker genes that can be included, for example, provide resistance to antibiotics or toxins, complement auxotrophic deficiencies, or supply critical nutrients not in the culture media. Expression control sequences can include constitutive and inducible promoters, transcription enhancers, transcription terminators, and the like, which are well known in the art. When two or more nucleic acid molecules are to be co-expressed (e.g., both an antibody heavy and light chain or an antibody VH and VL), both nucleic acid molecules can be inserted, for example, into a single expression vector or in separate expression vectors. For single vector expression, the encoding nucleic acids can be operationally linked to one common expression control sequence or linked to different expression control sequences. The introduction of nucleic acid molecules into a host cell can be confirmed using methods well known in the art. Such methods include, for example, nucleic acid analysis such as Northern blots or polymerase chain reaction (PCR) amplification of mRNA, immunoblotting for expression of gene products, or other suitable analytical methods to test the expression of an introduced nucleic acid sequence or its corresponding gene product. It is understood by those skilled in the art that the nucleic acid molecules are expressed in a sufficient amount to produce a desired product and it is further understood that expression levels can be optimized to obtain sufficient expression using methods well known in the art.

[0152] General methods in molecular and cellular biochemistry can be found in such standard textbooks as Molecular Cloning: A Laboratory Manual, 3rd Ed. (Sambrook et al., HaRBorAttorney Docket No. JANX-004 / 05WO 339516-2027 Laboratory Press 2001 ); Short Protocols in Molecular Biology, 4th Ed. (Ausubel et al. eds., John Wiley & Sons 1999); Protein Methods (Bollag et al., John Wiley & Sons 1996); Nonviral Vectors for Gene Therapy (Wagner et al. eds., Academic Press 1999); Viral Vectors (Kaplift & Loewy eds.. Academic Press 1995); Immunology Methods Manual (I. Lefkovits ed., Academic Press 1997); and Cell and Tissue Culture: Laboratory Procedures in Biotechnology (Doyle & Griffiths, John Wiley & Sons 1998), the disclosures of which are incorporated herein by reference.7.2. Multi- Specific Polypeptides

[0153] Provided herein are multi-specific polypeptides. In some embodiments, such multi¬ specific polypeptides are suitable for binding target cells and engaging T cells. In some embodiments, the multi-specific polypeptide comprises a first binding domain and a second binding domain. In some embodiments, the first binding domain specifically binds T cell receptor alpha variable region (TCRαV). In some embodiments, the first binding domain specifically binds T cell receptor beta variable region (TCRβV). In some embodiments, the first binding domain specifically binds CD3. In some embodiments, the second binding domain specifically binds CD 19.

[0154] In some embodiments, the multi-specific polypeptide further comprises a half-life extension moiety. In some embodiment, the half-life extension moiety’ comprises a fragment crystallizable (Fc) region.

[0155] In some embodiments, the multi-specific polypeptides of the disclosure do not comprise a cytokine. In some embodiments, the cytokine is selected from the group consisting of interleukin- 2 (IL-2), interleukin- 7 (IL-7), interleukin-10 (IL-10), interleukin- 12 (IL-12), mterleukin-15 (IL-15), interleukin- 18 (IL-18), interleukin-21 (IL-21), interferon gamma, a functional fragment therefore, a functional variant thereof, and a combination thereof,7.2.1. First Binding Domain

[0156] In some embodiments, the first binding domain specifically binds a T cell receptor. The T cell receptor (TCR) is expressed on the surface of T cells and is responsible for recognizing antigens bound to major histocompatibility complex (MHC) molecules. When the TCR engages with antigenic peptide and MHC (peptide / MHC), the T cell is activated through a series of biochemical events mediated by associated enzymes, co-receptors, specialized adaptor molecules, and activated or released transcription factors. The TCR is a disulfide-linked membrane-anchored heterodimer normally consisting of the highly variable alpha (a) and beta (P) chains expressed as part of a complex with the invariant CD3 chain molecules. T cells expressing this receptor are referred to as a:p (or up) T cells (-95% total T-cells). Each a and P chain is composed of twoAttorney Docket No. JANX-004 / 05WO 339516-2027 extracellular domains: a variable region and a constant region. The constant region is proximal to the cell membrane, followed by a transmembrane region and a short cytoplasmic tail, while the variable region binds to the peptide / MHC complex.

[0157] In some embodiments, the multi-specific polypeptides used in the methods of expanding T cells and the methods of treatment comprises a first binding domain that specifically binds to a T cell receptor beta variable region (TCRβV) (i.e., a TCRpV-bmding domain). In some embodiments, the multi-specific polypeptides used in the methods of expanding T cells and the methods of treatment comprises a first binding domain that specifically binds to a T cell receptor alpha variable region (TCRαV) (i.e., a TCRaV-binding domain).

[0158] In some embodiments, the TCRpV-binding domain comprises an immunoglobulin molecule. In some embodiments, the TCRpV-binding domain is an antibody (e.g, a polyclonal or monoclonal antibody). In some embodiments, the TCRpV-bmding domain is a chimeric antibody. In some embodiments, the TCRpV-binding domain is a humanized antibody. In some embodiments, the TCRpV-binding domain is a human antibody. In some embodiments, the TCRaV-binding domain comprises an immunoglobulin molecule. In some embodiments, the TCRaV-binding domain is an antibody (e.g., a polyclonal or monoclonal antibody). In some embodiments, the TCRaV -binding domain is a chimeric antibody. In some embodiments, the TCRaV -binding domain is a humanized antibody. In some embodiments, the TCRaV-binding domain is a human antibody.

[0159] In some embodiments, the TCRpV-binding domain is an antigen-binding fragment thereof. In some embodiments, the TCRaV-binding domain is an antigen-binding fragment thereof. Non-limiting examples of functional fragments include single-chain Fvs (scFv), Fab fragments, CrossFab fragments, F(ab’) fragments, F(ab)2 fragments, F(ab’)2 fragments, disulfide-lmked Fvs (dsFv), Fd fragments, Fv fragments, diabody, triabody, tetrabody, and minibody. In some embodiments, the TCRpV-binding domain is an scFv. In some embodiments, the TCRaV-binding domain is an scFv. In some embodiments, the TCRpV-binding domain is a Fab. In some embodiments, the TCRaV-binding domain is a Fab. In some embodiments, the TCRpV-binding domain is a CrossFab. In some embodiments, the TCRaV-binding domain is a CrossFab.

[0160] In some embodiments, the VI I region and the VL region are numbered with reference to the Kabat numbering scheme. In some embodiments, the VII region and the VL region are numbered with reference to the IMGT numbering scheme. In some embodiments, the VII region and the VL region are numbered with reference to the Chothia numbering scheme. In someAttorney Docket No. JANX-004 / 05WO 339516-2027 embodiments, the VII region and the VL region are numbered with reference to the Martin (Enhanced Chothia or AbM) numbering scheme. In some embodiments, the VII region and the VL region are numbered with reference to the Honneger’s (Allo) numbering scheme.

[0161] In some embodiments, the TCRpV-bindmg domain comprises an immunoglobulin heavy chain variable (VII) region and an immunoglobulin light chain variable (VL) region. In some embodiments, the VII region comprises a heavy chain CDRl (IICDRl), a heavy chain CDR2 (IICDR2), and a heavy chain CDR3 (HCDR3). In some embodiments, the VL region comprises a light chain CDRl (LCDR1), a light chain CDR2 (LCDR2), and a light chain CDR3 (LCDR3).

[0162] In some embodiments, the TCRpV-binding domain is a Fab comprising the VH region, the VL region, a first heavy chain constant region (CHI), and a light chain constant region (CL), wherein the C-terminus of the VH region is connected to the N-terminus of the CH1 region (e.g., a polypeptide chain comprising N’-VH-CH1-C’), and the C-terminus of the VL region is connected to the N-terminus of the CL region (e.g., a polypeptide chain comprising N’-VL-CL-C). In some embodiments, the CHI region and the CL region of the Fab are connected by a disulfide bond. In some embodiments, the Fab is a charge steering Fab.

[0163] In some embodiments, the TCRPV -binding domain is a CrossFab comprising the VH region, the VL region, a first heavy chain constant region (CHI), and a light chain constant region (CL), wherein the C-terminus of the VH region is connected to the N-terminus of the CL region (e.g., a polypeptide chain comprising N’-VH-CL-C’), and the C-terminus of the VL region is connected to the N-terminus of the CHI region (e.g., a polypeptide chain comprising N’-VL-CHl - C’). In some embodiments, the CHI region and the CL region of the CrossFab are connected by a disulfide bond. In some embodiments, the CrossFab is a charge steering CrossFab.

[0164] Exemplary anti-TCRpV CDRs are provided in Table I (Kabat numbering scheme) and Table 2 (IMGT numbering scheme) below.Table 1, TRBV CDRs (Kabat Numberings)Target HCDR1 HCDR2 HCDR3 LCDR1 LCDR2 LCDR3 DescriptionTRBV6-5 TYYIH WFFPGS SYYSYD KASQNV SSSHRYS QQFKSYP (SEQ ID GNIKYNE VLDY GINVV (SEQ ID LTNO: 1) KFKG (SEQ ID (SEQ ID NO: 5) (SEQ ID (SEQ ID NO: 3) NO: 4) NO: 6) NO: 2)TRBV6-5 LTYIH WFFPGS SYYSYD KASQNV SSSHRYS QQFKSYP (SEQ ID GNIKYNE VLDY GINVV (SEQ ID LTNO: 7) KFKG (SEQ ID (SEQ ID NO: 5) (SEQ IDNO: 3) NO: 4) NO: 6)Attorney Docket No. JANX-004 / 05WO 339516-2027 Target HCDR1 HCDR2 HCDR3 LCDR1 LCDR2 LCDR3 Description(SEQ IDNO: 2)TRBV6-5 LTYIH RVSAGS SYYSYD KASQNV SSSHRYK QQFKSYP (SEQ ID GNVKYN VLDY ADRW (SEQ ID LT NO: 7) EKFKG (SEQ ID (SEQ ID NO: 10) (SEQ ID (SEQ ID NO: 3) NO: 9) NO: 6) NO: 8)TRBV6-5 LYYIH WFFPGS SYYSFDV KASQNV SSSHRYS QQFKSYP (SEQ ID GNIKYNE LDY (SEQ GIRVV (SEQ ID IT (SEQ NO: 1138) KFKG ID NO: (SEQ ID NO: 5) ID NO:(SEQ ID 1139) NO: 1140) 1141) NO: 2)TRBV6-5 TYYIH WFFPRSG SYYSFDV KASQNV SSSHRYS QQFKSYP (SEQ ID NIKYNEK LDY (SEQ GIRW (SEQ ID IT (SEQ NO: 1) FKG (SEQ ID NO: (SEQ ID NO: 5) ID NO:ID NO: 1139) NO: 1140) 1141) 1142)TRBV6-5 TYYIH WIFPGSG SYYSYD KASQNV SSSHRYS QQFKSYP (SEQ ID NIKYNEK VLDY GNNVA (SEQ ID LT (SEQ NO: 1) FKG (SEQ (SEQ ID (SEQ ID NO: 5) ID NO: 6) ID NO: NO: 3) NO: 1182)1180)TRBV6-5 TYYIH WIYPGSG SYYSYD KASQNV SSSHRYS QQFKSYP (SEQ ID NIKYNEK VL DY GINVV (SEQ ID l. r (SEQ NO: 1) FKG (SEQ (SEQ ID (SEQ ID NO: 5) ID NO: 6) ID NO: NO: 3) NO: 4)1181)TRBV6-5 TYYIH WIYPGSG SYYSYD KASQNV SSSHRYS QQFKSYP (SEQ ID NIKYNEK VLDY GNNVA (SEQ ID LT (SEQ NO: 1) FKG (SEQ (SEQ ID (SEQ ID NO: 5) ID NO: 6) ID NO: NO: 3) NO: 1182)1181)TRBV6-5 TYYIH WIYPGSG SYYSYD RASQNV SSSHRYS QQFKSYP (SEQ ID NIKYNEK VLDY GNNVA (SEQ ID LT (SEQ NO: 1) FKG (SEQ (SEQ ID (SEQ ID NO: 5) ID NO: 6) ID NO: NO: 3) NO: 1183)1181)TRBV12- NFGMH YISSGSS RGEGAM RASSSVN YTSNLAP QQFTSSP 3 / 4 (SEQ ID TIYYADT DY YIY (SEQ ID FT NO: 11) LKG (SEQ ID (SEQ ID NO: 15) (SEQ ID (SEQ ID NO: 13) NO: 14) NO: 16) NO: 12)TRBV12- NFGMH YISSGSS RGEGAM RASQSV YTSNLAP QQYTSSP 3 / 4 (SEQ ID TIYYADT DY (SEQ NYIY (SEQ ID FT (SEQNO: 11) LKG (SEQ NO: 15)Attorney Docket No. JANX-004 / 05WO 339516-2027 Target HCDR1 HCDR2 HCDR3 LCDR1 LCDR2 LCDR3 DescriptionID NO: ID NO: (SEQ ID ID NO:12) 13) NO: 223) 224) TRBV12- NFGMH YISSGSS RGEGAM RASQSV YTSNLAP QQYTSSP 3 / 4 (SEQ ID TIYYADT DY (SEQ NYLY (SEQ ID FT (SEQ NO: 11) LKG (SEQ ID NO: (SEQ ID NO: 15) ID NO:ID NO: 13) NO: 225) 224)12)TRBV12- NYGMH YISSGSS RGEGAM RASQSV YTSNLAP QQYTSSP 3 / 4 (SEQ ID TIYYADA DY (SEQ NYLY (SEQ ID FT (SEQ NO: 221) LKG (SEQ ID NO: (SEQ ID NO: 15) ID NO:ID NO: 13) NO: 225) 224) 222)TRBV20-1 SAYMH RIDPATG SLNWDY RASKSVS AASNI. ES QQSIEDP (SEQ ID KTKYAP GLDY ILGTHLI (SEQ ID WT (SEQ NO: 228) KFQA (SEQ ID H (SEQ ID NO: 232) ID NO:(SEQ ID NO: 230) NO: 231) 233)NO: 229)Table 2. TRBV CDRs (IMGT Numberings)Target HCDR1 HCDR2 HCDR3 LCDR1 LCDR2 LCDR3 DescriptionTRBV6-5 GYSFTTY FFPGSGN AGSYYS QQFKSYP QNVGIN Y I YDVLDY LT(SEQ ID sss(SEQ ID (SEQ ID (SEQ ID (SEQ ID NO: 20)NO: 17) NO: 18) NO: 19) NO: 22) TRBV6-5 GYSFRLT FFPGSGN AGSYYS QQFKSYP QNVGIN Y I YDVLDY LT(SEQ ID sss(SEQ ID (SEQ ID (SEQ ID (SEQ ID NO: 20)NO: 23) NO: 18) NO: 19) NO: 22) TRBV6-5 GHDFRL VSAGSG AVSYYS QQFKSYP QNVADR TY NV YDVLDY LT(SEQ ID sss(SEQ ID (SEQ ID (SEQ ID (SEQ ID NO: 27)NO: 24) NO: 25) NO: 26) NO: 22) TRBV6-5 GYSFTLY FFPGSGN AASYYSF QNVGIR sss QQFKSYP Y (SEQ ID I (SEQ ID DVLDY (SEQ ID IT (SEQ NO: 1143) NO: 18) (SEQ ID NO: 1145) ID NO:NO: 1144) 1146) TRBV6-5 GYSFTTY FFPRSGN AASYYSF QNVGIR sss QQFKSYP Y (SEQ ID I (SEQ ID DVLDY (SEQ ID IT (SEQ NO: 17) NO: 1147) (SEQ ID NO: 1145) ID NO:NO: 1144) 1146) TRBV6-5 GYSFTTY IFPGSGNI AGSYYS QNVGNN sss QQFKSYP Y (SEQ ID (SEQ ID YDVLDY (SEQ ID LT (SEQ NO: 17) NO: 1184) (SEQ ID NO: 1187) ID NO:NO: 19) 22)Attorney Docket No. JANX-004 / 05WO 339516-2027 Target HCDR1 HCDR2 HCDR3 LCDR1 LCDR2 LCDR3 DescriptionTRBV6-5 GYSFTTY IYPGSGN AGSYYS QNVGIN SSS QQFKSYP Y (SEQ ID I (SEQ ID YDVLDY (SEQ ID LT (SEQ NO: 17) NO: 1185) (SEQ ID NO: 20) ID NO:NO: 19) 22) TRBV6-5 GYSFTTY IYPGSGN ARSYYS QNVGNN sss QQFKSYP Y (SEQ ID I (SEQ ID YDVLDY (SEQ ID LT (SEQ NO: 17) NO: 1185) (SEQ ID NO: 1187) ID NO:NO: 1186) 22) TRBV12- GFTFSNF ARRGEG QQFTSSP 3 / 4 G ISSGSSTI AMDY SSVNY YTS FT(SEQ ID (SEQ ID (SEQ ID (SEQ ID (SEQ ID NO: 28) NO: 29) NO: 30) NO: 31) NO: 33) TRBV12- GFTFSNF ISSGSSTI ARRGEG QSWY YTS QQYTSSP 3 / 4 G (SEQ ID (SEQ ID AMDY (SEQ ID FT (SEQ NO: 28) NO: 29) (SEQ ID NO: 227) ID NO:NO: 30) 224) TRBV12- GFTFSNY ISSGSSTI ARRGEG QSVNY YTS QQYTSSP 3 / 4 G (SEQ ID (SEQ ID AMDY (SEQ ID FT (SEQ NO: 226) NO: 29) (SEQ ID NO: 227) ID NO:NO: 30) 224) TRBV20-1 GFNIKSA IDPATGK TRSLNW KSVSILG AAS QQSIEDP Y (SEQ ID T (SEQ ID DYGLDY TI IL (SEQ WT (SEQ NO: 234) NO: 235) (SEQ ID ID NO: ID NO:NO: 236) 237) 239)

[0165] In some embodiments, the HCDR1 comprises an amino acid sequence of TYYIH (SEQ ID NO: 1), LTYIH (SEQ ID NO: 7), LYYIH (SEQ ID NO: 1138), NFGMH (SEQ ID NO: 11), GYSFTTYY (SEQ ID NO: 17), GYSFRLTY (SEQ ID NO: 23), GHDFRLTY (SEQ ID NO: 24), GYSFTLYY (SEQ ID NO: 1143), GFTFSNFG (SEQ ID NO: 28), NYGMH (SEQ ID NO: 221), GFTFSNYG (SEQ ID NO: 226), SAYMH (SEQ ID NO: 228), or GFNIKSAY (SEQ ID NO: 234). In some embodiments, the HCDR1 comprises 1, 2, 3, or more amino acid substitutions.

[0166] In some embodiments, the HCDR2 comprises an ammo acid sequence of WFFPGSGNIKYNEKFKG (SEQ ID NO: 2), WlFPGSGNIKYNEKFKG (SEQ ID NO: 1180), WIYPGSGNIKYNEKFKG (SEQ ID NO: 1181), IFPGSGNI (SEQ ID NO: 1184), IYPGSGNI (SEQ ID NO: 1185), RVSAGSGNVKYNEKFKG (SEQ ID NO: 8), WFFPRSGNIKYNEKFKG (SEQ ID NO: 1142), YISSGSSTIYYADTLKG (SEQ ID NO: 12), FFPGSGNI (SEQ ID NO: 18), VSAGSGNV (SEQ ID NO: 25), FFPRSGNI (SEQ ID NO: 1147), ISSGSSTI (SEQ ID NO: 29), YISSGSSTIYY DALKG (SEQ ID NO: 222), RIDPATGKTKYAPKFQA (SEQ ID NO: 229), orAttorney Docket No. JANX-004 / 05WO 339516-2027 IDPATGKT (SEQ ID NO: 235). In some embodiments, the IICDR2 comprises 1, 2, 3, or more amino acid substitutions.

[0167] In some embodiments, the HCDR3 comprises an amino acid sequence of SYYSYDVLDY (SEQ ID NO: 3), SYYSFDVLDY (SEQ ID NO: 1139), RGEGAMDY (SEQ ID NO: 13), ARSYYSYDVLDY (SEQ ID NO: 1186), AGSYYSYDVLDY (SEQ ID NO: 19), AVSYYSYDVLDY (SEQ ID NO: 26), AASYYSFDVLDY (SEQ ID NO: 1144), ARRGEGAMDY (SEQ ID NO: 30), SLNWDYGLDY (SEQ ID NO: 230), or TRSLNWDYGLDY (SEQ ID NO: 236). In some embodiments, the HCDR3 comprises 1, 2, 3, or more amino acid substitutions.

[0168] In some embodiments, the LCDR1 comprises an amino acid sequence of KASQNVGINVV (SEQ ID NO: 4), KASQNVGNNVA (SEQ ID NO: 1182), RASQNVGNNVA (SEQ ID NO: 1183), QNVGNN (SEQ ID NO: 1187), KASQNVADRVV (SEQ ID NO: 9), KASQNVGIRVV (SEQ ID NO: 1140), RASSSVNYIY (SEQ ID NO: 14), QNVGIN (SEQ ID NO: 20), QNVADR (SEQ ID NO: 27), QNVGIR (SEQ ID NO: 1145), SSVNY (SEQ ID NO: 31), RASQSVNYIY (SEQ ID NO: 223), RASQSVNYLY (SEQ ID NO: 225), QSVNY (SEQ ID NO: 227), RASKSVSILGTHLIH (SEQ ID NO: 231), or KSVSILGTHL (SEQ ID NO: 237). In some embodiments, the LCDR1 comprises 1, 2, 3, or more amino acid substitutions.

[0169] In some embodiments, the LCDR2 comprises an amino acid sequence of SSSHRYS (SEQ ID NO: 5), SSSHRYK (SEQ ID NO: 10), YTSNLAP (SEQ ID NO: 15), SSS, YTS, AASNLES (SEQ ID NO: 232), or AAS. In some embodiments, the LCDR2 comprises 1, 2, 3, or more amino acid substitutions.

[0170] In some embodiments, the LCDR3 comprises an amino acid sequence of QQFKSYPLT (SEQ ID NO: 6), QQFKSYPIT (SEQ ID NO: 1141), QQFTSSPFT (SEQ ID NO: 16), QQFKSYPLT (SEQ ID NO: 22), QQFKSYPIT (SEQ ID NO: 1146), QQFTSSPFT (SEQ ID NO: 33), QQYTSSPFT (SEQ ID NO: 224), QQSIEDPWT (SEQ ID NO: 233), or QQSIEDPWT (SEQ ID NO: 239). In some embodiments, the LCDR3 comprises 1, 2, 3, or more amino acid substitutions.

[0171] In some embodiments, the HCDR1 comprises an amino acid sequence of TYYIH (SEQ ID NO: 1), the HCDR2 comprises an amino acid sequence of WFFPGSGNIKYNEKFKG (SEQ ID NO: 2), the HCDR3 comprises an amino acid sequence of SYYSYDVLDY (SEQ ID NO: 3), the LCDR1 comprises an amino acid sequence of KASQNVGINVV (SEQ ID NO: 4), the LCDR2 comprises an amino acid sequence of SSSHRYS (SEQ ID NO: 5), and the LCDR3 comprises anAttorney Docket No. JANX-004 / 05WO 339516-2027 ammo acid sequence of QQFKSYPLT (SEQ ID NO: 6). In some embodiments, the CDRs comprise 1, 2, 3, or more amino acid substitutions.

[0172] In some embodiments, the HCDR1 comprises an amino acid sequence of TYYIH (SEQ ID NO: 1), the HCDR2 comprises an amino acid sequence of WIFPGSGNIKYNEKFKG (SEQ ID NO: 1180), the HCDR3 comprises an amino acid sequence of SYYSYDVLDY (SEQ ID NO: 3), the LCDR1 comprises an amino acid sequence of KASQNVGNNVA (SEQ ID NO: 1182), the LCDR2 comprises an amino acid sequence of SSSHRYS (SEQ ID NO: 5), and the LCDR3 comprises an amino acid sequence of QQFKSYPLT (SEQ ID NO: 6). In some embodiments, the CDRs comprise 1, 2, 3, or more amino acid substitutions.

[0173] In some embodiments, the HCDRl comprises an amino acid sequence of GYSFTTYY (SEQ ID NO: 17), the HCDR2 comprises an amino acid sequence of IFPGSGNI (SEQ ID NO: 1184), the HCDR3 comprises an ammo acid sequence of AGSYYSYDVLDY (SEQ ID NO: 19), the LCDR1 comprises an amino acid sequence of QNVGNN (SEQ ID NO: 1187), the LCDR2 comprises an amino acid sequence of SSS, and the LCDR3 comprises an ammo acid sequence of QQFKSYPLT (SEQ ID NO: 22). In some embodiments, the CDRs comprise 1, 2, 3, or more amino acid substitutions.

[0174] In some embodiments, the HCDRl comprises an amino acid sequence of TYYIH (SEQ ID NO: 1), the HCDR2 comprises an amino acid sequence of WIYPGSGNIKYNEKFKG (SEQ ID NO: 1181), the HCDR3 comprises an amino acid sequence of SYYSYDVLDY (SEQ ID NO: 3), the LCDR1 comprises an ammo acid sequence of KASQNVGINVV (SEQ ID NO: 4), the LCDR2 comprises an amino acid sequence of SSSHRYS (SEQ ID NO: 5), and the LCDR3 comprises an ammo acid sequence of QQFKSYPLT (SEQ ID NO: 6). In some embodiments, the CDRs comprise 1, 2, 3, or more amino acid substitutions.

[0175] In some embodiments, the HCDRl comprises an ammo acid sequence of GYSFTTYY (SEQ ID NO: 17), the HCDR2 comprises an amino acid sequence of IYPGSGNI (SEQ ID NO: 1185), the HCDR3 comprises an amino acid sequence of AGSYYSYDVLDY (SEQ ID NO: 19), the LCDR1 comprises an amino acid sequence of QNVGIN (SEQ ID NO: 20), the LCDR2 comprises an ammo acid sequence of SSS, and the LCDR3 comprises an amino acid sequence of QQFKSYPLT (SEQ ID NO: 22). In some embodiments, the CDRs comprise 1, 2, 3, or more amino acid substitutions.

[0176] In some embodiments, the HCDRl comprises an ammo acid sequence of TYYIH (SEQ ID NO: 1), the IICDR2 comprises an ammo acid sequence of WIYPGSGNIKYNEKFKG (SEQ IDAttorney Docket No. JANX-004 / 05WO 339516-2027 NO: 1181), the IICDR3 comprises an amino acid sequence of SYYSYDVLDY (SEQ ID NO: 3), the LCDR1 comprises an amino acid sequence of KASQNVGNNVA (SEQ ID NO: 1182), the LCDR2 comprises an ammo acid sequence of SSSHRYS (SEQ ID NO: 5), and the LCDR3 comprises an amino acid sequence of QQFKSYPLT (SEQ ID NO: 6). In some embodiments, the CDRs comprise 1, 2, 3, or more amino acid substitutions.

[0177] In some embodiments, the HCDR1 comprises an amino acid sequence of TYYIH (SEQ ID NO: 1), the HCDR2 comprises an amino acid sequence of WIYPGSGNIKYNEKFKG (SEQ ID NO: 1181), the HCDR3 comprises an amino acid sequence of SYYSYDVLDY (SEQ ID NO: 3), the LCDR1 comprises an amino acid sequence of RASQNVGNNVA (SEQ ID NO: 1183), the LCDR2 comprises an amino acid sequence of SSSHRYS (SEQ ID NO: 5), and the LCDR3 comprises an amino acid sequence of QQFKSYPLT (SEQ ID NO: 6). In some embodiments, the CDRs comprise 1, 2, 3, or more amino acid substitutions.

[0178] In some embodiments, the HCDR1 comprises an ammo acid sequence of GYSFTTYY (SEQ ID NO: 17), the HCDR2 comprises an amino acid sequence of IYPGSGNI (SEQ ID NO: 1185), the HCDR3 comprises an amino acid sequence of ARSYYSYDVLDY (SEQ ID NO: 1186), the LCDRl comprises an amino acid sequence of QNVGNN (SEQ ID NO: 1187), the LCDR2 comprises an ammo acid sequence of SSS, and the LCDR3 comprises an amino acid sequence of QQFKSYPLT (SEQ ID NO: 22). In some embodiments, the CDRs comprise 1, 2, 3, or more amino acid substitutions.

[0179] In some embodiments, the HCDR1 comprises an ammo acid sequence of LTYIH (SEQ ID NO: 7), the HCDR2 comprises an amino acid sequence of WFFPGSGNIKYNEKFKG (SEQ ID NO: 2), the HCDR3 comprises an amino acid sequence of SYYSYDVLDY (SEQ ID NO: 3), the LCDR1 comprises an amino acid sequence of KASQNVGINVV (SEQ ID NO: 4), the LCDR2 comprises an ammo acid sequence of SSSHRYS (SEQ ID NO: 5), and the LCDR3 comprises an amino acid sequence of QQFKSYPLT (SEQ ID NO: 6). In some embodiments, the CDRs comprise 1, 2, 3, or more amino acid substitutions.

[0180] In some embodiments, the HCDR1 comprises an amino acid sequence of LTYIH (SEQ ID NO: 7), the HCDR2 comprises an amino acid sequence of RVSAGSGNVKYNEKFKG (SEQ ID NO: 8), the HCDR3 comprises an amino acid sequence of SYYSYDVLDY (SEQ ID NO: 3), the LCDR1 comprises an amino acid sequence of KASQNVADRVV (SEQ ID NO: 9), the LCDR2 comprises an amino acid sequence of SSSHRYK (SEQ ID NO: 10), and the LCDR3 comprises anAttorney Docket No. JANX-004 / 05WO 339516-2027 ammo acid sequence of QQFKSYPLT (SEQ ID NO: 6). In some embodiments, the CDRs comprise 1, 2, 3, or more amino acid substitutions.

[0181] In some embodiments, the HCDR1 comprises an amino acid sequence of LYYIH (SEQ ID NO: 1138), the HCDR2 comprises an amino acid sequence of WFFPGSGNIKYNEKFKG (SEQ ID NO: 2), the HCDR3 comprises an amino acid sequence of SYYSFDVLDY (SEQ ID NO: 1139), the LCDR1 comprises an amino acid sequence of KASQNVGIRVV (SEQ ID NO: 1140), the LCDR2 comprises an ammo acid sequence of SSSHRYS (SEQ ID NO: 5), and the LCDR3 comprises an amino acid sequence of QQFKSYPIT (SEQ ID NO: 1141). In some embodiments, the CDRs comprise 1, 2, 3, or more amino acid substitutions.

[0182] In some embodiments, the HCDRl comprises an ammo acid sequence of TYYIH (SEQ ID NO: 1), the HCDR2 comprises an amino acid sequence of WFFPRSGNIKYNEKFKG (SEQ ID NO: 1142), the HCDR3 comprises an amino acid sequence of SYYSFDVLDY (SEQ ID NO: 1139), the LCDR1 comprises an amino acid sequence of KASQNVGIRW (SEQ ID NO: 1140), the LCDR2 comprises an amino acid sequence of SSSHRYS (SEQ ID NO: 5), and the LCDR3 comprises an amino acid sequence of QQFKSYPIT (SEQ ID NO: 1141). In some embodiments, the CDRs comprise 1, 2, 3, or more amino acid substitutions.

[0183] In some embodiments, the HCDRl comprises an amino acid sequence of GYSFTTYY (SEQ ID NO: 17), the HCDR2 comprises an amino acid sequence of FFPGSGNI (SEQ ID NO: 18), the HCDR3 comprises an amino acid sequence of AGSYYSYDVLDY (SEQ ID NO: 19), the LCDR1 comprises an amino acid sequence of QNVGIN (SEQ ID NO: 20), the LCDR2 comprises an ammo acid sequence of SSS, and the LCDR3 comprises an amino acid sequence of QQFKSYPLT (SEQ ID NO: 22). In some embodiments, the CDRs comprise 1, 2, 3, or more amino acid substitutions.

[0184] In some embodiments, the HCDRl comprises an ammo acid sequence of GYSFRLTY (SEQ ID NO: 23), the HCDR2 comprises an amino acid sequence of FFPGSGNI (SEQ ID NO: 18), the HCDR3 comprises an amino acid sequence of AGSYYSYDVLDY (SEQ ID NO: 19), the LCDR1 comprises an ammo acid sequence of QNVGIN (SEQ ID NO: 20), the LCDR2 comprises an amino acid sequence of SSS, and the LCDR3 comprises an ammo acid sequence of QQFKSYPLT (SEQ ID NO: 22). In some embodiments, the CDRs comprise 1, 2, 3, or more amino acid substitutions.

[0185] In some embodiments, the HCDRl comprises an ammo acid sequence of GHDFRLTY (SEQ ID NO: 24), the HCDR2 comprises an amino acid sequence of VSAGSGNV (SEQ ID NO:Attorney Docket No. JANX-004 / 05WO 339516-2027 25), the HCDR3 comprises an amino acid sequence of / XVSYYSYDVLDY (SEQ ID NO: 26), the LCDR1 comprises an amino acid sequence of Q NV ADR (SEQ ID NO: 27), the LCDR2 comprises an amino acid sequence of SSS, and the LCDR3 comprises an ammo acid sequence of QQFKSYPLT (SEQ ID NO: 22). In some embodiments, the CDRs comprise 1, 2, 3, or more amino acid substitutions.

[0186] In some embodiments, the HCDRl comprises an amino acid sequence of GYSFTLYY (SEQ ID NO: 1143), the I ICDR2 comprises an amino acid sequence of FFPGSGNI (SEQ ID NO: 18), the HCDR3 comprises an amino acid sequence of AASYYSFDVLDY (SEQ ID NO: 1144), the LCDR1 comprises an amino acid sequence of QNVGIR (SEQ ID NO: 1145), the LCDR2 comprises an amino acid sequence of SSS, and the LCDR3 comprises an ammo acid sequence of QQFKSYPIT (SEQ ID NO: 1146). In some embodiments, the CDRs comprise 1, 2, 3, or more amino acid substitutions.

[0187] In some embodiments, the HCDRl comprises an ammo acid sequence of GYSFTTYY (SEQ ID NO: 17), the HCDR2 comprises an amino acid sequence of FFPRSGNI (SEQ ID NO: 1147), the HCDR3 comprises an amino acid sequence of AASYYSFDVLDY (SEQ ID NO: 1144), the LCDR1 comprises an amino acid sequence of QNVGIR (SEQ ID NO: 1145), the LCDR2 comprises an ammo acid sequence of SSS, and the LCDR3 comprises an amino acid sequence of QQFKSYPIT (SEQ ID NO: 1146). In some embodiments, the CDRs comprise 1, 2, 3, or more amino acid substitutions.

[0188] In some embodiments, the HCDRl comprises an amino acid sequence of NFGMH (SEQ ID NO: 11), the HCDR2 comprises an ammo acid sequence of YISSGSSTIYYADTLKG (SEQ ID NO: 12), the HCDR3 comprises an amino acid sequence of RGEGAMDY (SEQ ID NO: 13), the LCDR1 comprises an amino acid sequence of RASSSVNYIY (SEQ ID NO: 14), the LCDR2 comprises an amino acid sequence of YTSNLAP (SEQ ID NO: 15), and the LCDR3 comprises an amino acid sequence of QQFTSSPFT (SEQ ID NO: 16). In some embodiments, the CDRs comprise 1, 2, 3, or more amino acid substitutions.

[0189] In some embodiments, the HCDRl comprises an ammo acid sequence of NFGMH (SEQ ID NO: 11), the HCDR2 comprises an amino acid sequence of YISSGSSTIYYADTLKG (SEQ ID NO: 12), the HCDR3 comprises an ammo acid sequence of RGEGAMDY (SEQ ID NO: 13), the LCDRl comprises an amino acid sequence of RASQSVNYIY (SEQ ID NO: 223), the LCDR2 comprises an ammo acid sequence of YTSNLAP (SEQ ID NO: 15), and the LCDR3 comprises anAttorney Docket No. JANX-004 / 05WO 339516-2027 ammo acid sequence of QQYTSSPFT (SEQ ID NO: 224). In some embodiments, the CDRs comprise 1, 2, 3, or more amino acid substitutions.

[0190] In some embodiments, the I ICDRl comprises an amino acid sequence of NFGMH (SEQ ID NO: 11), the FICDR2 comprises an ammo acid sequence of YISSGSSTIYYADTLKG (SEQ ID NO: 12), the IICDR3 comprises an amino acid sequence of RGEGAMDY (SEQ ID NO: 13), the LCDRl comprises an amino acid sequence of R / XSQSVNYLY (SEQ ID NO: 225), the LCDR2 comprises an amino acid sequence of YTSNLAP (SEQ ID NO: 15), and the LCDR3 comprises an amino acid sequence of QQYTSSPFT (SEQ ID NO: 224). In some embodiments, the CDRs comprise 1, 2, 3, or more amino acid substitutions.

[0191] In some embodiments, the HCDR1 comprises an amino acid sequence of NYGMH (SEQ ID NO: 221), the HCDR2 comprises an ammo acid sequence of YISSGSSTIYYADALKG (SEQ ID NO: 222), the HCDR3 comprises an amino acid sequence of RGEGAMDY (SEQ ID NO: 13), the LCDRl comprises an amino acid sequence of RASQSVNYLY (SEQ ID NO: 225), the LCDR2 comprises an ammo acid sequence of YTSNLAP (SEQ ID NO: 15), and the LCDR3 comprises an amino acid sequence of QQYTSSPFT (SEQ ID NO: 224). In some embodiments, the CDRs comprise 1, 2, 3, or more amino acid substitutions.

[0192] In some embodiments, the HCDR1 comprises an amino acid sequence of SAYMH (SEQ ID NO: 228), the HCDR2 comprises an amino acid sequence of RIDPATGKTKYAPKFQA (SEQ ID NO: 229), the HCDR3 comprises an amino acid sequence of SLNWDYGLDY (SEQ ID NO: 230), the LCDRl comprises an ammo acid sequence of RASKS VSILGTHLIH (SEQ ID NO: 2 1), the LCDR2 comprises an ammo acid sequence of AASNLES (SEQ ID NO: 232), and the LCDR3 comprises an ammo acid sequence of QQSIEDPWT (SEQ ID NO: 233). In some embodiments, the CDRs comprise 1, 2, 3, or more amino acid substitutions.

[0193] In some embodiments, the HCDR1 comprises an amino acid sequence of GFTFSNFG (SEQ ID NO: 28), the HCDR2 comprises an ammo acid sequence of ISSGSSTI (SEQ ID NO: 29), the HCDR3 comprises an amino acid sequence of ARRGEGAMDY (SEQ ID NO: 30), the LCDRl comprises an ammo acid sequence of SSVNY (SEQ ID NO: 31), the LCDR2 comprises an amino acid sequence of YTS, and the LCDR3 comprises an amino acid sequence of QQFTSSPFT (SEQ ID NO: 33). In some embodiments, the CDRs comprise 1, 2, 3, or more amino acid substitutions.

[0194] In some embodiments, the HCDR1 comprises an amino acid sequence of GFTFSNFG (SEQ ID NO: 28), the FICDR2 comprises an ammo acid sequence of ISSGSSTI (SEQ ID NO: 29), the IICDR3 comprises an ammo acid sequence of / XRRGEG / XMDY (SEQ ID NO: 30), the LCDRlAttorney Docket No. JANX-004 / 05WO 339516-2027 comprises an ammo acid sequence of QSVNY (SEQ ID NO: 227), the LCDR2 comprises an ammo acid sequence of YTS, and the LCDR3 comprises an amino acid sequence of QQYTSSPFT (SEQ ID NO: 224). In some embodiments, the CDRs comprise 1, 2, 3, or more amino acid substitutions.

[0195] In some embodiments, the IICDRl comprises an amino acid sequence of GFTFSNYG (SEQ ID NO: 226), the IICDR2 comprises an ammo acid sequence of ISSGSSTI (SEQ ID NO: 29), the HCDR3 comprises an amino acid sequence of ARRGEGAMDY (SEQ ID NO: 30), the LCDRl comprises an ammo acid sequence of QSVNY (SEQ ID NO: 227), the LCDR2 comprises an ammo acid sequence of YTS, and the LCDR3 comprises an amino acid sequence of QQYTSSPFT (SEQ ID NO: 224). In some embodiments, the CDRs comprise 1, 2, 3, or more amino acid substitutions.

[0196] In some embodiments, the HCDRl comprises an ammo acid sequence of GFNIKSAY (SEQ ID NO: 234), the HCDR2 comprises an amino acid sequence of IDPATGKT (SEQ ID NO: 235), the HCDR3 comprises an amino acid sequence of TRSLNWDYGLDY (SEQ ID NO: 236), the LCDRl comprises an amino acid sequence of KSVSILGTHL (SEQ ID NO: 237), the LCDR2 comprises an amino acid sequence of AAS, and the LCDR3 comprises an amino acid sequence of QQSIEDPWT (SEQ ID NO: 239). In some embodiments, the CDRs comprise 1, 2, 3, or more amino acid substitutions.

[0197] In some embodiments, the VH region of the TCRpV-binding domain is the VH region of an IgA, IgD, IgE, IgG, or IgM. In some embodiments, the VH region of the TCRPV -binding domain is the VH region of a subclass of an IgA, IgD, IgE, IgG, or IgM, such as, e.g., IgGi, IgG>, lgG.< IgG4, IgAi, and Ig 2. In some embodiments, the VL region of the TCRpV-binding domain is the VL region of a kappa light chain. In some embodiments, the VL region of the TCRpV-binding domain is the VL region of a lambda light chain.

[0198] Exemplary anti-TCRpV VHs and VLs are provided in Table 3.Table 3. TRBV VH and VLTarget VH VLDescriptionTRBV6-5 QVQLVQSGAEVKKPGSSVKVSCK DIQMTQ SPSFLS A S VGDRVTITCK ASGYSFTTYYII IWVRQAPGQGLE ASQNVGINVVWI IQQKPGKAPKA WMGWFFPGSGNIKYNEKFKGRV LIYSSSI IRYSGVPSRFSGSGSGTEF TITADTSTSTAYMELSSLRSEDTA TLTISSLQPEDFATYFCQQFKSYPL VYYCAGSYYSYDVLDYWGQGTT TFGQGTKLEIK (SEQ ID NO: 35) VTVSS (SEQ ID NO: 34)TRBV6-5 QVQLVQSGAEVKKPGASVKVSC DIQMTQ SPSFLS AS VGDRVTITCK KASGYSFTTYYIHWVRQAPGQGL ASQNVGINVVWHQQKPGKAPKAEWMGWFFPGSGNIKYNEKFKGR LIYSSSHRYSGVPSRFSGSGSGTEFAttorney Docket No. JANX-004 / 05WO 339516-2027 Target ATI VLDescriptionVTITADTSTSTAYMELSSLRSEDT TLTISSLQPEDFATYFCQQFKSYPL AVYYCAGSYYSYDVLDYWGQGT TFGQGTKLEIK (SEQ ID NO: 35) LVTVSS (SEQ ID NO: 36)TRBV6-5 QVQLVQSGAEVKKPGSSVKVSCK DIQMTQ SPSFLS AS VGDRVTITCK ASGYSFRLTYIHWVRQAPGQGLE ASQNVGINVVWHQQKPGKAPKA WMGWFFPGSGNIKYNEKFKGRV LIYSSSHRYSGVPSRFSGSGSGTEF TITADTSTSTAYMELSSLRSEDTA TLTISSLQPEDFATYFCQQFKSYPL VYYCAGSYYSYDVLDYWGQGTT TFGQGTKLEIK (SEQ ID NO: 35) VTVSS (SEQ ID NO: 37)TRBV6-5 QVQLVQSGAEVKKPGSSVKVSCK DIQMTQ SPSFLS AS VGDRVTITCK ASGHDFRLTYIHWVRQAPGQGLE ASQNVADRVVWHQQKPGKAPKA WMGRVSAGSGNVKYNEKFKGRV LIYSSSHRYKGVPSRFSGSGSGTEF TITADTSTSTAYMELSSLRSEDTA TLTISSLQPEDFATYFCQQFKSYPL V YYC AV S YYS YD VLD YWGQGTT TFGQGTKLEIK (SEQ ID NO: 39) VTVSS (SEQ ID NO: 38)TRBV6-5 QVQLVQSGAEVKKPGSSVKVSCK DIQMTQ SPSFLS AS VGDRVTITCK ASGYSFTTYYIHWVRQAPGQGLE ASQNVGINVVWHQQKPGKAPKA WMGWFFPGSGNIKYNEKFKGRV LIYSSSHRYSGVPSRFSGSGSGTEF TITADTSTSTAYMELSSLRSEDTA TLTISSLQPEDFATYFCQQFKSYPL V YYC AGS YYS YD VLD YWGQGTT TFGQGTKLEIK (SEQ ID NO: 1001) VTVSS (SEQ ID NO: 1009)TRBV6-5 QVQLVQSGAEVKKPGASVKVSC DIQMTQ SPSFLS AS VGDRVTITCK KASGYSFTTYYIHWVRQAPGQGL ASQNVGINVVWHQQKPGKAPKA EWMGWFFPGSGNIKYNEKFKGR LIYSSSHRYSGVPSRFSGSGSGTEF VTITADTSTSTAYMELSSLRSEDT TLTISSLQPEDFATYFCQQFKSYPL AVYYCAGSYYSYDVLDYWGQGT TFGQGTKLEIK (SEQ ID NO: 1002) LVTVSS (SEQ ID NO: 1010)TRBV6-5 QVQLVQSGAEVKKPGASVKVSC DI QMTQ S PSFLS / X S VGDRVTITCK KASGYSFTTYYIHWVRQAPGQGL ASQNVGNNVAWYQQKPGKAPKL EWMGWIFPGSGNIKYNEKFKGRV LIYSSSHRYSGVPSRFSGSGSGTEF TITADTSTSTAYMELSSLRSEDTA FLITS SLQPEDF ATYFCQQFKS YPL V YYC AGS YYS YD VLD YWGQGTL TFGQGTKLEIK (SEQ ID NO: 1003) VTVSS (SEQ ID NO: 1011)TRBV6-5 QVQLVQSGAEVKKPGASVKVSC DIQMTQ SPS SLS A S VGDRVTITCK KASGYSFTTYYIHWVRQAPGQGL ASQNVGINVVWYQQKPGKAPKL EWMGWIYPGS GNIKYNEKFKGR LIYSSSHRYSGVPSRFSGSGSGTEF VTITADTSTSTAYMELSSLRSEDT TLTISSLQPEDFATYYCQQFKSYP AVYYCAGSYYSYDVLDYWGQGT LTFGQGTKLEIK (SEQ ID NO:LVTVSS (SEQ ID NO: 1012) 1004)TRBV6-5 QVQLVQSGAEVKKPGASVKVSC DIQMTQ SPS SLS AS VGDRVTITCK KASGYSFTTYYIHWVRQAPGQGL ASQNVGNNVAWYQQKPGKAPKL EWMGWI YPGS GNIKYNEKFKGR LIYSSSHRYSGVPSRFSGSGSGTEF VTITADTSTSTAYMELSSLRSEDT TLHSSLQPEDFATYYCQQFKSYP AVYYCARSYYSYDVLDYWGQGT LTFGQGTKLEIK (SEQ ID NO:LVTVSS (SEQ ID NO: 1013) 1005)Attorney Docket No. JANX-004 / 05WO 339516-2027 Target ATI VLDescriptionTRBV6-5 QVQLVQSGAEVKKPGASVKVSC DIQMTQSPSSLSASVGDRVTITCR KASGYSFTTYYITIWVRQAPGQGL ASQNVGNNVAWYQQKPGKAPKL EWMGWIYPGSGNIKYNEKFKGR LIYSSSHRYSGVPSRFSGSGSGTEF VTITADTSTSTAYMELSSLRSEDT TLTI S SLQPEDF ATYYCQQFKS YP AVYYCARSYYSYDVLDYWGQGT LTFGQGTKLEIK (SEQ ID NO:L VTVSS (SEQ ID NO: 1014) 1006)TRBV6-5 QVQLVQSGAEVKKPGSSVKVSCK DIQMTQ SPSFLS AS VGDRVTITCK ASGYSFRLTYIHWVRQAPGQGLE ASQNVGINVVWHQQKPGKAPKA WMGWFFPGSGNIKYNEKFKGRV LIYSSSHRYSGVPSRFSGSGSGTEF TITADTSTSTAYMELSSLRSEDTA TLTISSLQPEDFATYFCQQFKSYPL VYYC A GS YYS YD VLD YWGQGTT TFGQGTKLEIK (SEQ ID NO: 1007) VTVSS (SEQ ID NO: 1015)TRBV6-5 QVQLVQSGAEVKKPGSSVKVSCK DIQMTQ SPSFLS AS VGDRVTITCK ASGHDFRLTYIHWVRQAPGQGLE ASQNVADRVVWHQQKPGKAPKA WMGRVSAGSGNVKYNEKFKGRV LIYSSSHRYKGVPSRFSGSGSGTEF TITADTSTSTAYMELSSLRSEDTA TLTISSLQPEDFATYFCQQFKSYPL VYYC AV S YYS YD VLD YWGQGTT TFGQGTKLEIK (SEQ ID NO: 1008) VTVSS (SEQ ID NO: 1016)TRBV6-5 QVQLVQSGAEVKKPGSSVKVSCK DIQMTQ SPSFLS AS VGDRVTITCK ASGYSFTLYYIHWVRQAPGQGLE ASQNVGIRVVWHQQKPGKAPKA WMGWFFPGSGNIKYNEKFKGRV LIYSSSHRYSGVPSRFSGSGSGTEF TITADTSTSTAYMELSSLRSEDTA TLTISSLQPEDFATYFCQQFKSYPI V YYC AA S YYS FD VLD YWGQGTT TFGQGTKLEIK (SEQ ID NO: 1149) VTVSS (SEQ ID NO: 1148)TRBV6-5 QVQLVQSGAEVKKPGSSVKVSCK DIQMTQ SPSFLS AS VGDRVTITCK ASGYSFTTYYIHWVRQAPGQGLE ASQNVGIRVVWHQQKPGKAPKA WMGWFFPRSGNIKYNEKFKGRV LIYSSSHRYSGVPSRFSGSGSGTEF TITADTSTSTAYMELSSLRSEDTA TLTISSLQPEDFATYFCQQFKSYPI VYYC AA S YYSFDVLD YWGQGTT TFGQGTKLEIK (SEQ ID NO: 1149) VTVSS (SEQ ID NO: 1150)TRBV6-5 QVQLVQSGAEVKKPGSSVKVSCK DIQMTQSPSFLSASVGDRVTITCK ASGYSFTLYYIHWVRQAPGQCLE ASQNVGIRVVWHQQKPGKAPKA WMGWFFPGSGNIKYNEKFKGRV LIYSSSHRYSGVPSRFSGSGSGTEF TITADTSTSTAYMELSSLRSEDTA T'LTIS SLQPEDF ATYFCQQFKS YPI V YYC AAS YYSFDVLD YWGQGTT TFGCGTKLE1K (SEQ ID NO: 1192) VTVSS (SEQ ID NO: 1190)TRBV6-5 QVQLVQSGAEVKKPGSSVKVSCK DIQMTQ SPSFLS A S VGDRVTITCK ASGYSFTTYYIHWVRQAPGQGLE ASQNVGIRVVWHQQKPGKAPKA WMGWFFPRSGNIKYNEKFKGRV LIYSSSHRYSGVPSRFSGSGSGTEF TITADTSTSTAYMELSSLRSEDTA. TLTISSLQPEDFATYFCQQFKSYPI VYYC A AS YYSFDVLD YWGQGTT TFGCGTKLEIK (SEQ ID NO: 1192) VTVSS (SEQ ID NO: 1191)TRB VI 2-3 / 4 EVQLVESGGGLVQPGGSLRLSCA DNQLTQSPSFLSASVGDRVHTCR ASGFTFSNFGMHWVRQAPGKGL AS S S VNYIYWYQQKPGKAPKLLI EWVSYISSGSSTIYYADTLKGRFTI YYTSNLAPGVPSRFSGSGSGNEYTSRDNSKNTLYLQMNSLRAEDTAVAttorney Docket No. JANX-004 / 05WO 339516-2027 Target ATI VLDescriptionYYCARRGEGAMDYWGQGTTVT LTISSLQPEDFATYYCQQFTSSPFT VSS (SEQ ID NO: 40) FGQGTKLEIK (SEQ ID NO: 41) TRB VI 2-3 / 4 EVQLVESGGGLVQPGGSLRLSCA DNQLTQSPSFLSASVGDRVHTCR ASGFTFSNFGMHWVRQAPGKGL AS S S VNYIYWYQQKPGKAPKLLI EWVSYISSGSSTIYYADTLKGRFTI YYTSNLAPGVPSRFSGSGSGNEYT SRDNSKNTLYLQMNSLRAEDTAV LTISSLQPEDFATYYCQQFTSSPFT YYCARRGEGAMDYWGQGTLVT FGQGTKLEIK (SEQ ID NO: 41) VSS (SEQ ID NO: 42)TRBV12-3 / 4 EVQLVESGGGLVQPGGSLRLSCA DNQLTQSPSFLSASVGDRVHTCR ASGFTFSNFGMHWVRQAPGKGL AS S S VNYIYWYQQKPGKAPKLLI EWVSYISSGSSTIYYADTLKGRFTI YYTSNLAPGVPSRFSGSGSGNEYT SRDNSKNTLYLQMNSLRAEDTAV LTISSLQPEDFATYYCQQFTSSPFT YYCARRGEGAMDYWGQGTTVT FGQGTKLEIK (SEQ ID NO: 1087) VSS (SEQ ID NO: 1093)TRBV12-3 / 4 EVQLVESGGGLVQPGGSLRLSCA DNQLTQSPSFLSASVGDRVTITCR ASGFTFSNFGMHWVRQAPGKGL AS S S VNYIYWYQQKPGKAPKLLI EWVSYISSGSSTIYYADTLKGRFTI YYTSNLAPGVPSRFSGSGSGNEYT SRDNSKNTLYLQMNSLRAEDTAV LTISSLQPEDFATYYCQQFTSSPFT YYCARRGEGAMDYWGQGTLVT FGQGTKLEIK (SEQ ID NO: 1088) VSS (SEQ ID NO: 1094)TRBV 12-3 / 4 EVQLVESGGGLVQPGGSLRLSCA DIQLTQSPSFLSASVGDRVHTCRA ASGFTFSNFGMHWVRQAPGKGL S S S VNYI YWYQQKPGKAPKLLI Y EWVSYISSGSSTIYYADTLKGRFTI YTSNLAPGVPSRFSGSGSGTEFTL SRDNSKNTLYLQMNSLRAEDTAV TISSLQPEDFATYYCQQYTSSPFTF YYCARRGEGAMDYWGQGTLVT GQGTKLEIK (SEQ ID NO: 1089) VSS (SEQ ID NO: 1095)TRB VI 2-3 / 4 EVQLVESGGGLVQPGGSLRLSCA DIQLTQSPSFLSASVGDRVTITCRA ASGFTFSNFGMHWVRQAPGKGL SQSVNYIYWYQQKPGKAPKLLIY EWVSYISSGSSTIYYADTLKGRFTI YTSNLAPGVPSRFSGSGSGTEFTL SRDNSKNTLYLQMNSLRAEDTAV TIS SLQPEDF ATYYCQQ YTS SPFTF YYC ARRGEGAMD YWGQGTI VT GQGTKLEIK (SEQ ID NO: 1090) VSS (SEQ ID NO: 1096)TRBV12-3 / 4 EVQLVESGGGLVQPGGSLRLSCA DIQLTQSPSFLSASVGDRVHTCRA ASGFTFSNFGMHWVRQAPGKGL SQSVNYLYWYQQKPGKAPKLLIY EWVSYISSGSSTIYYADTLKGRFTI YTSNLAPGVPSRFSGSGSGTEFTL SRDNSKNTLYLQMNSLRAEDTAV TISSLQPEDFATYYCQQYTSSPFTF YYCARRGEGAMDYWGQGTLVT GQGTKLEIK (SEQ ID NO: 1091) VSS (SEQ ID NO: 1097)TRBV12-3 / 4 EVQLVESGGGLVQPGGSLRLSCA DIQLTQSPSFLSASVGDRVHTCRA ASGFTFSNYGMHWVRQAPGKGL SQSVNYLYWYQQKPGKAPKLLIY EWVSYISSGSSTIYYADALKGRFT YTSNLAPGVPSRFSGSGSGTEFTL I SRDNSKNTLYLQMN S LRAEDT A TISSLQPEDFATYYCQQYTSSPFTF GQGTKLEIK (SEQ ID NO: 1092)Attorney Docket No. JANX-004 / 05WO 339516-2027 Target ATI VLDescriptionVYYCARRGEGAMDYWGQGTLV TVSS (SEQ ID NO: 1098)TRBV20-1 DIVLTQSPASLAVSLGQRATISCR EVQLQQSVADLVRPGASLKLSCT ASKSVSILGTHLIHWYQQKPGQPP ASGFNIKSAYMHWVIQRPDQGPE KLLIYAASNLESGVPARFSGSGSE CLGRIDPATGKTKYAPKFQAKATI TVFTLNIHPVEEEDAATYFCQQSI TADTSSNTAYLQLSSLTSEDTAIY EDPWTFGGGTKLGIK YCTRSLNWDYGLDYWGQGTSVT(SEQ ID NO: 241)VSS (SEQ ID NO: 240)

[0199] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of SEQ ID NOs: 34, 36.37.38, 40, 42, 240, 1009-1016, 1093-1098, 1148, 1150, 1190, and 1191. In some embodiments, the VH region comprises or consists of an amino acid sequence of any one of SEQ ID NOs: 34, 36, 37.38, 40, 42, 240, 1009-1016, 1093-1098, 1148, 1150, 1190, and 1191.

[0200] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of SEQ ID NOs: 34, 36, 37, 38, 40, 42, 240, 1009-1016, 1093-1098, 1148, and 1150 and comprises a cysteine residue at amino acid position 44. In some embodiments, the VH region comprises or consists of an amino acid sequence of any one of SEQ ID NOs: 34, 36, 37, 38, 40, 42, 240, 1009-1016, 1093-1098, 1148, and 1150 and comprises a cysteine substitution at amino acid position 44.

[0201] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of SEQ ID NOs: 34, 36, 37, 38, 40, 42, 240, 1009-1016, 1093-1098, 1148, and 1150 and comprises a cysteine residue at ammo acid position 100. In some embodiments, the VH region comprises or consists of an ammo acid sequence of any one of SEQ ID NOs: 34, 36, 37, 38, 40, 42, 240, 1009-1016, 1093-1098, 1148, and 1150 and comprises a cysteine substitution at ammo acid position 100,

[0202] In some embodiments, the AHI region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of SEQ ID NOs: 34, 36, 37, 38, 40, 42, 240, 1009-1016, 1093-1098, 1148, and 1150 and comprises a cysteine residue atAttorney Docket No. JANX-004 / 05WO 339516-2027 ammo acid position I00B. In some embodiments, the VI I region comprises or consists of an ammo acid sequence of any one ofSEQ ID NOs: 34, 36, 37, 38, 40, 42, 240, 1009-1016, 1093-1098, 1148, and 1150 and comprises a cysteine substitution at ammo acid position 100B.

[0203] In some embodiments, the VI I region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of SEQ ID NOs: 34, 36, 37, 38, 40, 42, 240, 1009-1016, 1093-1098, 1148, and 1150 and comprises a cysteine residue at amino acid position 101. In some embodiments, the VH region comprises or consists of an amino acid sequence of any one ofSEQ ID NOs: 34, 36, 37, 38, 40, 42, 240, 1009-1016, 1093-1098, 1148, and 1150 and comprises a cysteine substitution at amino acid position 101.

[0204] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of SEQ ID NOs: 34, 36, 37, 38, 40, 42, 240, 1009-1016, 1093-1098, 1148, and 1150 and comprises a cysteine residue at amino acid position 105. In some embodiments, the VH region comprises or consists of an amino acid sequence of any one of SEQ ID NOs: 34, 36, 37, 38, 40, 42, 240, 1009-1016, 1093-1098, 1148, and 1150 and comprises a cysteine substitution at ammo acid position 105.

[0205] In some embodiments, the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of SEQ ID NOs: 35, 39, 41, 241, 1001-1008, 1087-1092, 1149, and 1192. In some embodiments, the VI., region comprises or consists of an amino acid sequence of any one of SEQ ID NOs: 35, 39, 41, 241, 1001 -1008, 1087-1092, 1149, and 1192.

[0206] In some embodiments, the VI., region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of SEQ ID NOs: 35, 39, 41, 241, 1001-1008, 1087-1092, and 1149 and comprises a cysteine residue at ammo acid position 100. In some embodiments, the VL region comprises or consists of an amino acid sequence of any one of SEQ ID NOs: 35, 39, 41, 241, 1001-1008, 1087-1092, and 1149 and comprises a cysteine substitution at amino acid position 100.

[0207] In some embodiments, the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%,Attorney Docket No. JANX-004 / 05WO 339516-2027 at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of SEQ ID NOs: 35, 39, 41, 241, 1001-1008, 1087-1092, and 1149 and comprises a cysteine residue at ammo acid position 49. In some embodiments, the VL region comprises or consists of an ammo acid sequence of any one of SEQ ID NOs: 35, 39, 41, 241, 1001-1008, 1087-1092, and 1149 and comprises a cysteine substitution at amino acid position 49.

[0208] In some embodiments, the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of SEQ ID NOs: 35, 39, 41, 241, 1001-1008, and 1087-1092, and 1149 and comprises a cysteine residue at amino acid position 50. In some embodiments, the VL region comprises or consists of an amino acid sequence of any one of SEQ ID NOs: 35, 39, 41, 241, 1001-1008, 1087-1092, and 1149 and comprises a cysteine substitution at ammo acid position 50.

[0209] In some embodiments, the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of SEQ ID NOs: 35, 39, 41, 241, 1001-1008, and 1087-1092, and 1149 and comprises a cysteine residue at amino acid position 46. In some embodiments, the VL region comprises or consists of an amino acid sequence of any one of SEQ ID NOs: 35, 39, 41, 241, 1001-1008, 1087-1092, and 1149 and comprises a cysteine substitution at amino acid position 46.

[0210] In some embodiments, the VL. region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any one of SEQ ID NOs: 35, 39, 41, 241, 1001-1008, 1087-1092, and 1149 and comprises a cysteine residue at amino acid position 43. In some embodiments, the VL region comprises or consists of an ammo acid sequence of any one of SEQ ID NOs: 35, 39, 41, 241, 1001-1008, 1087-1092, and 1149 and comprises a cysteine substitution at amino acid position 43,

[0211] In some embodiments, the VI I region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 34, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 35.Attorney Docket No. JANX-004 / 05WO 339516-2027

[0212] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 34 and comprises a cysteine residue at amino acid position 44, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 35 and comprises a cysteine residue at amino acid position 100.

[0213] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 34 and comprises a cysteine residue at amino acid position 100B, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 35 and comprises a cysteine residue at amino acid position 49.

[0214] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 34 and comprises a cysteine residue at amino acid position 100, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 35 and comprises a cysteine residue at amino acid position 50.

[0215] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 34 and comprises a cysteine residue at amino acid position 101, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 35 and comprises a cysteine residue at amino acid position 46.

[0216] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 34 and comprises a cysteine residue at ammo acid position 105, and the VL region comprises an ammo acid sequenceAttorney Docket No. JANX-004 / 05WO 339516-2027 that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 35 and comprises a cysteine residue at amino acid position 43.

[0217] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 36, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 35.

[0218] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 36 and comprises a cysteine residue at amino acid position 44, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 35 and comprises a cysteine residue at amino acid position 100.

[0219] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 36 and comprises a cysteine residue at amino acid position 100B, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 35 and comprises a cysteine residue at amino acid position 49.

[0220] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 36 and comprises a cysteine residue at amino acid position 100, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 35 and comprises a cysteine residue at amino acid position 50.

[0221] In some embodiments, the VI I region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%,Attorney Docket No. JANX-004 / 05WO 339516-2027 at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 36 and comprises a cysteine residue at amino acid position 101, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 35 and comprises a cysteine residue at amino acid position 46.

[0222] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 36 and comprises a cysteine residue at amino acid position 105, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 35 and comprises a cysteine residue at amino acid position 43.

[0223] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 37, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 35.

[0224] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 37 and comprises a cysteine residue at amino acid position 44, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 35 and comprises a cysteine residue at amino acid position 100.

[0225] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 37 and comprises a cysteine residue at amino acid position 100B, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 35 and comprises a cysteine residue at amino acid position 49.Attorney Docket No. JANX-004 / 05WO 339516-2027

[0226] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 37 and comprises a cysteine residue at amino acid position 100, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 35 and comprises a cysteine residue at amino acid position 50.

[0227] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 37 and comprises a cysteine residue at amino acid position 101, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 35 and comprises a cysteine residue at amino acid position 46.

[0228] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 37 and comprises a cysteine residue at amino acid position 105, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 35 and comprises a cysteine residue at amino acid position 43.

[0229] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 38, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 39.

[0230] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 38 and comprises a cysteine residue at amino acid position 44, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%,Attorney Docket No. JANX-004 / 05WO 339516-2027 at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 39 and comprises a cysteine residue at amino acid position 100.

[0231] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 38 and comprises a cysteine residue at amino acid position 100B, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 39 and comprises a cysteine residue at amino acid position 49.

[0232] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 38 and comprises a cysteine residue at amino acid position 100, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 39 and comprises a cysteine residue at amino acid position 50.

[0233] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 38 and comprises a cysteine residue at amino acid position 101, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 39 and comprises a cysteine residue at amino acid position 46.

[0234] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 38 and comprises a cysteine residue at amino acid position 105, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 39 and comprises a cysteine residue at amino acid position 43.

[0235] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%,Attorney Docket No. JANX-004 / 05WO 339516-2027 at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1148, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1149.

[0236] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1148 and comprises a cysteine residue at amino acid position 44, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1149 and comprises a cysteine residue at amino acid position 100.

[0237] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1148 and comprises a cysteine residue at amino acid position 100B, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1149 and comprises a cysteine residue at amino acid position 49.

[0238] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1148 and comprises a cysteine residue at amino acid position 100, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1149 and comprises a cysteine residue at amino acid position 50.

[0239] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1148 and comprises a cysteine residue at amino acid position 101, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1149 and comprises a cysteine residue at amino acid position 46.Attorney Docket No. JANX-004 / 05WO 339516-2027

[0240] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1148 and comprises a cysteine residue at amino acid position 105, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1149 and comprises a cysteine residue at amino acid position 43.

[0241] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1150, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1149.

[0242] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1150 and comprises a cysteine residue at amino acid position 44, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1149 and comprises a cysteine residue at amino acid position 100,

[0243] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1150 and comprises a cysteine residue at amino acid position 100B, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1149 and comprises a cysteine residue at amino acid position 49.

[0244] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1150 and comprises a cysteine residue at amino acid position 100, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%,Attorney Docket No. JANX-004 / 05WO 339516-2027 at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1149 and comprises a cysteine residue at amino acid position 50.

[0245] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1150 and comprises a cysteine residue at amino acid position 101, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1149 and comprises a cysteine residue at amino acid position 46.

[0246] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1150 and comprises a cysteine residue at amino acid position 105, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1149 and comprises a cysteine residue at amino acid position 43.

[0247] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1190, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1192,

[0248] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1191, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1192.

[0249] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 40, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at leastAttorney Docket No. JANX-004 / 05WO 339516-2027 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 41.

[0250] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 40 and comprises a cysteine residue at amino acid position 44, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 41 and comprises a cysteine residue at amino acid position 100.

[0251] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 40 and comprises a cysteine residue at amino acid position 100B, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 41 and comprises a cysteine residue at amino acid position 49.

[0252] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 40 and comprises a cysteine residue at amino acid position 100, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 41 and comprises a cysteine residue at amino acid position 50.

[0253] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 40 and comprises a cysteine residue at amino acid position 101, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 41 and comprises a cysteine residue at amino acid position 46.

[0254] In some embodiments, the VI I region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%,Attorney Docket No. JANX-004 / 05WO 339516-2027 at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 40 and comprises a cysteine residue at amino acid position 105, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 41 and comprises a cysteine residue at amino acid position 43.

[0255] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 42, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 41.

[0256] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 42 and comprises a cysteine residue at amino acid position 44, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 41 and comprises a cysteine residue at amino acid position 100.

[0257] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 42 and comprises a cysteine residue at amino acid position 100B, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 41 and comprises a cysteine residue at amino acid position 49.

[0258] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 42 and comprises a cysteine residue at amino acid position 100, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 41 and comprises a cysteine residue at amino acid position 50.Attorney Docket No. JANX-004 / 05WO 339516-2027

[0259] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 42 and comprises a cysteine residue at amino acid position 101, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 41 and comprises a cysteine residue at amino acid position 46.

[0260] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 42 and comprises a cysteine residue at amino acid position 105, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 41 and comprises a cysteine residue at amino acid position 43.

[0261] In some embodiments, the VH region comprises or consists of an amino acid sequence of SEQ ID NO: 34, and the VL region comprises or consists of an amino acid sequence of SEQ ID NO: 35.

[0262] In some embodiments, the VH region comprises an amino acid sequence of SEQ ID NO:34 with a cysteine substitution at amino acid position 44, and the VL region comprises an amino acid sequence of SEQ ID NO: 35 with a cysteine substitution at amino acid position 100.

[0263] In some embodiments, the VH region comprises an amino acid sequence of SEQ ID NO:34 with a cysteine substitution at amino acid position 100B, and the VL region comprises an amino acid sequence of SEQ ID NO: 35 with a cysteine substitution at amino acid position 49.

[0264] In some embodiments, the VH region comprises an amino acid sequence of SEQ ID NO:34 with a cysteine substitution at amino acid position 100, and the VL region comprises an amino acid sequence of SEQ ID NO: 35 with a cysteine substitution at amino acid position 50.

[0265] In some embodiments, the VH region comprises an ammo acid sequence of SEQ ID NO:34 with a cysteine substitution at amino acid position 101, and the VL region comprises an amino acid sequence of SEQ ID NO: 35 with a cysteine substitution at amino acid position 46.

[0266] In some embodiments, the VH region comprises an amino acid sequence of SEQ ID NO: 34 with a cysteine substitution at amino acid position 105, and the VL region comprises an amino acid sequence of SEQ ID NO: 35 with a cysteine substitution at amino acid position 43.Attorney Docket No. JANX-004 / 05WO 339516-2027

[0267] In some embodiments, the VH region comprises or consists of an amino acid sequence of SEQ ID NO: 36, and the VL region comprises or consists of an ammo acid sequence of SEQ ID NO: 35.

[0268] In some embodiments, the VH region comprises an ammo acid sequence of SEQ ID NO: 36 with a cysteine substitution at amino acid position 44, and the VL region comprises an amino acid sequence of SEQ ID NO: 35 with a cysteine substitution at ammo acid position 100.

[0269] In some embodiments, the VH region comprises an amino acid sequence of SEQ ID NO: 36 with a cysteine substitution at ammo acid position 100B, and the VL region comprises an amino acid sequence of SEQ ID NO: 35 with a cysteine substitution at amino acid position 49.

[0270] In some embodiments, the VH region comprises an ammo acid sequence of SEQ ID NO: 36 with a cysteine substitution at amino acid position 100, and the VL region comprises an amino acid sequence of SEQ ID NO: 35 with a cysteine substitution at ammo acid position 50.

[0271] In some embodiments, the VH region comprises an amino acid sequence of SEQ ID NO: 36 with a cysteine substitution at amino acid position 101, and the VL region comprises an amino acid sequence of SEQ ID NO: 35 with a cysteine substitution at amino acid position 46.

[0272] In some embodiments, the VH region comprises an amino acid sequence of SEQ ID NO: 36 with a cysteine substitution at amino acid position 105, and the VL region comprises an amino acid sequence of SEQ ID NO: 35 with a cysteine substitution at amino acid position 43.

[0273] In some embodiments, the VH region comprises or consists of an amino acid sequence of SEQ ID NO: 37, and the VL region comprises or consists of an amino acid sequence of SEQ ID NO: 35.

[0274] In some embodiments, the VH region comprises an amino acid sequence of SEQ ID NO: 37 with a cysteine substitution at amino acid position 44, and the VL region comprises an amino acid sequence of SEQ ID NO: 35 with a cysteine substitution at amino acid position 100.

[0275] In some embodiments, the VH region comprises an amino acid sequence of SEQ ID NO: 37 with a cysteine substitution at amino acid position 100B, and the VL region comprises an ammo acid sequence of SEQ ID NO: 35 with a cysteine substitution at ammo acid position 49.

[0276] In some embodiments, the VH region comprises an amino acid sequence of SEQ ID NO: 37 with a cysteine substitution at amino acid position 100, and the VL region comprises an amino acid sequence of SEQ ID NO: 35 with a cysteine substitution at amino acid position 50.Attorney Docket No. JANX-004 / 05WO 339516-2027

[0277] In some embodiments, the VI I region comprises an amino acid sequence of SEQ ID NO: 37 with a cysteine substitution at amino acid position 101, and the VL region comprises an amino acid sequence of SEQ ID NO: 35 with a cysteine substitution at amino acid position 46.

[0278] In some embodiments, the VII region comprises an ammo acid sequence of SEQ ID NO: 37 with a cysteine substitution at ammo acid position 105, and the VL region comprises an amino acid sequence of SEQ ID NO: 35 with a cysteine substitution at ammo acid position 43.

[0279] In some embodiments, the VI I region comprises or consists of an amino acid sequence of SEQ ID NO: 38, and the VL region comprises or consists of an ammo acid sequence of SEQ ID NO: 39.

[0280] In some embodiments, the VH region comprises an ammo acid sequence of SEQ ID NO:38 with a cysteine substitution at amino acid position 44, and the VL region comprises an amino acid sequence of SEQ ID NO: 39 with a cysteine substitution at ammo acid position 100.

[0281] In some embodiments, the VH region comprises an amino acid sequence of SEQ ID NO: 38 with a cysteine substitution at ammo acid position 100B, and the VL region comprises an amino acid sequence of SEQ ID NO: 39 with a cysteine substitution at amino acid position 49.

[0282] In some embodiments, the VH region comprises an amino acid sequence of SEQ ID NO: 38 with a cysteine substitution at amino acid position 100, and the VL region comprises an amino acid sequence of SEQ ID NO: 39 with a cysteine substitution at amino acid position 50.

[0283] In some embodiments, the VH region comprises an amino acid sequence of SEQ ID NO: 38 with a cysteine substitution at ammo acid position 101, and the VL region comprises an amino acid sequence of SEQ ID NO: 39 with a cysteine substitution at ammo acid position 46.

[0284] In some embodiments, the VH region comprises an amino acid sequence of SEQ ID NO: 38 with a cysteine substitution at amino acid position 105, and the VL region comprises an amino acid sequence of SEQ ID NO: 39 with a cysteine substitution at amino acid position 43.

[0285] In some embodiments, the VH region comprises or consists of an ammo acid sequence of SEQ ID NO: 1148, and the VL region comprises or consists of an ammo acid sequence of SEQ ID NO: 1149.

[0286] In some embodiments, the VH region comprises an amino acid sequence of SEQ ID NO: 1148 with a cysteine substitution at amino acid position 44, and the VL region comprises an amino acid sequence of SEQ ID NO: 1149 with a cysteine substitution at amino acid position 100.Attorney Docket No. JANX-004 / 05WO 339516-2027

[0287] In some embodiments, the VI I region comprises an amino acid sequence of SEQ ID NO: 1148 with a cysteine substitution at amino acid position 100B, and the VL region comprises an ammo acid sequence of SEQ ID NO: 1149 with a cysteine substitution at ammo acid position 49.

[0288] In some embodiments, the VII region comprises an ammo acid sequence of SEQ ID NO: 1148 with a cysteine substitution at ammo acid position 100, and the VL region comprises an amino acid sequence of SEQ ID NO: 1149 with a cysteine substitution at ammo acid position 50.

[0289] In some embodiments, the VI I region comprises an amino acid sequence of SEQ ID NO: 1148 with a cysteine substitution at amino acid position 101, and the VL region comprises an amino acid sequence of SEQ ID NO: 1149 with a cysteine substitution at amino acid position 46.

[0290] In some embodiments, the VH region comprises an ammo acid sequence of SEQ ID NO: 1148 with a cysteine substitution at ammo acid position 105, and the VL region comprises an amino acid sequence of SEQ ID NO: 1149 with a cysteine substitution at ammo acid position 43.

[0291] In some embodiments, the VH region comprises or consists of an amino acid sequence of SEQ ID NO: 1150, and the VL region comprises or consists of an amino acid sequence of SEQ ID NO: 1149.

[0292] In some embodiments, the VH region comprises an amino acid sequence of SEQ ID NO: 1150 with a cysteine substitution at amino acid position 44, and the VL region comprises an amino acid sequence of SEQ ID NO: 1149 with a cysteine substitution at ammo acid position 100.

[0293] In some embodiments, the VH region comprises an amino acid sequence of SEQ ID NO: 1150 with a cysteine substitution at ammo acid position I00B, and the VL region comprises an amino acid sequence of SEQ ID NO: 1149 with a cysteine substitution at amino acid position 49.

[0294] In some embodiments, the VH region comprises an amino acid sequence of SEQ ID NO: 1150 with a cysteine substitution at amino acid position 100, and the VL region comprises an amino acid sequence of SEQ ID NO: 1149 with a cysteine substitution at amino acid position 50.

[0295] In some embodiments, the VH region comprises an amino acid sequence of SEQ ID NO: 1150 with a cysteine substitution at ammo acid position 101, and the VL region comprises an amino acid sequence of SEQ ID NO: 1149 with a cysteine substitution at ammo acid position 46.

[0296] In some embodiments, the VI I region comprises an amino acid sequence of SEQ ID NO: 1150 with a cysteine substitution at amino acid position 105, and the VL region comprises an amino acid sequence of SEQ ID NO: 1149 with a cysteine substitution at amino acid position 43.Attorney Docket No. JANX-004 / 05WO 339516-2027

[0297] In some embodiments, the VH region comprises or consists of an amino acid sequence of SEQ ID NO: 40, and the VL region comprises or consists of an ammo acid sequence of SEQ ID NO: 41.

[0298] In some embodiments, the VH region comprises an ammo acid sequence of SEQ ID NO: 40 with a cysteine substitution at amino acid position 44, and the VL region comprises an amino acid sequence of SEQ ID NO: 41 with a cysteine substitution at ammo acid position 100.

[0299] In some embodiments, the VH region comprises an amino acid sequence of SEQ ID NO: 40 with a cysteine substitution at ammo acid position 100B, and the VL region comprises an amino acid sequence of SEQ ID NO: 41 with a cysteine substitution at amino acid position 49.

[0300] In some embodiments, the VH region comprises an ammo acid sequence of SEQ ID NO: 40 with a cysteine substitution at amino acid position 100, and the VL region comprises an amino acid sequence of SEQ ID NO: 41 with a cysteine substitution at ammo acid position 50.

[0301] In some embodiments, the VH region comprises an amino acid sequence of SEQ ID NO: 40 with a cysteine substitution at amino acid position 101, and the VL region comprises an amino acid sequence of SEQ ID NO: 41 with a cysteine substitution at amino acid position 46.

[0302] In some embodiments, the VH region comprises an amino acid sequence of SEQ ID NO: 40 with a cysteine substitution at amino acid position 105, and the VL region comprises an amino acid sequence of SEQ ID NO: 41 with a cysteine substitution at amino acid position 43.

[0303] In some embodiments, the VH region comprises or consists of an amino acid sequence of SEQ ID NO: 42, and the VL region comprises or consists of an amino acid sequence of SEQ ID NO: 41.

[0304] In some embodiments, the VH region comprises an amino acid sequence of SEQ ID NO: 42 with a cysteine substitution at amino acid position 44, and the VL region comprises an amino acid sequence of SEQ ID NO: 41 with a cysteine substitution at amino acid position 100.

[0305] In some embodiments, the VH region comprises an amino acid sequence of SEQ ID NO: 42 with a cysteine substitution at amino acid position 100B, and the VL region comprises an amino acid sequence of SEQ ID NO: 41 with a cysteine substitution at ammo acid position 49.

[0306] In some embodiments, the VH region comprises an amino acid sequence of SEQ ID NO: 42 with a cysteine substitution at amino acid position 100, and the VL region comprises an amino acid sequence of SEQ ID NO: 41 with a cysteine substitution at amino acid position 50.Attorney Docket No. JANX-004 / 05WO 339516-2027

[0307] In some embodiments, the VI I region comprises an amino acid sequence of SEQ ID NO: 42 with a cysteine substitution at amino acid position 101, and the VL region comprises an amino acid sequence of SEQ ID NO: 41 with a cysteine substitution at amino acid position 46.

[0308] In some embodiments, the VII region comprises an ammo acid sequence of SEQ ID NO: 42 with a cysteine substitution at ammo acid position 105, and the VL region comprises an amino acid sequence of SEQ ID NO: 41 with a cysteine substitution at ammo acid position 43.

[0309] In some embodiments, one engineered disulfide bond connects the VII region and the VL region of the TCRpV-binding domain. In some embodiments, two engineered disulfide bonds connect the VH region and the VL region of the TCRpV-binding domain. In some embodiments, three engineered disulfide bonds connect the VH region and the VL region of the TCRpV-binding domain. In some embodiments, four engineered disulfide bonds connect the VH region and the VL region of the TCRpV-bmding domain. In some embodiments, five engineered disulfide bonds connect the VH region and the VL region of the TCRpV-binding domain.

[0310] In some embodiments, the TCRpV-binding domain comprises a disulfide bond at the position of VH44-VL100. In some embodiments, the TCRpV-binding domain comprises a disulfide bond at the position of VH100B-VL49. In some embodiments, the TCRpV-binding domain comprises a disulfide bond at the position of VH100-VL50. In some embodiments, the TCRPV- binding domain comprises a disulfide bond at the position of VH101-VL46. In some embodiments, the TCRpV-binding domain comprises a disulfide bond at the position of VH105-VL43.

[0311] In some embodiments, the TCRpV-bindmg domain is an scFv. Exemplary scFvs are provided in Table 4 below.Table 4. TRBV scFvsID Description Amino Acid Sequence SEQ ID NO TCRBD-1 TRBV6-5 QVQLVQSGAEVKKPGSSVKVSCKASGYSFTTYYI 43scFv HWVRQAPGQGLEVTUGWFFPGSGNIKYNEKFKG (VH-VL) RVTITADTSTSTAYMELSSLRSEDTAVYYCAGSY YSYDVLDYWGQGTTVTVSSGGGGSGGGGSGGG GSDIQMTQSPSFLSASVGDRVTITCKASQNVGIN WWHQQKPGKAPKALIYSSSHRYSGVPSRFSGSG SGTEFTLTISSLQPEDFATYFCQQFKSYPLTFGQG TKLEIK TCRBD-2 TRBV6-5 DIQMTQSPSFLSASVGDRVTITCKASQNVGINVV 44scFv WHQQKPGKAPKALIYSSSHRYSGVPSRFSGSGSG (VL-VH) TEFTLTISSLQPEDFATYFCQQFKSYPLTFGQGTK LEIKGGGGSGGGGSGGGGSQVQLVQSGAEVKKP GS S VKVS CKASGYSFTTYYIHWVRQ APGQGLEWAttorney Docket No. JANX-004 / 05WO 339516-2027 ID Description Amino Acid Sequence SEQ ID NO MGWFFPGSGNIKYNEKFKGRVTITADTSTSTAY MELSSLRSEDTAVYYCAGSYYSYDVLDYWGQG TTVTVSSTCRBD-3 TRBV6-5 QVQLVQSGAEVKKPGSSVKVSCKASGYSFTTYYI 45scFv HWVRQAPGQCLEWMGWFFPGSGNIKYNEKFKG (VH-VL; RVUTADTSTSTAYMELSSLRSEDTAVYYCAGSY C44: C100) YSYDVLDYWGQGTTVTVSSGGGGSGGGGSGGG GSDIQMTQSPSFLSASVGDRVTITCKASQNVGIN WWHQQKPGKAPKALIYSSSHRYSGVPSRFSGSG SGTEFTLTISSLQPEDFATYFCQQFKSYPLTFGCG TKLEIK TCRBD-4 TRBV6-5 DIQMTQSPSFLSASVGDRVTITCKASQNVGINVV 46scFv WHQQKPGKAPKALIYSSSHRYSGVPSRFSGSGSG (VL-VH; TEFTLTISSLQPEDFATYFCQQFKSYPLTFGCGTK C44: C100) LEIKGGGGSGGGGSGGGGSQVQLVQSGAEVKKP GSSVKVSCKASGYSFI'TYYIHWVRQAl’GQCLEW MGWFFPGSGNIKYNEKFKGRVirTADTSTSTAY MELSSLRSEDTAVYYCAGSYYSYDVLDYWGQG TTVTVSS TCRBD-5 TRBV6-5 QVQLVQSGAEVKKPGSSVKVSCKASGYSFTTYYI 47scFv HWVRQAPCXX^EWMGWFFPGSGNIKYNEKFKG (VH-VL; RVTITADTSTSTAYMELSSLRSEDTAVYYCAGSY C100B: C49) YSYDVCDYWGQGTTVTVSSGGGGSGGGGSGGG GSDIQMTQSPSFLSASVGDRVTITCKASQNVGIN VVWHQQKPGKAPKALICSSSHRYSGVPSRFSGSG SGTEFTLTISSLQPEDFATYFCQQFKSYPLTFGQG TKLEIK TCRBD-6 TRBV6-5 DIQMTQSPSFLSASVGDRVTITCKASQNVGINVV 48scFv WHQQKPGKAPKALICSSSHRYSGVPSRFSGSGSG (VL-VH; TEFTLTISSLQPEDFATYFCQQFKSYPLTFG()GTK C100B: C49) LEIKGGGGSGGGGSGGGGSQVQLVQSGAEVKKPGS S VKVS CK ASGYSFTTYYIHWVRQ APGQGLEW MGWFFPGSGNIKYNEKFKGRVTITADTSTSTAY MELSSLRSEDTAVYYCAGSYYSYDVCDWGQG TWTVSS TCRBD-7 TRBV6-5 QVQLVQSGAEVKKPGSSVKVSCKASGYSFTTYYI 49scFv HWVRQAPGQGLEWMGWFFPGSGNIKYNEKFKG (VH-VL; RV1TTADTSTSTAYMELSSLRSEDTAVYYCAGSY Cl 00:050) YSYCVLDYWGQGITVFVSSGGGGSGGGGSGGG GSDIQMTQSPSFLSASVGDRVTITCKASQNVGIN VVWHQQKPGKAPKALIYCSSHRYSGVPSRFSGS GSGTEFTLTISSLQPEDFATYFCQQFKSYPLTFGQGTKLEIKAttorney Docket No. JANX-004 / 05WO 339516-2027 ID Description Amino Acid Sequence SEQ ID NO TCRBD-8 TRBV6-5 DIQMTQSPSFLSASVGDRVTTTCKASQNVGINVV 50scFv WHQQKPGKAPKALIYCSSHRYSGVPSRFSGSGSG (VL-VH; TEFTLTISSLQPEDFATYFCQQFKSYPLTFGQGTK C100: C50) LEIKGGGGSGGGGSGGGGSQVQLVQSGAEVKKP GSSVKVSCKASGYSFTTYYIHWVRQAPGQGLEW MGWFFPGSGNIKYNEKFKGRVTITADTSTSTAY MELSSLRSEDTAVYYCAGSYYSYCVLDYWGQG TTVTVSS TCRBD-9 TRBV6-5 QVQLVQSGAEVKKPGSSVKVSCKASGYSFTTYYI 51scFv HWVRQAPGQGLEWMGWFFPGSGNTKYNEKFKG (VH-VL; RVTITADTSTSTAYMELSSLRSEDTAVYYCAGSY C105: C43) YSYDVLDYWGCGTTVTVSSGGGGSGGGGSGGG GSDIQMTQSPSFLSASVGDRVTITCKASQNVGIN WAVHQQKPGKCPKALIYSSSHRYSGVPSRFSGSG SGTEFTLTISSLQPEDFATYFCQQFKSYPLTFGQG TKLEIK TCRBD-10 TRBV6-5 D1QMTQSPSFLSASVGDRVTITCKASQNVGINVV 52scFv WHQQKPGKCPKAL1YSSSHRYSGVPSRFSGSGSG (VL-VH; TEFTLTISSLQPEDFATYFCQQFKSYPLTFGQGTK C105: C43) LEIKGGGGSGGGGSGGGGSQVQLVQSGAEVKKPGS SVKVS CKASGYSFTTYYIHWVRQ APGQGLEW MGWFFPGSGNIKYNEKFKGRVTITADTSTSTAY MELSSLRSEDTAVYYCAGSYYSYDVLDYWGCG TTVTVSS TCRBD-11 TRBV6-5 QVQLVQSGAEVKKPGSSVKVSCKASGYSFTTYYI 53scFv HWVRQAPGQGLEWMGWFFPGSGNIKYNEKFKG (VH-VL; RVTTTADTSTSTAYMELSSLRSEDTAVYYCAGSY C10LC46) YSYDVLCYWGQGTTVWSSGGCKTSGGCKiSGGGGS DIQMTQSPSFLS AS VGDRVTITCKA SQNVGIN VVWHQQKI’GKAPKCLIYSSSHRYSGVPSRFSGSG SGTEFTLTISSLQPEDFATYFCQQFKSYPLTFGQG TKLEIK TCRBD-12 TRBV6-5 DlQMTQSPSFLSASVGDRVTITCKASQVA'rGlNVV 54scFv WHQQKPGKAPKCLIYSSSHRYSGVPSRFSGSGSG (VL-VH; TEFTLTIS SLQPEDF ATYFCQQFKS YPLTFGQGTK C101: C46) LE1KGGGGSGGGGSGGGGSQVQLVQSGAEVKKPGS SVKVS CK ASGYSFTTYYIHWVRQ APGQGLEW MGWTFPGSGNIKYNEKFKGRVTITADTSTSTAY NIELS SLR SEDTAVYYC AGS YYSYDVLCYWGQG TTVTVSS TCRBD-13 TRBV6-5 QVQLVQSGAEVKKPGASWVSCKASGYSFTTYY 55scFv IHWVRQAPGQGLEWMGWFFPGSGNIKYNEKFK (VH-VL) GRVTITADTSTSTAYMELSSLRSEDTAVYYCAGS YYSYDVLDYWGQGTLVTVSSGGGGSGGGGSGG GGSDIQMTQSPSFLSASVGDRVTITCKASQNVGINWWHQQKPGKAPKALIYSSSHRYSGVPSRFSGSAttorney Docket No. JANX-004 / 05WO 339516-2027 ID Description Amino Acid Sequence SEQ ID NO GSGTEFTLTISSLQPEDFATYFCQQFKSYPLTFGQ GTKLEIKTCRBD-14 TRBV6-5 QVQLVQSGAEVKKPGASVKVSCKASGYSFTTYY 56scFv IHWVRQAPGQCLEWMGWFFPGSGNIKYNEKFK (VH-VL; GRVHTADTSTSTAYMELSSLRSEDTAVYYCAGS C44: C100) YYSYDVLDYWGQGTLVTVSSGGGGSGGGGSGG GGSDIQMTQSPSFLSASVGDRVTITCKASQNVGI NWWHQQKPGKAPKALIYSSSHRYSGVPSRFSGS GSGTEFTLTISSEQPF. DFATYFCQQFKSYPETFGC GTKLEIK TCRBD-15 TRBV6-5 QVQLVQSGAEVKKPGSSVKVSCKASGYSFRLTYI 57scFv HWVRQAPGQGLEWMGWFFPGSGNIKYNEKFKG (VH-VL) RVTITADTSTSTAYMELSSLRSEDTAVYYCAGSY YSYDVLDYWGQGTTVTVSSGGGGSGGGGSGGG GSDIQMTQSPSFLSASVGDRVITTCKASQNVGIN VVWHQQKPGKAPKALIYSSSHRYSGVPSRFSGSG SGTEFILTISSLQPEDFATYFCQQFKSYPLTFGQG TKLEIK TCRBD-16 TRBV6-5 DIQMTQSPSFLSASVGDRVHTCKASQNVGINVV 58scFv WHQQKPGKAPKALIYSSSHRYSGVPSRFSGSGSG (VL-VH) TEFTLTISSLQPEDFATYFCQQFKSYPLTFGQGTK LEIKGGGGSGGGCISGGGGSQVQLVQSGAEVKKP GSSVKVSCKASGYSFRLTYIHWVRQAPGQGLEW MGWFFPGSGNIKYNEKFKGRVTITADTSTSTAY MELSSLRSEDTAVYYCAGSYYSYDVLDYWGQG TTVTVSS TCRBD-17 TRBV6-5 QVQLVQSGAEVKKPGSSVKVSCKASGYSFRLTYI 59scFv HWX'KQAPGQCLEWJMGXWFPGSGNIKYNEKFKG (VH-VL; RVHTADTSTSTAYMELSSLRSEDTAVYYCAGSY C44: C100) YSYDVLDYWGQGTTVTVSSGGGGSGGGGSGGG GSDIQMTQSPSFLSASVGDRVTITCKASQNVGIN VVWHQQKPGKAPKALIYSSSHRYSGVPSRFSGSG SGTEFTLTISSLQPEDFATYFCQQFKSYPLTFGCG TKLEIK TCRBD-18 TRBV6-5 DIQMTQSPSFLSASVGDRVm’CKASQNVGINVV 60scFv WHQQKPGKAPKALIYSSSHRYSGVPSRFSGSGSG (VL-VH; TEFTLTISSLQPEDFATYFCQQFKSYPLTFGCGTK C44: C100) LE1KGGGGSGGGGSGGGGSQVQLVQSGAEVKKPGS S VKV S CKASGYSFRLTYIHWVRQ APGQCLEW MGWFFPGSGNIKYNEKFKGRVTITADTSTSTAY MELSSLRSEDTAVYYCAGSYYSYDVLDYWGQGTWTVSSAttorney Docket No. JANX-004 / 05WO 339516-2027 ID Description Amino Acid Sequence SEQ ID NO TCRBD-19 TRBV6-5 QVQLVQSGAEVKKPGSSVKVSCKASGYSFRLTYI 61scFv HWVRQAPGQGLEWMGWFFPGSGNIKYNEKFKG (VH-VL; RVHTADTSTSTAYMELSSLRSEDTAVYYCAGSY C100B: C49) YSYDVCDYWGQGTTVTVSSGGGGSGGGGSGGG GSDIQMTQSPSFLSASVGDRVTITCKASQNVGIN VVWHQQKPGKAPKALICSSSHRYSGVPSRFSGSG SGTEFTLTISSLQPEDFATYFCQQFKSYPLTFGQG TKLEIK TCRBD-20 TRBV6-5 DIQMTQSPSFLSASVGDRVHTCKASQNVGINW 62scFv WHQQKPGKAPKALICSSSHRYSGVPSRFSGSGSG (VL-VH; TEFTETISSLQPEDFATYFCQQFKSYPETFGQGTK C100B: C49) LEIKGGGGSGGGGSGGGGSQVQLVQSGAEVKKPGS SVK VS CK ASGYSFRLTYIHWVR Q APGQGLEW MGWFFPGSGNIKYNEKFKGRVTITADTSTSTAY MELSSLRSEDTAVYYCAGSYYSYDVCDWGQG TWTVSS TCRBD-21 TRBV6-5 QVQLVQSGAEVKKPGSSVKVSCKASGYSFRLTY1 63scFv HVVVRQAI’GQGLEWMGWFFPGSGNIKYNEKFKG (VH-VL; RV TITADTSTSTAYMELS SLRSED TAV YY C AGS Y C100: C50) YSYCVLDYWGQGTTVTVSSGGGGSGGGGSGGG GSDIQMTQSPSFLSASVGDRVTITCKASQNVGIN WAVHQQKPGKAPKALIYCSSHRYSGVPSRFSGS GSGTEFTLTISSLQPEDFATYFCQQFKSYPLTFGQ GTKLEIK TCRBD-22 TRBV6-5 DIQMTQSPSFLSASVGDRVTITCKASQNVGINVV 64scFv WHQQKPGKAPKALIYCSSHRYSGVPSRFSGSGSG (VL-VH; TEFTLTISSLQPEDFATYFCQQFKSYPLTFGQGTK C100: C50) LEIKG<}(3GS(]GGGS(]GGGSQVQLVQS(] / XEVKKP GSSVKVSCKASGYSFRLTYimWRQAPGQGLEW MGWFFPGSGNIKYNEKFKGRVI1TADTSTSTAYMELS SLRSEDTAVYYC AGS YYSYCVLDYWGQG TTVTVSS TCRBD-23 TRBV6-5 QVQLVQSGAEVXKPGSSVKVSCKASGYSFRLTYI 65scFv HV'7V7RQAPGQGI. E^7MGWFFPGSGNIKYNEKFKG (VH-VL; RVTITADTSTSTAYMELSSLRSEDTAVYYCAGSY C105: C43) YSYDVLDYWGCGTTVTVSSGGGGSGGGGSGGG GSDIQMTQSPSFLSASVGDRVHITCKASQNVGIN WWHQQKPGKCPKALIYSSSHRYSGVPSRFSGSG SGTEFTLTISSLQPFDFATYFCQQFKSYPETFGQG TKLEIK TCRBD-24 TRBV6-5 DIQMTQSPSFLSASVGDRVTITCKASQNVGINVV 66scFv WHQQKPGKCPKALIYSSSHRYSGVPSRFSGSGSG (VL-VH; TEFTLTISSLQPEDFATYFCQQFKSYPLTFGQGTK C105: C43) LEIKGGGGSGGGGSGGGGSQVQLVQSGAEVKKPGS S VKVS CKASGYSFRLTYIHWVRQ APGQGLEWMGWFFPGSGNIKYNEKFKGRVTITADTSTSTAYAttorney Docket No. JANX-004 / 05WO 339516-2027 ID Description Amino Acid Sequence SEQ ID NO MELSSLRSEDTAVYYCAGSYYSYDVLDYWGCG TTVTVSSTCRBD-25 TRBV6-5 QVQLVQSGAEVKKPGSSVKVSCKASGYSFRLTYI 67scFv HWVRQAPGQGLEWMGWFFPGSGNIKYNEKFKG (VH-VL; RVUTADTSTSTAYMELSSLRSEDTAVYYCAGSY C10LC46) YSYDVLCYWGQGTTVTVSSGGGGSGGGGSGGG GSDIQMTQSPSFLSASVGDRVTITCKASQNVGIN WWHQQKPGKAPKCLIYSSSHRYSGVPSRFSGSG SGTEFTLTISSLQPEDFATYFCQQFKSYPLTFGQG TKLEIK TCRBD-26 TRBV6-5 DIQMTQSPSFLSASVGDRVTITCKASQNVGINVV 68scFv WHQQKPGKAPKCLIYSSSHRYSGVPSRFSGSGSG (VL-VH; TEFTLTISSLQPEDFATYFCQQFKSYPLTFGQGTK C101: C46) LEIKGGGGSGGGGSGGGGSQVQLVQSGAEVKKP GSSVKVSCKASGYSFRLTYIHWVRQAI’GQGLEW MGWFFPGSGNIKYNEKFKGRVirTADTSTSTAY MELSSLRSEDTAVYYCAGSYYSYDVLCYWGQG TTVTVSS TCRBD-27 TRBV6-5 QVQLVQSGAEVKKPGSSVKVSCKASGHDFRLTY 69scFv niWRQAPGQGLEWMGRVSAGSGNVKYNEKFK (VH-VL) GRVTITADTSTSTAYMELSSLRSEDTAVYYCAVS YYSYDVLDYWGQGTTVTVSSGGGGSGGGGSGG GGSDIQMTQSPSFLSASVGDRVTITCKASQNVGI NVVWHQQKPGKAPKALIYSSSHRYSGVPSRFSGS GSGTEFTLTISSLQPEDFATYFCQQFKSYPLTFGQ GTKLEIK TCRBD-28 TRBV6-5 DIQMTQSPSFLSASVGDRVTITCKASQNVGINVV 70scFv WHQQKPGKAPKALIYSSSHRYSGVPSRFSGSGSG (VL-VH) TEFTLTISSLQPEDFATYFCQQFKSYPLTFGQGTK I. EIKGGGGSGGGGSGGGGSQVQI. VQSGAEWKPGS S VK VS CK ASGHDFRLTYIHWVR Q APGQGLEW MGRVSAGSGNVKYNEKFKGRVTITADTSTSTAY MELSSLRSEDTAVYYCAVSYYSYDVI. DYWGQG TWTVSS TCRBD-29 TRBV6-5 QVQLVQSGAEVKKPGSSVKVSCKASGHDFRLTY 71scFv IHWVRQAI’GQCLEWMGRVSAGSGNVKYNEKFK (VH-VL; GRVTTI 'AD IS TSTAYMELSSLRSEDTAVYYCAVS C44: C100) YYSYDVLDYWGQGTTVTVSSGGGGSGGGGSGG GGSD1QMTQSPSFLSASVGDRVTTTCKASQNVG1 NVVWHQQKPGKAPKALIYSSSHRYSGVPSRFSGS GSGTEFTLTISSLQPEDFATYFCQQFKSYPLTFGCGTKLEIKAttorney Docket No. JANX-004 / 05WO 339516-2027 ID Description Amino Acid Sequence SEQ ID NO TCRBD-30 TRBV6-5 DIQMTQSPSFLSASVGDRVTTTCKASQNVGINVV 72scFv WHQQKPGKAPKALIYSSSHRYSGVPSRFSGSGSG (VL-VH; TEFTLTISSLQPEDFATYFCQQFKSYPLTFGCGTK C44: C100) LEIKGGGGSGGGGSGGGGSQVQLVQSGAEVKKPGS S VKVS CK ASGHDFRLTYIH WVRQ APGQCLE W MGRVSAGSGNVKYNEKFKGRVTITADTSTSTAY MELSSLRSEDTAVYYCAVSYYSYDVLDYWGQG TTVTVSS TCRBD-31 TRBV6-5 Q VQLVQSGAEVKKPGS SVKVS CKAS GHDFRLTY 73scFv IHWVRQAPGQGLEWMGRVSAGSGNVKYNEKFK (VH-VL; GRVTTTADTSTSTAYNLELSSLRSEDTAVYYCAVS C100B: C49) YYSYDVCDYWGQGTTVTVSSGGGGSGGGGSGG GGSDIQMTQSPSFLSASVGDRVTITCKASQNVGI NVWWHQQKPGKAPKALICSSSHRYSGVPSRFSGS GSGTFTTLTISSLQPEDFATYFCQQFKSYPLTFGQ GTKLEIK TCRBD-32 TRBV6-5 DlQMTQSPSFLSASVGDRVm’CKASQNVGlNVV 74scFv WHQQKPGKAPKALICSSSHRYSGVPSRFSGSGSG (VL-VH; TEFTLTISSLQPEDFATYFCQQFKSYPLTFGQGTK C100B: C49) LEIKGGGGSGGGGSGGGGSQVQLVQSGAEVKKPGS SVKVS CKAS GHDFRLTYIHWVRQ APGQGLEW MGRVSAGSGNVKYNEKFKGRVTITADTSTSTAY MELSSLRSEDTAVYYCAVSYYSYDVCDYWGQG TTVTVSS TCRBD-33 TRBV6-5 QVQLVQSGAEVKKPGSSVKVSCKASGHDFRLTY 75scFv IHWVRQAPGQGLEWMGRVSAGSGNVKYNEKFK (VH-VL; GRVHTADTSTSTAYMELSSLRSEDTAVYYCAVS C100: C50) YYSYCVLDYWCXXrTTVTVSSGGGGSGGGGSGG GGSDIQMTQSPSFLSASVGDRVTITCKASQNVGI NVVWHQQKPGKAPKALIYCSSHRYSGVPSRFSG SGSGTEFTLTISSLQPEDFATYFCQQFKSYPLTFG QGTKLEIK TCRBD-34 TRBV6-5 DIQMTQSPSFLSASVGDRVTITCT< ASQN\'rGINV'A'r76scFv WHQQKPGKAPKALIYCSSHRYSGVTSRFSGSGSG (VL-VH; TEFTLTIS SLQPEDF ATYFCQQFKS YPLTFGQGTK C100: C50) LE1KGGGGSGGGGSGGGGSQVQLVQSGAEVKKPGS SVKVS CKAS GHDFRLTYIHWVRQ APGQGLEW MGRVSAGSGNVKYNEKFKGRVTTTADTSTSTAY NIELS SLR SEDTAVYYC A VS YYS YCVI -DYWGQG TTVTVSS TCRBD-35 TRBV6-5 QVQLVQSGAEVKKPGSSVKVSCKASGHDFRLTY 77scFv IHWVRQAPGQGLEWMGRVSAGSGNVKYNEKFK (VH-VL; GRVTITADTSTSTAYMELSSLRSEDTAVYYCAVS C105: C43) YYSYDVLDYWGCGTTVTVSSGGGGSGGGGSGGGGSDIQMTQSPSFLSASVGDRVTITCKASQNVGINWWHQQKPGKCPKALIYSSSHRYSGVPSRFSGSAttorney Docket No. JANX-004 / 05WO 339516-2027 ID Description Amino Acid Sequence SEQ ID NO GSGTEFTLTISSLQPEDFATYFCQQFKSYPLTFGQ GTKLEIKTCRBD-36 TRBV6-5 DIQMTQSPSFLSASVGDRVTITCKASQNVGINVV 78scFv WHQQKPGKCPKALIYSSSHRYSGVPSRFSGSGSG (VL-VH; TEFTLTISSLQPEDFATYFCQQFKSYPLTFGQGTK C105: C43) LEIKGGGGSGGGGSGGGGSQVQLVQSGAEVKKPGS S VKVS CKAS GHDFRLTYIHWVRQ APGQGLEW MGRVSAGSGNVKYNEKFKGRVHTADTSTSTAY NIELS SLR SEDTAVYYC A VS YYSYDVLD YWGCG TTVTVSS TCRBD-37 TRBV6-5 QVQLVQSGAEVKKPGSSVKVSCKASGHDFRLTY 79scFv IHWVRQAPGQGLEWMGRVSAGSGNVKYNEKFK (VH-VL; GRVTUADTSTSTAYMELSSLRSEDrAVYYCAVS C101: C46) YYSYDVLCYWGQGTTV1VSSGGGGSGGGGSGG GGSDIQMTQSPSFLSASVGDRVTITCKASQNVGI NV VWHQQKPGKAPKCLIYS S SHRYS GVPSRF SGS GSGTEFTLTISSLQPEDFATYFCQQFKSYPLTFGQ GTKLEIK TCRBD-38 TRBV6-5 DIQMTQSPSFLSASVGDRVTITCKASQNVGINVV 80scFv WHQQKPGKAPKCLIYSSSHRYSGVPSRFSGSGSG (VL-VH; TEFTLTISSLQPEDFATYFCQQFKSYPLTFGQGTK C10LC46) LEIKGGGGSGGGCISGGGGSQVQLVQSGAEVKKPGS S VKVS CKAS GHDFRLTYIHWVRQ APGQGLEW MGRVSAGSGNVKYNEKFKGRVTITADTSTSTAY MELSSLRSEDTAVYYCAVSYYSYDVLCYWGQG TTVTVSS CL Y- 172 TRBV6-5 QVQLVQSGAEVKKPGSSVKVSCKASGYSFTLYYI 1151 scFv (VH- HW\7RQAPGQGI.JEWMGWTFPGSGNTKYNEKFKG VL) RVTITADTSTSTAYMELSSLRSEDTAVYYCAASY YSFDVLDYWGQGTTVTVSSGGGGSGGGGSGGG GSDIQMTQSPSFLSASVGDRVTITCKASQNVGIRV VWHQQKPGKAPKALIYSSSHRYSGVPSRFSGSGS GTEFTLTISSLQPEDFATYFCQQFKSYPITFGQGT KLEIK CLY-190 TRBV6-5 QVQLVQSGAEVKKPGSSVKVSCKASGYSFTLYY1 1152 scFv (VH- HWVRQAPGQCLEWMGWFFPGSGNIKYNEKFKG VL; RV1TTADTSTSTAYMELSSLRSEDTAVYYCAASY C44: C100) YSFDVLDYWGQGTTVTVSSGGGGSGGGGSGGG GSDIQMTQSPSFLSASVGDRVTITCKASQNVGIRV VWHQQKPGKAPKALIYSSSHRYSGVPSRFSGSGS GTEFTLTISSLQPEDFATYFCQQFKSYPITFGCGTKLEIKAttorney Docket No. JANX-004 / 05WO 339516-2027 ID Description Amino Acid Sequence SEQ ID NO CLY-175 TRBV6-5 QVQLVQSGAEVKKPGSSVKVSCKASGYSFTTYYI 1153 scFv (VH- HWVzRQAP<iQGLEWMGWFFPRSGNIKYNEKFKG VL) RVTITADTSTSTAYMELSSLRSEDTAVYYCAASY YSFDVTDYWGQGTTVTVSSGGFiGSGGGGSGGG GSDIQMTQSPSFLSASVGDRVTITCKASQNVGIRV VWHQQKPGKAPKALIYSSSHRYSGVPSRFSGSGS GTEFTLTISSLQPEDFATYFCQQFKSYPITFGQGT KLE1KCLY-193 TRBV6-5 QVQLVQSGAEVKKPGSSVKVSCKASGYSFTTYYI 1154 scFv (VH- HWXTRQAPGQCLEWMGWFFPRSGNIKYNEKFKG VL; RVHTADTSTSTAYMELSSLRSEDTAVYYCAASY C44: C100) YSFDVLDYWGQGTTVTVSSGGGGSGGGGSGGG GSDIQMTQSPSFLSASVGDRVTITCKASQNVGIRV VWHQQKPGKAPKALIYSSSHRYSGVPSRFSGSGS GTEFTLTIS SLQPEDF ATYFCQQFKS YPITFGCGTK LEIK TCRBD-39 TRBV 12-3 / 4 EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFGM 81scFv HW VRQ APGKGLEWV S YIS SGS STI Y YADTLKGR (VH-VL) FTISRDN SKN TLYLQMN SLRAEDTAV Y YC ARRG EGAMDYWGQGTTVTVSSGGGGSGGGGSGGGGS DNQLTQSPSFLS AS VGDRVTITCRAS S S VNYIYW YQQKPGKAPKLLIYYTSNLAPGVPSRFSGSGSGN EYTLTIS SLQPEDF ATYYCQQFTSSPFTFGQGTKL EIK TCRBD-40 TRBV 12-3 / 4 DNQLTQSPSFLS AS VGDRVTITCRAS S S VN YI YW 82scFv YQQKPGKAPKLLIYYTSNLAPGVPSRFSGSGSGN (VL-VH) EYTLTIS SLQPEDF ATYYCQQFTSSPFTFGQGTKL EII< GGGGSG< IGGSG< IGGSEVQLVESGGGLVQPG GSLRLSCAASGFTFSNFGMHWVRQAPGKGLEW VS YISSGSSTIYYADTLKGRFTISRDNSKNTLYLQ MNSLRAEDTAVYYCARRGEGAMDYWGQGTTV TVSS TCRBD-41 TRBV12-3 / 4 EVQLWSGGGLVQPGGSLRLSCAASGFTFSNFGM 83scFv HV'VRQAPGKCLEVWSTTSSGSSTIYYADTLKGRF (VH-VL; TISRDNSKNTLYLQMNSLRAEDTAVYYCARRGE C44: C100) GAMDYWGQGTTVTVSSGGGGSGGGGSGGGGSD NQLTQSPSFLSASVGDRVTTTCRASSSVNYIYWY QQKPGKAPKILIYYTSNI. APGA'T’SRFSGSGSGNE YTLTIS SLQPEDF ATYYCQQFTS SPFTFGCGTKLEIKAttorney Docket No. JANX-004 / 05WO 339516-2027 ID Description Amino Acid Sequence SEQ ID NO TCRBD-42 TRBV12-3 / 4 DNQLTQSPSFLS ASVGDRVHTCRASSSVNYIYW 84scFv YQQKPGKAPKLLIYYTSNLAPGVPSRFSGSGSGN (VL-VH; EYTLTIS SLQPEDF AT YYCQQFTSSPFTFGCGTKL C44: C100) EIKGG<1GSGG<1GSGG<1GSEVQLVESG<1GLVQPG < ISLRLSCAAS< IFTFSNF< IMHWVRQAPGKCLEWV SYISSGSSTIYYADTLKGRFTISRDNSKNTLYLQM NSLRAEDTAVYYCARRGEGAMDYWGQGTTVTV SS TCRBD-43 TRBV12-3 / 4 EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFGM 85scFv HWVKQAPGKGLEWVSYISSGSSUYYADTIXGR (VH-VL; FTISRDNSKNTLYLQMNSLRAEDTAVYYCARRG C100: C50) EGACDYWGQGTTVTVSSGGGGSGGGGSGGGGS DNQLTQSPSFLS AS VGDRVTITCRA S S S VNYIYW YQQKPGKAPKLL1YCTSNLAPGVPSRFSGSGSGN EYTLTIS SLQPEDF ATYYCQQFTS S PFTFGQGTK L.EIK TCRBD-44 TRBV 12-3 / 4 DNQLTQSPSFLSASVGDRVTITCRASSSVNYIYW 86scFv YQQKPGKAPKLLIYCTSNLAPGVPSRFSGSGSGN (VL-VH; EYTLTIS SLQPEDF ATYYCQQFTS SPFTFGQGTKL C100: C50) EIKGGGGSGGGGSGGGGSEVQLVESGGGLVQPG GSLRLSCAASGFTFSNFGMHWVRQAPGKGLEW VSYISSGSSHYYADTLKGRFHSRDNSKNTLYLQ MNSLRAEDTAVYYCARRGEGACDYWGQGTTVTvssTCRBD-45 TRBV 12-3 / 4 EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFGM 87scFv HW VRQ APGKGLEWVS YI S SGS STI Y Y ADTLKGR (VH-VL; FTISRDN S KNTLYLQMN SLRAEDTA VY YC ARRG C105: C43) EGAMDYWGCGTTVTVSSGGGGSGGGGSGGGGS DNQLTQSPSFLS AS VGDRVTITCRAS S S VN YI YW YQQKPGKCPKLLIYYTSNLAPGVPSRFSGSGSGN EYTLTIS SLQPEDF ATYYCQQFTS SPFTFGQGTKL EIK TCRBD-46 TRBV12-3 / 4 DNQLTQSPSFLS AS VGDRVTITCRAS SS VNYIYW 88scFv YQQKPGKCPKLLIYYTSNLAPGVPSRFSGSGSGN (VL-VH; EYTI. TIS SLQPEDF ATYYCQQFTS SPFTFGQGTKL C105: C43) EIKGGGGSGGGGSGGGGSEVQLVESGGGLVQPG GSLRLSCAASGFTFSNFGMHVVA / RQAPGKGILW VSYISSGSSTIYYADTLKGRFTISRDNSKNTLYLQ VINSLRAEDTAVYYCARRGEGAMDYWGCGTTVTVSSAttorney Docket No. JANX-004 / 05WO 339516-2027 ID Description Amino Acid Sequence SEQ ID NO TCRBD-47 TRBV12-3 / 4 EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFGM 89scFv HWRQAPGKGLEWVSYISSGSSTIYYADTLKGR (VH-VL; FTISRDNSKNTLYLQMNSLRAEDTAVYYCARRG C10LC46) EGAMCYWGQGTTVTVSSGGGGSGGGGSGGGGS DNQLTQSPSFLS ASVGDRVTITCRASSSVNYIYW YQQKPGKAPKCLIYYTSNLAPGVPSRFSGSGSGN EYTLTIS SLQPEDF AT YYCQQFTSSPFTFGQGTKL EIK TCRBD-48 TRBV12-3 / 4 DNQLTQSPSFLS AS VGDRVTITCRAS S S VNYIYW 90scFv YQQKPGKAPKCLIYYTSNLAPGVPSRFSGSGSGN (VL-VH; EYTLTIS SLQPEDF ATYYCQQFTS SPFTFGQGTKL C10EC46) EIKGGGGSGGGGSGGGGSEVQLVESGGGLVQPG GSLRLSCAASGFTFSNFGMHWVRQAPGKGLEW VSYISSGSSTIYYADTLKGRFTISRDNSKNTLYLQ MNSLRAEDTAVYYCARRGEGAMCYWGQGTTV TVSS TCRBD-49 TRBV 12-3 / 4 EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFGM 91scFv (VH- HW VRQ APGKGLEWV S YIS SGS STI Y YADTLKGR VL) FTISRDN SKN TLYLQMN SLRAEDTAV Y YC ARRG EGAMDYWGQGTLVTVSSGGGGSGGGGSGGGGS DNQLTQSPSFLS AS VGDRVTITCRAS S SVNYIYW YQQKPGKAPKLLIYYTSNLAPGVPSRFSGSGSGN EYTLTISSLQPEDFATYYCQQFTSSPFTFGQGTKL EIK TCRBD-50 TRBV12-3 / 4 EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFGM 92scFv (VH- HV'A’RQAPGKCLEAWSYTSSGSSTIYYADTLKGRF VL; HSRDNSKNTLYLQMNSLRAEDTAVYYCARRGE C44: C100) GAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSD NQLTQSPSFLSASVGDRVTITCRASSSVNYIYWY QQKPGKAPKLLIYYTSNLAPGVPSRFSGSGSGNE YTLTI S SLQPEDF ATY YCQQFTS S PFTFGCGTKLEI K TCRBD-55 TRBV12-3 / 4 EVQLWSGGGLVQPGGSLRLSCAASGFTFSNFGM 1099 scFv (VH- HWVRQAPGKGLEWVSYISSGSSTIYYADTLKGR VL) FTISRDNSKNTLYLQMNSLRAEDTAVYYCARRG EGAMDYWGQGTTVTVSSGGGGSGGGGSGGGGS DNQLTQSPSFLS AS VGDRVTITCRAS S S VNYIYW YQQKPGKAPKLLIYYTSNLAPGVPSRFSGSGSGN EYTLTIS SLQPEDF ATYYCQQFTSSPFTFGQGTKLEIKAttorney Docket No. JANX-004 / 05WO 339516-2027 ID Description Amino Acid Sequence SEQ ID NO TCRBD-68 TRBV20-1 EVQLQQSVADLVRPGASLKLSCTASGFNIKSAY 242scFv (VH- MHWVIQRPDQGPECLGRIDPATGKTKYAPKFQ / X VL) KATITADTSSNTAYLQLSSLTSEDTAIYYCTRSLN WDYGLDYWGQGTSVTVSSGGGGSGGGGSGGG GSDIVLTQSPASLAVSLGQRATISCRASKSVSILG TI ILII IWYQQKPGQPPKLLIYAASNLESGVPARFS GSGSETVFTLNIIIPVEEEDAATYFCQQSIEDPWTF GGGTKLGIK

[0312] In some embodiments, the TCRpV-bindmg domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 45. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 46. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 47. In some embodiments, the TCRPV -binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 48. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 49. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 50. In some embodiments, the TCRPV -binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 51. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 52. In someAttorney Docket No. JANX-004 / 05WO 339516-2027 embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 53. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 54. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 56. In some embodiments, the TCRPV -binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 59. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 60. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 61. In some embodiments, the TCRPV -binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 62. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 63. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 64. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 65. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, atAttorney Docket No. JANX-004 / 05WO 339516-2027 least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 66. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 67. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 68. In some embodiments, the TCRPV -binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 71. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 72. In some embodiments, the TCRPV -binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 73. In some embodiments, the TCRPV -binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 74. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 75. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 76. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 77. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 78. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%,Attorney Docket No. JANX-004 / 05WO 339516-2027 at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 79. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 80. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1151. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1152. In some embodiments, the TCRPV -binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1153. In some embodiments, the TCRPV -binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1154. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 83. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 84. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 85. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 86. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 87. In someAttorney Docket No. JANX-004 / 05WO 339516-2027 embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 88. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 89. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 90. In some embodiments, the TCRPV -binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 92. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 242. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1017. In some embodiments, the TCRPV -binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1018. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1019, In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1020. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1021. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, atAttorney Docket No. JANX-004 / 05WO 339516-2027 least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1022. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1023. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1024. In some embodiments, the TCRPV -binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1025. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1026. In some embodiments, the TCRPV -binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1027. In some embodiments, the TCRPV -binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1028. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1029. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1030. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1031. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1032. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%,Attorney Docket No. JANX-004 / 05WO 339516-2027 at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1033. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1034. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1035. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1036. In some embodiments, the TCRPV -binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1037. In some embodiments, the TCRPV -binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1038. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1039. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1040. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1041. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1042. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1043. In someAttorney Docket No. JANX-004 / 05WO 339516-2027 embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1044. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1045. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1046. In some embodiments, the TCRPV -binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1047. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1048. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1049. In some embodiments, the TCRPV -binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1050. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1051. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1052. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1053. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, atAttorney Docket No. JANX-004 / 05WO 339516-2027 least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1054. In some embodiments, the TCRpV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 1099.

[0313] In some embodiments, the TCRpV-binding domain comprises or consists of an ammo acid sequence of SEQ ID NO: 45. In some embodiments, the TCRpV-binding domain comprises or consists of an ammo acid sequence of SEQ ID NO: 46. In some embodiments, the TCRPV-binding domain comprises or consists of an ammo acid sequence of SEQ ID NO: 47. In some embodiments, the TCRpV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 48. In some embodiments, the TCRpV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 49. In some embodiments, the TCRpV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 50. In some embodiments, the TCRPV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 51. In some embodiments, the TCRpV-binding domain comprises or consists of an ammo acid sequence of SEQ ID NO: 52. In some embodiments, the TCRpV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 53. In some embodiments, the TCRpV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 54. In some embodiments, the TCRPV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 56. In some embodiments, the TCRpV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 59. In some embodiments, the TCRpV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 60. In some embodiments, the TCRpV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 61. In some embodiments, the TCRPV-binding domain comprises or consists of an ammo acid sequence of SEQ ID NO: 62. In some embodiments, the TCRpV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 63. In some embodiments, the TCRpV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 64. In some embodiments, the TCRpV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 65. In some embodiments, the TCRPV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 66. In some embodiments, the TCRpV-binding domain comprises or consists of an ammo acid sequence of SEQ ID NO: 67. In some embodiments, the TCRpV-bmdmg domain comprises or consists of an ammo acid sequence of SEQ ID NO: 68. In some embodiments, the TCRpV-binding domain comprises or consists of an ammo acid sequence of SEQ ID NO: 71. In some embodiments, the TCRPV-Attorney Docket No. JANX-004 / 05WO 339516-2027 binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 72. In some embodiments, the TCRpV-binding domain comprises or consists of an ammo acid sequence of SEQ ID NO: 73. In some embodiments, the TCRpV-binding domain comprises or consists of an ammo acid sequence of SEQ ID NO: 74. In some embodiments, the TCRpV-binding domain comprises or consists of an ammo acid sequence of SEQ ID NO: 75. In some embodiments, the TCRPV-binding domain comprises or consists of an ammo acid sequence of SEQ ID NO: 76. In some embodiments, the TCRpV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 77. In some embodiments, the TCRpV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 78. In some embodiments, the TCRpV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 79. In some embodiments, the TCRPV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 80. In some embodiments, the TCRpV-binding domain comprises or consists of an ammo acid sequence of SEQ ID NO: 1151. In some embodiments, the TCRpV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 1152. In some embodiments, the TCRpV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 1153. In some embodiments, the TCR V-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 1154. In some embodiments, the TCRpV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 83. In some embodiments, the TCRpV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 84. In some embodiments, the TCR V-binding domain comprises or consists of an ammo acid sequence of SEQ ID NO: 85. In some embodiments, the TCRPV-binding domain comprises or consists of an ammo acid sequence of SEQ ID NO: 86. In some embodiments, the TCRpV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 87. In some embodiments, the TCRpV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 88. In some embodiments, the TCRpV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 89. In some embodiments, the TCR V-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 90. In some embodiments, the TCRpV-binding domain comprises or consists of an ammo acid sequence of SEQ ID NO: 92, In some embodiments, the TCRpV-binding domain comprises or consists of an ammo acid sequence of SEQ ID NO: 242. In some embodiments, the TCRpV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 1017. In some embodiments, the TCRPV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 1018. In some embodiments, the TCRpV-binding domain comprises or consists of an amino acid sequence of SEQAttorney Docket No. JANX-004 / 05WO 339516-2027 ID NO: 1019. In some embodiments, the TCRpV-binding domain comprises or consists of an ammo acid sequence of SEQ ID NO: 1020. In some embodiments, the TCRpV-bindmg domain comprises or consists of an amino acid sequence of SEQ ID NO: 1021. In some embodiments, the TCRPV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 1022. In some embodiments, the TCRpV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 1023. In some embodiments, the TCRpV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 1024. In some embodiments, the TCRpV-binding domain comprises or consists of an ammo acid sequence of SEQ ID NO: 1025. In some embodiments, the TCRPV-binding domain comprises or consists of an ammo acid sequence of SEQ ID NO: 1026. In some embodiments, the TCRpV-binding domain comprises or consists of an ammo acid sequence of SEQ ID NO: 1027. In some embodiments, the TCRpV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 1028. In some embodiments, the TCRpV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 1029. In some embodiments, the TCRPV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 1030. In some embodiments, the TCRpV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 1031. In some embodiments, the TCRpV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 1032. In some embodiments, the TCRPV -binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 1033. In some embodiments, the TCRPV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 1034. In some embodiments, the TCRpV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 1035. In some embodiments, the TCRpV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 1036. In some embodiments, the TCRpV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 1037, In some embodiments, the TCRPV- binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 1038. In some embodiments, the TCR pV-binding domain comprises or consists of an ammo acid sequence of SEQ ID NO: 1039. In some embodiments, the TCRpV-bindmg domain comprises or consists of an amino acid sequence of SEQ ID NO: 1040. In some embodiments, the TCRpV-bindmg domain comprises or consists of an amino acid sequence of SEQ ID NO: 1041. In some embodiments, the TCRPV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 1042. In some embodiments, the TCRpV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 1043. In some embodiments, the TCRpV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 1044. In some embodiments, the TCRpV-binding domain comprisesAttorney Docket No. JANX-004 / 05WO 339516-2027 or consists of an amino acid sequence of SEQ ID NO: 1045. In some embodiments, the TCRPV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 1046. In some embodiments, the TCRpV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 1047. In some embodiments, the TCRpV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 1048. In some embodiments, the TCRpV-binding domain comprises or consists of an ammo acid sequence of SEQ ID NO: 1049. In some embodiments, the TCRPV-binding domain comprises or consists of an ammo acid sequence of SEQ ID NO: 1050. In some embodiments, the TCRpV-binding domain comprises or consists of an ammo acid sequence of SEQ ID NO: 1051. In some embodiments, the TCRpV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 1052. In some embodiments, the TCRpV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 1053. In some embodiments, the TCRPV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 1054. In some embodiments, the TCRpV-binding domain comprises or consists of an amino acid sequence of SEQ ID NO: 1099.

[0314] In some embodiments, the TCRPV- binding domain comprises a heavy chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to any one of SEQ ID NOs listed in the heavy chain column of Table 5.

[0315] In some embodiments, the TCRpV-binding domain comprises a light chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to any one of SEQ ID NOs listed in the light chain column of Table 5.

[0316] In some embodiments, the TCRpV-bmdmg domain comprises a heavy chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to one of SEQ ID NOs l isted in the heavy chain column of Table 5, and a light chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the corresponding light chain SEQ ID NO listed in the same row of Table 5.

[0317] In some embodiments, the TCRpV-binding domain comprises a heavy chain comprising one of SEQ ID NOs listed in the heavy chain column of Table 5, and a light chain comprising theAttorney Docket No. JANX-004 / 05WO 339516-2027 corresponding light chain SEQ ID NO listed in the same row of Table 5. In some embodiments, the TCRpV-binding domain comprises a heavy chain comprising one of SEQ ID NOs listed in the heavy chain column of Table 5 with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more mutations therein. In some embodiments, the TCRpV-binding domain comprises a light chain comprising the corresponding light chain SEQ ID NO listed in the same row of Table 5 with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more mutations therein. In some embodiments, the TCRpV-binding domain is a Fab or a Cross-Fab.

[0318] In some embodiments, the TCRpV-binding domain comprises a heavy chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1155, and a light chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1156.

[0319] In some embodiments, the TCRpV-bmding domain comprises a heavy chain comprising SEQ ID NO: 1155, and a light chain comprising SEQ ID NO: 1156. In some embodiments, the TCRpV-binding domain comprises a heavy chain comprising SEQ ID NO: 1155 with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more mutations therein. In some embodiments, the TCRpV-binding domain comprises a light chain comprising SEQ ID NO: 1156 with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more mutations therein. In some embodiments, the TCRpV-binding domain is a Fab or a Cross-Fab.

[0320] In some embodiments, the TCRpV-binding domain comprises a heavy chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1157, and a light chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1158.

[0321] In some embodiments, the TCRpV-binding domain comprises a heavy chain comprising SEQ ID NO: 1157, and a light chain comprising SEQ ID NO: 1158. In some embodiments, the TCRpV-binding domain comprises a heavy chain comprising SEQ ID NO: 1157 with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more mutations therein. In some embodiments, the TCRpV-binding domain comprises a light chain comprising SEQ ID NO: 1158 with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more mutations therein. In some embodiments, the TCRpV-binding domain is a Fab or a Cross-Fab.Attorney Docket No. JANX-004 / 05WO 339516-2027Table 5. TRBV Fab or CrossFabSEQ ID NO for SEQ ID NO for Light ID Description Heavy Chain Amino Chain Amino Acid Acid Sequence SequenceTCRBD-39 TRBV6-5 Fabl 1071 1055TCRBD-40 TRBV6-5 Fab2 1072 1056TCRBD-41 TRBV6-5 Fab3 1073 1057TCRBD-42 TRBV6-5 Fab4 1074 1058TCRBD-43 TRBV6-5 Fab5 1075 1059TCRBD-44 TRBV6-5 Fab6 1076 1060TCRBD-45 TRBV6-5 Fab7 1077 1061TCRBD-46 TRBV6-5 Fab8 1078 1062TCRBD-47 TRBV6-5 CrossFab 1 1079 1063TCRBD-48 TRBV6-5 CrossFab2 1080 1064TCRBD-49 TRBV6-5 CrossFab3 1081 1065TCRBD-50 TRBV6-5 CrossFab4 1082 1066TCRBD-51 TRBV6-5 CrossFab5 1083 1067TCRBD-52 TRBV6-5 CrossFab6 1084 1068TCRBD-53 TRBV6-5 CrossFab7 1085 1069TCRBD-54 TRBV6-5 CrossFab8 1086 1070TCRBD-56 TRBV12-3 Fabl 1112 1100TCRBD-57 TRBV 12-3 Fab2 1113 1101TCRBD-58 TRBV12-3 Fab3 1114 1102TCRBD-59 TRBV 12-3 Fab4 1115 1103TCRBD-60 TRBV12-3 Fab5 1116 1104TCRBD-61 TRBV12-3 Fab6 1117 1105TCRBD-62 TRBV12-3 CrossFab! 1118 1106TCRBD-63 TRBV 12-3 CrossFab 2 1119 1107TCRBD-64 TRBV12-3 CrossFab3 1120 1108TCRBD-65 TRBV12-3 CrossFab4 1121 1109TCRBD-66 TRBV12-3 CrossFab5 1122 1110TCRBD-67 TRBV 12-3 CrossFab6 1123 m iTCRBD-69 TRBV20-1 Fabl 243 244TCRBD-70 TRBV20-1 CrossFab 1 245 246CLY-010 TRBV6-5 1155 1156CLY-013 TRBV6-5 1157 1158

[0322] Additional exemplary CDRs, VL, ATI, scFvs, Fabs, CrossFab, and / or other binding fragments that can be comprised within the first binding domain can be found, for example, in US 2023 / 0227552 and US 2021 / 0277119, the content of each of which is hereby incorporated by reference in its entirety. In some embodiments, the first binding domain comprises CDRs, a VL, a VH, an scFv, a Fab, a CrossFab, and / or other binding fragments from one of the TCR-bmdingAttorney Docket No. JANX-004 / 05WO 339516-2027 molecules selected from IMMU 546, FIN9, AMKB1-2, ZOE, 3G5, ZIZOU4, IMMU 157, LC4, 3D11, 1C1, W112, MH3-2, 4H11, 36213, BAM13, H131, H132, IMMU 222, JU-74, JU74.3, OTI45, BL37.2, S511, VER2.32.1, IG125, 56C5, 5605.2, 16G8, MX-6, JR2, AF-23, AF23, AHUT7, TAMAYA1.2, BA62, BA62.6, CI, EI7.5F3, EI7.5F3.15.13, MPB2D5, C2I, CAS1.1.3, CFI92, 8F10, JOVI-3, WJF24, ELL1.4, JOVI-l, SP305, LG.3AI0, 5A8AI0, 5D9FI, KFN, A-H.l, A-H.2, A-H.3, A-H.4, A-FI.5, A-H.6, A-H.7, A-FI.8, A-H.9, A-FI.10, A-H.ll, A-H.12, A-H.13, A-H.14, A-H.15, A-H.16, A-FI. I7, A-H.18, A-H.19, A-H.20, A-FI.21, A-H.22, A-H.23, A-H.24, A- H.25, A-H.26, A-H.27, A-H.28, A-H.29, A-H.30, A-H.31, A-H.32, A-H.33, A-H.34, A-H.35, A- H.36, A-H.37, A-H.38, A-H.39, A-H.40, A-H.41, A-H.42, A-H.43, A-H.44, A-H.45, A-H.46, A- H.47, A-H.48, A-H.49, A-H.50, A-H.51, A-H.52, A-H.53, A-H.54, A-H.55, A-H.56, A-H.57, A- H.58, A-H.59, A-H.60, A-H.61, A-H.62, A-H.63, A-H.64, A-H.65, A-H.66, A-H.67, A-H.68, A- H.69, A-H.70, A-H.71, A-H.72, A-H.73, A-H.74, A-H.75, A-H.76, A-H.77, A-H.78, A-H.79, A- H.80, A-H.81, A-H.82, A-H.83, A-H.84, A-H.85, B-H.1A, B-H.1B, B-H.1C, B-H.1D, B-H.1E, B-H.1F, B-H.1G, B-H.1H, B-H.l, B-H.l, B-H.2, B-H.3, B-H.4, B-H.5, B-H.6, C-H.l, C-H.2, C-H.3, C-H.4, C-H.5, C-H.6, C-H.7, C-H 8, C-H 9, C-H.10, C-H.ll, C-H.12, C-H.13, C-H.14, C-H.15, C- H.16, C-H.17, C-H.18, C-H.19, C-H.20, C-H.21, C-H.22, C-H 23, C-H.24, C-H.25, C-H.26, C- H.27, C-H.28, C-H.29, C-H.30, C-H.31, C-H.32, C-H.33, C-H.34, C-H.35, C-H.36, C-H.37, C- H.38, C-H.39, C-H.40, C-H.41, C-H.42, C-H.43, C-H.44, C-H.45, C-H.46, C-H.47, C-H.48, C- H.49, C-H.50, D-H.1, D-H.2, D-H.3, D-H.4, D-H.5, D-H.6, D-H.7, D-H.8, D-H.9, D-H 10, D-H.11, D-H.12, D-H 13, D-H.14, D-H.15, D-H.16, D-H.17, D-H.18, D-H.19, D-H.20, D-H.21, D-H.22, D-H.23, D-H.24, D-H.25, D-H.26, D-H.27, D-H.28, D-H.29, D-H.30, D-H.31, D-H 32, D-H.33, D-H.34, D-H 35, D-H.36, D-H.37, D-H.38, D-H.39, D-H.40, D-H.41, D-H.42, D-H.43, D-H.44, D-H.45, D-H 46, D-H.47, D-H.48, D-H 49, D-H.50, E-Hl, E-H.2, E-H.3, E-H.4, E-H.5, E-H6, E- H.7, E-H.8, E-H9, E-H.10, E-H.ll, E-H12, E-H13, E-H.14, E-H15, E-H16, E-H.17, E-H.18, E-H.19, E-H.20, E-H.21, E-H22, E-H.23, E-H.24, E-H.25, E-H26, E-H.27, E-H.28, E-H.29, E-H.30, E-H.31, E-H.32, E-H33, E-H.34, E-H.35, E-H.36, E-H37, E-H.38, E-H.39, E-H.40, E-H.41, E-H.42, E-FI.43, E-H.44, E-H.45, E-H.46, E-H.47, E-H.48, E-H.49, and E-H.50.

[0323] In some embodiments, the TCRaV-binding domain comprises an immunoglobulin heavy chain variable (VH) region and an immunoglobulin light chain variable (VL) region. In some embodiments, the VH region comprises a heavy chain CDRl (IICDRl), a heavy chain CDR2 (HCDR2), and a heavy chain CDR3 (HCDR3). In some embodiments, the VL region comprises a light chain CDRl (LCDRl), a light chain CDR2 (LCDR2), and a light chain CDR3 (LCDR3).Attorney Docket No. JANX-004 / 05WO 339516-2027

[0324] In some embodiments, the TCRaV-binding domain is a Fab comprising the VH region, the VL region, a first heavy chain constant region (CHI), and a light chain constant region (CL), wherein the C-terminus of the VH region is connected to the N-terminus of the CH1 region (e.g., a polypeptide chain comprising N’-VH-CHl-C ), and the C-terminus of the VL region is connected to the N-terminus of the CL region (e.g., a polypeptide chain comprising N'-VL-CL-C'). In some embodiments, the CHI region and the CL region of the Fab are connected by a disulfide bond. In some embodiments, the Fab is a charge steering Fab.

[0325] In some embodiments, the TCRaV-binding domain is a CrossFab comprising the VH region, the VL region, a first heavy chain constant region (CHI), and a light chain constant region (CL), wherein the C-terminus of the VH region is connected to the N-terminus of the CL region (e.g., a polypeptide chain comprising N’-VH-CL-C’), and the C-terminus of the VL region is connected to the N-terminus of the CHI region (e.g., a polypeptide chain comprising N’-VL-CHl- C’). In some embodiments, the CHI region and the CL region of the CrossFab are connected by a disulfide bond. In some embodiments, the CrossFab is a charge steering CrossFab.

[0326] Exemplary anti-TCRaV CDRs are provided in Table 6 (Kabat numbering scheme) and Table 7 (IMGT numbering scheme) below.Table 6. TRAV CDRs (Kabat Numberings)Target HCDRI HCDR2 HCDR3 LCDR1 LCDR2 LCDR3 DescriptionTRAV1-2 DTHMH RTDPASG YYRDDV KARQNV SSSFRYS QQYNTY (SEQ ID DTKYDP NYAMDY GSNVA (SEQ ID PYT (SEQ NO: 134) KFQG (SEQ ID (SEQ ID NO: 138) ID NO:(SEQ ID NO: 136) NO: 137) 139)NO: 135)Table 7. TRAV CDRs (IMGT Numberings)Target HCDRI HCDR2 HCDR3 LCDR1 LCDR2 LCDR3 DescriptionTRAV 1-2 GFN1KDT TDPASG AHYYRD QNVGSN SSS (SEQ QQYNTY H (SEQ ID DI (SEQ DVNYAM (SEQ ID ID NO: PYT (SEQ NO: 140) ID NO: DY (SEQ NO: 143) 144) ID NO:141) ID NO: 145)142) _

[0327] In some embodiments, the HCDRI comprises an amino acid sequence of DTHMH (SEQ ID NO: 134) or GFNIKDTH (SEQ ID NO: 140).Attorney Docket No. JANX-004 / 05WO 339516-2027

[0328] In some embodiments, the HCDR2 comprises an amino acid sequence of RTDPASGDTKYDPKFQG (SEQ ID NO: 135) or TDPASGDT (SEQ ID NO: 141).

[0329] In some embodiments, the HCDR3 comprises an amino acid sequence of YYRDDVNYAMDY (SEQ ID NO: 136) or AHYYRDDVNYAMDY (SEQ ID NO: 142).

[0330] In some embodiments, the LCDR1 comprises an ammo acid sequence of KARQNVGSNV / X (SEQ ID NO: 137) or QNVGSN (SEQ ID NO: 143).

[0331] In some embodiments, the LCDR2 comprises an amino acid sequence of SSSFRYS (SEQ ID NO: 138) or SSS (SEQ ID NO: 144).

[0332] In some embodiments, the LCDR3 comprises an amino acid sequence of QQYNTYPYT (SEQ ID NO: 139) or QQYNTYPYT (SEQ ID NO: 145).

[0333] In some embodiments, the HCDR1 comprises an amino acid sequence of DTHMH ( SEQ ID NO: 134), the HCDR2 comprises an amino acid sequence of RTDPASGDTKYDPKFQG (SEQ ID NO: 135), the HCDR3 comprises an amino acid sequence of YYRDDVNYAMDY (SEQ ID NO: 136), theLCDRl comprises an ammo acid sequence ofKARQNVGSNVA (SEQ ID NO: 137), the LCDR2 comprises an ammo acid sequence of SSSFRYS (SEQ ID NO: 138), the LCDR3 comprises an amino acid sequence of QQYNTYPYT (SEQ ID NO: 139). In some embodiments, the HCDR1 comprises an amino acid sequence of GFNIKDTH (SEQ ID NO: 140), the HCDR2 comprises an amino acid sequence of TDPASGDT (SEQ ID NO: 141), the HCDR3 comprises an amino acid sequence of AHYYRDDVNYAMDY (SEQ ID NO: 142), the LCDR1 comprises an ammo acid sequence of QNVGSN (SEQ ID NO: 143), the LCDR2 comprises an amino acid sequence of SSS (SEQ ID NO: 144), the LCDR3 comprises an amino acid sequence of QQYNTYPYT (SEQ ID NO: 145). In some embodiments, the CDRs comprise 1, 2, 3, or more amino acid substitutions.

[0334] In some embodiments, the VH region of the TCRaV -binding domain is the VH region of an IgA, IgD, IgE, IgG, or IgM. In some embodiments, the VH region of the TCRaV-bmding domain is the VH region of a subclass of an IgA, IgD, IgE, IgG, or IgM, such as, e.g., IgGi, IgGz, IgGa, IgG-t, IgAi, and IgAa. In some embodiments, the VL region of the TCRaV-bmding domain is the VL region of a kappa light chain. In some embodiments, the VL region of the TCRaV-binding domain is the VL region of a lambda light chain.

[0335] Exemplary anti-TCRaV VH and VL are provided in Table 8 below.Attorney Docket No. JANX-004 / 05WO 339516-2027Table 8. TRAV VH and VLTarget VH VLDescriptionTRAV 1-2 EVQLQQSGAELVKPGASVKLSCT DIVMTQSQKFLSTSVGDRVSVTC ASGFNIKDTHMHWVKQRPEQGL KARQNVGSNVAWYQQKPGQSPK EWIGRTDPASGDTKYDPKFQGKA SLIYSSSFRYSGVPDRFTGSGSGTD DTADTSSNTAYLHLSSLTSEDTA FTLTI S N VQSEDL AE YFCQQ YNTY VYYCAHYYRDDVNYAMDYWGQ PYTFGGGTELEIK (SEQ ID NO:GTTVTVSS (SEQ ID NO: 146) 147)

[0336] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 146. In some embodiments, the VH region comprises or consists of an amino acid sequence of SEQ ID NO: 146,

[0337] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 146 and comprises a cysteine residue at amino acid position 44. In some embodiments, the VH region comprises or consists of an amino acid sequence of SEQ ID NO: 146 and comprises a cysteine substitution at amino acid position 44.

[0338] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 146 and comprises a cysteine residue at amino acid position 100. In some embodiments, the VH region comprises or consists of an amino acid sequence of SEQ ID NO: 146 and comprises a cysteine substitution at ammo acid position 100.

[0339] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 146 and comprises a cysteine residue at amino acid position 100B. In some embodiments, the XT! region comprises or consists of an amino acid sequence of SEQ ID NO: 146 and comprises a cysteine substitution at amino acid position 100B.

[0340] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 146 and comprisesAttorney Docket No. JANX-004 / 05WO 339516-2027 a cysteine residue at amino acid position 101. In some embodiments, the VII region comprises or consists of an amino acid sequence of SEQ ID NO: 146 and comprises a cysteine substitution at ammo acid position 101.

[0341] In some embodiments, the VI I region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 146 and comprises a cysteine residue at amino acid position 105. In some embodiments, the VII region comprises or consists of an amino acid sequence of SEQ ID NO: 146 and comprises a cysteine substitution at ammo acid position 105.

[0342] In some embodiments, the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 147. In some embodiments, the VL region comprises or consists of an ammo acid sequence of SEQ ID NO: 147.

[0343] In some embodiments, the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 147 and comprises a cysteine residue at amino acid position 100. In some embodiments, the VL region comprises or consists of an amino acid sequence of SEQ ID NO: 147 and comprises a cysteine substitution at amino acid position 100.

[0344] In some embodiments, the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 147 and comprises a cysteine residue at ammo acid position 49, In some embodiments, the VL region comprises or consists of an ammo acid sequence of SEQ ID NO: 147 and comprises a cysteine substitution at amino acid position 49.

[0345] In some embodiments, the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 147 and comprises a cysteine residue at ammo acid position 50. In some embodiments, the VL region comprises or consists of an ammo acid sequence of SEQ ID NO: 147 and comprises a cysteine substitution at amino acid position 50.Attorney Docket No. JANX-004 / 05WO 339516-2027

[0346] In some embodiments, the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 147 and comprises a cysteine residue at ammo acid position 46. In some embodiments, the VL region comprises or consists of an ammo acid sequence of SEQ ID NO: 147 and comprises a cysteine substitution at amino acid position 46.

[0347] In some embodiments, the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 147 and comprises a cysteine residue at ammo acid position 43. In some embodiments, the VL region comprises or consists of an ammo acid sequence of SEQ ID NO: 147 and comprises a cysteine substitution at amino acid position 43.

[0348] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 146, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 147.

[0349] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 146 and comprises a cysteine residue at amino acid position 44, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 147 and comprises a cysteine residue at amino acid position 100.

[0350] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 146 and comprises a cysteine residue at amino acid position 100B, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 147 and comprises a cysteine residue at amino acid position 49.Attorney Docket No. JANX-004 / 05WO 339516-2027

[0351] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 146 and comprises a cysteine residue at amino acid position 100, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 147 and comprises a cysteine residue at amino acid position 50.

[0352] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 146 and comprises a cysteine residue at ammo acid position 101, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 147 and comprises a cysteine residue at amino acid position 46.

[0353] In some embodiments, the VH region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 146 and comprises a cysteine residue at amino acid position 105, and the VL region comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 147 and comprises a cysteine residue at amino acid position 43.

[0354] In some embodiments, the VH region comprises or consists of an amino acid sequence of SEQ ID NO: 146, and the VL region comprises or consists of an amino acid sequence of SEQ ID NO: 147.

[0355] In some embodiments, the VH region comprises an amino acid sequence of SEQ ID NO: 146 with a cysteine substitution at amino acid position 44, and the VL region comprises an ammo acid sequence of SEQ ID NO: 147 with a cysteine substitution at ammo acid position 100.

[0356] In some embodiments, the VH region comprises an amino acid sequence of SEQ ID NO: 146 with a cysteine substitution at ammo acid position 100B, and the VL region comprises an amino acid sequence of SEQ ID NO: 147 with a cysteine substitution at amino acid position 49.Attorney Docket No. JANX-004 / 05WO 339516-2027

[0357] In some embodiments, the VI I region comprises an amino acid sequence of SEQ ID NO:146 with a cysteine substitution at amino acid position 100, and the VL region comprises an amino acid sequence of SEQ ID NO: 147 with a cysteine substitution at amino acid position 50.

[0358] In some embodiments, the VII region comprises an ammo acid sequence of SEQ ID NO: 146 with a cysteine substitution at ammo acid position 101, and the VL region comprises an amino acid sequence of SEQ ID NO: 147 with a cysteine substitution at ammo acid position 46.

[0359] In some embodiments, the VI I region comprises an amino acid sequence of SEQ ID NO: 146 with a cysteine substitution at amino acid position 105, and the VL region comprises an amino acid sequence of SEQ ID NO: 147 with a cysteine substitution at amino acid position 43.

[0360] In some embodiments, one engineered disulfide bond connects the VH region and the VL region of the TCRaV-binding domain. In some embodiments, two engineered disulfide bonds connect the VH region and the VL region of the TCRaV-binding domain. In some embodiments, three engineered disulfide bonds connect the VH region and the VL region of the TCRaV-binding domain. In some embodiments, four engineered disulfide bonds connect the VH region and the VL region of the TCRaV-binding domain. In some embodiments, five engineered disulfide bonds connect the VH region and the VL region of the TCRaV-binding domain.

[0361] In some embodiments, the TCRaV-binding domain comprises a disulfide bond at the position of VH44-VL100. In some embodiments, the TCRaV-binding domain comprises a disulfide bond at the position of VH100B-VL49. In some embodiments, the TCRaV-binding domain comprises a disulfide bond at the position of VH100-VL50. In some embodiments, the TCRaV- binding domain comprises a disulfide bond at the position of VH101-VL46. In some embodiments, the TCRaV-binding domain comprises a disulfide bond at the position of VH105-VL43,

[0362] In some embodiments, the TCRaV-binding domain is an scFv, An exemplary scFv is provided in Table 9 below.Table 9. TRAV scFvID Description Amino Acid Sequence SEQ ID NO TCRBD- TRAV1-2 EVQLQQS GAEL VKPGAS VKLS CTAS GFNIKDTHM 148 71 scFv (VH- HWVKQRPEQGLEWIGRTDPAS GDTK YDPKF QGKVL ) ' ATIIADTS SN TAYLHLS SL TSEDTAV Y YC AHY YRD DVNYAMDYWGQGT1VTVSSGGGGSGGGGSGGG GSDIVMTQSQKFLSTS VGDRVS VTCKARQNVGSN VAWYQQKPGQSPKSLIYSSSFRYSGVPDRFTGSGS GTDFTLTISNVQSEDLAEYFCQQYNTYPYTFGGGTELEIKAttorney Docket No. JANX-004 / 05WO 339516-2027

[0363] In some embodiments, the TCRaV-binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 148. In some embodiments, the TCRaV-binding domain comprises or consists of an ammo acid sequence of SEQ ID NO: 148.

[0364] In some embodiments, the TCRaV-binding domain comprises a heavy chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to any one of SEQ ID NOs: 1129 and 1130.

[0365] In some embodiments, the TCRaV-bmding domain comprises a light chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to any one of SEQ ID NOs: 1127 and 1128.

[0366] In some embodiments, the TCRaV-binding domain comprises a heavy chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1129, and a light chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1 127, In some embodiments, the TCRaV -binding domain comprises a heavy chain comprising SEQ ID NO: 1129, and a light chain comprising SEQ ID NO: 1127, In some embodiments, the TCRaV-binding domain comprises a heavy chain comprising SEQ ID NO: 1129 with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more mutations therein. In some embodiments, the TCRaV-binding domain comprises a light chain comprising SEQ ID NO: 1127 with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more mutations therein. In some embodiments, the TCRaV-binding domain is a Fab.

[0367] In some embodiments, the TCRaV-binding domain comprises a heavy chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1130, and a light chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:Attorney Docket No. JANX-004 / 05WO 339516-2027 1128. In some embodiments, the TCRaV-binding domain comprises a heavy chain comprising SEQ ID NO: 1130, and a light chain comprising SEQ ID NO: 1128. In some embodiments, the TCRaV- binding domain comprises a heavy chain comprising SEQ ID NO: 1130 with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more mutations therein. In some embodiments, the TCRaV-binding domain comprises a light chain comprising SEQ ID NO: 1128 with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more mutations therein. In some embodiments, the TCRaV-binding domain is a Cross-Fab.

[0368] In some embodiments, the TCRpV-binding domain is an scFv and the C-terminus of the VH region is linked to the N-terminus of the VL region. In some embodiments, the TCRpV-binding domain is an scFv and the C-terminus of the VL region is linked to the N-terminus of the VH region. In some embodiments, the VH region and the VL region are linked by a linker.

[0369] In some embodiments, the TCRa V-bmding domain is an scFv and the C-terminus of the VH region is linked to the N-terminus of the VL region. In some embodiments, the TCRa V-binding domain is an scFv and the C-terminus of the VL region is linked to the N-terminus of the VH region. In some embodiments, the VH region and the VL region are linked by a linker. In some embodiments, the TCRpV-binding domain is an antibody selected from the group consisting of: S511, VER2.32.1, IG125, 56C5, 16G8, MX-6, JR2, AF23, AHUT7, TAMAYA1.2, BA62.6, Cl, E17.5F3.15.13, IMMU546, MPB2D5, C21, CAS1.1.3, CH92, 8F10, JOVI-3, WJF24, ELL1.4, FIN9, AMKB1-2, ZOE, 3G5, ZIZOU4, IMMU157, LC4, 3D11, ICl, W112, MH3-2, 36213, BAM13, H132, IMMU222, H131, JU-74, JU743, OT145, and BL37.2, or a fragment or variant thereof. In some embodiments, the TCRpV-binding domain comprises a VH region from an antibody selected from the group consisting of: S511, VER2.32.1, IG125, 56C5, 16G8, MX-6, JR2, AF23, AHUT7, TAMAYA1.2, BA62.6, Cl, E17.5F3.15.13, IMMU546, MPB2D5, C21, CAS1.1.3, CH92, 8F10, JOVI-3, WJF24, ELL1.4, FIN9, AMKB1-2, ZOE, 3G5, ZIZOU4, IMMU157, LC4, 3D11, ICl, W112, MH3-2, 36213, BAM13, Hi 32. IMMU222, H131, JU- 74, JU743, OT145, and BL37.2, or a fragment or variant thereof. In some embodiments, the TCRpV-bmding domain comprises a VL region from an antibody selected from the group consisting of: S511, VER2.32.1, IG125, 56C5, 16G8, MX-6, JR2, AF23, AHUT7, TAMAYA1.2, BA62.6, Cl, E17.5F3.15.13, IMMU546, MPB2D5, C21, CAS1.1.3, CH92, 8F10, JOVI-3, WJF24, ELL1.4, FIN9, AMKB1-2, ZOE, 3G5, ZIZOU4, IMMU157, LC4, 3D11, ICl, W112, MH3-2, 36213, BAM13, 11132, IMMU222, III 31, JU-74, JU743, OT145, and BL37.2, or a fragment or variant thereof. In some embodiments, the TCRpV-binding domain comprises a VH region and a VL region from an antibody selected from the group consisting of: S511, VER2.32.1, IG125, 56C5, 16G8, MX-6, JR2,Attorney Docket No. JANX-004 / 05WO 339516-2027 AF23, AHUT7, TAMAYAI.2, BA62.6, Cl, E17.5F3.15.13, IMMU546, MPB2D5, C21, CASI.1.3, CI 192, 8F10, JOVI-3, WJF24, ELL1.4, FIN9, AMKB1-2, ZOE, 3G5, ZIZOU4, IMMUI57, LC4, 3D11, 1C1, W112, MFI3-2, 36213, BAM13, FI132, IMMU222, H131, JU- 74, JU743, OT145, and BL37.2, or a fragment or variant thereof. In some embodiments, the TCRpV-binding domain comprises CDRs from an antibody selected from the group consisting of S511, VER2.32.1, IG125, 56C5, 16G8, MX-6, JR2, AF23, AHUT7, TAMAYAI.2, BA62.6, Cl, E17.5F3.15.13, IMMU546, MPB2D5, C21, CASI.1.3, CH92, 8F10, JOVI-3, WJF24, ELLI.4, FIN9, AMKB1-2, ZOE, 3G5, ZIZOU4, IMMU157, LC4, 3D11, 1C1, W112, MH3-2, 36213, BAM13, H132, IMMU222, H131, JU-74, JU743, OT145, and BL37.2, or a fragment or variant thereof. In some embodiments, the CDRs comprise 1, 2, 3, or more amino acid substitutions.

[0370] In some embodiments, the TCRaV-binding domain is an antibody selected from the group consisting of: C15, 6B11, SFB280, 3C10, Fl, 6D6.6, clone 34, or a fragment or variant thereof. In some embodiments, the TCRaV-binding domain comprises a VH region from an antibody selected from the group consisting of: C15, 6B11, SFB280, 3C10, FT, 6D6.6, clone 34, or a fragment or variant thereof. In some embodiments, the TCRaV-binding domain comprises a VL region from an antibody selected from the group consisting of: C15, 6B11, SFB280, 3C10, Fl, 6D6.6, clone 34, or a fragment or variant thereof. In some embodiments, the TCRaV-binding domain comprises a VH region and a VL region from an antibody selected from the group consisting of: C15, 6B11, SFB280, 3C10, Fl, 6D6.6, clone 34, or a fragment or variant thereof. In some embodiments, the TCRaV-binding domain comprises CDRs from an antibody selected from the group consisting of: Cl 5, 6B11, SFB280, 3C10, Fl, 6D6.6, clone 34, or a fragment or variant thereof. In some embodiments, the CDRs comprise 1, 2, 3, or more amino acid substitutions.

[0371] In some embodiments, the TCRpV -binding domain specifically binds to human TCR V (e.g., a TCR[3V family, subfamily, or variant thereof). TCRpV families and subfamilies are known in the art, e.g., as described in Yassai et al,, (2009) Immunogenetics 61(7) pp:493-502; and Wei S. and Concannon P. (1994) Human Immunology 41(3) pp: 201-206. Different gene nomenclatures for any one of the TCRPV families and subfamilies described herein are also encompassed by the present disclosure. For example, the TCRPV nomenclature as described by Folch, G. and Lefranc, M.-P., Exp. Clin. Immunogenet., 17, 42-54 (2000); Lefranc, M -P and Lefranc, G., The T Cell Receptor Facts Book, Academic Press, Harcourt, 398 pages (2001); Slightom, J L. etal., Genomics, 20, 149-168 (1994); Wei et al., Immunogenetics, 40, 27-36 (1994); Arden, B. et al., Immunogenetics, 42, 455-500 (1995); Rowen, L. et al., Science, 272, 1755-1762 (1996); andAttorney Docket No. JANX-004 / 05WO 339516-2027 Wilson, R. K et al., Immunological Reviews 101, 149-172 (1988) are encompassed by the present invention, each of which are hereby incorporated by reference in their entirety.TCR Targets

[0372] In some embodiments, the TCRpV-binding domain specifically binds to any one of: TCRpVl, TCRPV2, TCRPV3, TCRPV4, TCRPV5, TCRPV6, TCRPV7, TCRpV8, TCRpV9, TCRPV10, TCRPVI 1, TCRpV12, TCRPV13, TCRPV14, TCRpV15, TCRPV16, TCRPV17, TCRpVl 8, TCRpVl 9, TCRPV20, TCRpV21, TCRpV22, TCRPV23, TCRpV24, TCRpV25, TCRPV26, TCRPV27, TCRPV28, TCRPV29, TCRPV30, TCR VA, TCRPVB, TCR VC, or a variant thereof. See, also, Folch and Lefranc, Exp. Clin. Immunogenet, 17, 42-54 (2000).

[0373] In some embodiments, the TCRpV-binding domain specifically binds to any one of TCRPV2*O1, TCRPV2*O2, TCRPV2*O3, TCRPV3-1*O1, TCRPV3-1*O2, TCRPV4-1*O1, TCRPV4-1*O2, TCRPV4-2*O1, TCRPV4-2*O2, TCRPV4-3*O1, TCRPV4-3*O2, TCRPV4-3*O3, TCRPV4-3*O4, TCRPV5-1*O1, TCRPV5-1*O2, TCRPV5-4*O1, TCRPV5-4*O2, TCRPV5-4*O3, TCRPV5-4*O4, TCRPV5-5*O1, TCRpV5-5*02, TCRPV5-5*O3, TCRPV5-6*O1, TCRPV5-8*O1, TCRPV5-8*O2, TCRPV6-1*O1, TCRPV6-2*O1, TCRPV6-3*O1, TCRPV6-4*O1, TCRPV6-4*O2, TCRPV6-5*O1, TCRPV6-6*O1, TCRPV6-6*O2, TCRPV6-6*O3, TCRPV6-6*O4, TCRPV6-6*O5, TCRPV6-8*O1, TCRPV6-9*O1, TCRPV7-2*O1, TCRPV7-2*O2, TCRPV7-2*O3, TCRPV7-2*O4, TCRPV7-3*O1, TCRPV7-3*O4, TCRPV7-3*O5, TCRPV7-4*O1, TCRPV7-6*O1, TCRPV7-6*O2, TCRPV7-7*O1, TCRPV7-7*O2, TCRPV7-8*O1, TCRPV7-8*O2, TCRPV7-8*O3, TCRPV7-9*O1, TCRpV7-9*02, TCRPV7-9*O3, TCRPV7-9*O4, TCRpV7-9*05, TCRpV7-9*06, TCRPV7-9*O7, TCRPV9*O1, TCRPV9*O2, TCRPV9*O3, TCRpV10-l*01, TCRPV1O-1*O2, TCRPV1O-2*O1, TCRpVl 0-2*02, TCRpV10-3*01, TCRpVl 0-3*02, TCRpV10-3*03, TCRPV1O-3*O4, TCRpVl 1- 1*01, TCRpVl 1-2*01, TCRPV11-2*O2, TCRpVl 1-2*03, TCRpVl 1-3*01, TCRpVl 1-3*02, TCRpVl 1-3*03, TCRpVl l-3*04, TCRpV12-3*01, TCRPV12-4*O1, TCRPV12-4*O2, TCRPV12- 5*01, TCRPV13*O1, TCRpV13*02, TCRpV14*01, TCRPV14*O2, TCR V15*O1, TCRPV15*O2, TCRpVl 5*03, TCRPV16*O1, TCRPV16*O3, TCRPV18*O1, TCRPV19*O1, TCRPV19*O2, TCRPV19*O3, TCRPV2O-1*O1, TCRpV20-l*02, TCRPV2O-1*O3, TCRpV20-l*04, TCRpV20- 1*05, TCRPV2O-I*O6, TCRPV2O-1*O7, TCRpV24-l*01, TCRpV25-l*01, TCRpV27*01, TCRPV28*O1, TCRpV29-l*01, TCRPV29-1 *02, TCRPV29-1*O3, TCRpV30*01, TCRPV3O*O2, TCRpV30*03, TCRPV3O*O4, or a variant thereof.

[0374] In some embodiments, the TCRaV-bindmg domain specifically binds to human TCRaV (e.g., a TCRaV family, subfamily, or variant thereof). TCRaV families and subfamilies are knownAttorney Docket No. JANX-004 / 05WO 339516-2027 in the art, e.g., as described in Yassai et al., (2009) Immunogenetics 61(7) pp:493-502. Different gene nomenclatures for any one of the TCRaV families and subfamilies described herein are also encompassed by the present disclosure. For example, the TCRaV nomenclature as described by Scaviner D. and Lefranc, M.-P., Exp. Clin. Immunogenet, 17, 83-96 (2000); Lefranc, M -P. and Lefranc, G., The T Cell Receptor FactsBook, Academic Press, Harcourt, 398 pages (2001); Arden, B et al., Immunogenetics, 42, 455-500 (1995); and Wilson, R. K. et al., Immunological Reviews 101, 149-172 (1988) are encompassed by the present invention, each of which are hereby incorporated by reference in their entirety.

[0375] In some embodiments, the TCRaV-binding domain specifically binds to any one of: TCRaVl, TCRaV2, TCRaV3, TCRaV4, TCRaV5, TCRaV6, TCRaV7, TCRaV8, TCRaV9, TCRaVIO, TCRaVl 1, TCRaV12, TCRaV13, TCRaV14 / DV4, TCRaV15, TCRaV16, TCRaV17, TCRaVl 8, TCRaV19, TCRaV20, TCRaV21, TCRaV22, TCRaV23 / DV6, TCRaV24, TCRaV25, TCRaV26, TCRaV27, TCRaV28, TCRaV29 / DV5, TCRaV30, TCRaV31, TCRaV32, TCRaV33, TCRaV34, TCRaV35, TCRaV36 / DV7, TCRaV37, TCRaV38, TCRaV39, TCRaV40, TCRaV41, or a variant thereof. In some embodiments, the TCRaV-binding domain specifically binds to any one of: TCRaVl-1, TCRaVl-2, TCRaV8-l, TCRaV8-2, TCRaV8-3, TCRaV8-4, TCRaV8-5, TCRaV8-6, TCRaV8-7, TCRaV9-l, TCRaV9-2, TCRaV12-l, TCRaV12-2, TCRaV12-3, TCRaV13-l, TCRaV13-2, TCRaV26-l, TCRaV26-2, TCRaV38-l, TCRaV38-2 / DV8, or a variant thereof. See, also, Scaviner D. and Lefranc, M.-P., Exp. Clin. Immunogenet, 17, 83-96 (2000).

[0376] Exemplary amino acid sequences for TCRβV family members are shown in Table 10 below and can also be found on the ImMunoGeneTics Information System website: http: / / www.imgt.org / , or in a similar resource.Table 10. TCRβVTarget Species Amino Acid Sequence SEQ ID NO TCRβV5-5 Human DAGVTQSPTHLIKTRGQQVTLRCSPISGH 93KSVSWYQQVLGQGPQFIFQYYEKEERG RGNFPDRFSARQFPNYSSELNVN ALLLG DSALYLCASSL TCRPV5-5 Cynomolgus DGGVTQSPRHLIKTTGQQVTLRCSPISGH 94Monkey TSVSWYQQALGQGPQFIFEYEEKERERGNFPDRFSGHQFSNYSSELNVNALEAGDSALYLCASSLAttorney Docket No. JANX-004 / 05WO 339516-2027 Target Species Amino Acid Sequence SEQID NO TCRβV5-6 Human DAGVTQSPTHLIKTR GQQVTLRCSPKSG 95HDTVSWYQQALGQGPQFIFQYYEEEER QRGNFPDRFSGHQFPNYSSELNVNALLL GDSALYLCASSL TCRβV5-6 Cynomolgus DGGVTQSPRHLIKTTGQQVTLRCSPISGH 96Monkey TSVSWYQQALGQGPQFIFEYEEKERERG NFPDRFSGHQFSNYSSELNVNALEAGDS ALYLCASSL TCRPV5-6 Rhesus DTGVTQSPTHLIRKRGQQVTLRCSPISGH 97Monkey NWSWYQQALGQGPQFIFQYYEKEERE RGNFPGRF SGHQFPN YSSELNVSALLLG DSALYLCASSL TCRpV6-5 Human NAGVTQTPKFQVLKTGQSMTLQCAQD 98MNHEYMSWYRQDPGMGLRLIHYSVGA GITDQGEVPNGYNVSRSTTEDFPLRLLS A APSQTSVYFCASSY TCRPV6-5 Cynomolgus NVGVTQTPKFQ VLK TGQSMTVQCAQD 99Monkey MNHNFMYWYRQDPGMGLRLIHYSGAA GTTDKGEVPSGYNVSRLNTEDFPLRLES ADPSQTSVYICASSY TCRPV6-5 Rhesus NWGVTQTTKFQVLKTGQSMTVQCAQD 100Monkey MNHNFMYWYRQDPGMGLRLIHYSGAAGT TDKGEVPSGYNVSRLNTEDFPLRLESAD P SQTSVYFCASSY TCRβV12-3 Human DAGVIQSPRHEVTEMGQEVTLRCKPISG 101HNSLFWYRQTMMRGLELLIYFNNNVPID DSGMPEDRFSAKMPNASFSTLKIQPSEPR DSAVYFCASSL TCRβV12-3 Cynomolgus DAGVIQSPRHEVTEMGKEVTLRCEPISG 102Monkey HTYLFWYRQTMMRGLEFLIYFNNKSPID DSGMPKDRFSAKMI’DASFSTLKIQPSEP RDSAVYFCASSL TCRβV12-3 Rhesus DAGVIQSPQHEVTEMGKEVTLRCEPI 103Monkey SGHTYLFWYRQTMMRGLEFLIYFNNKSP IDDSGMPKDRFSATMPEVSFSTLKIQPSE P RDSAVYFCASSL TCRPV12-4 Human DAGVIQSPRHEVIEMGQEVTLRCKl’ISG 104HDYLFWYRQTMMRGLELLIYFNNNVPI DDSGMPEDRFSAKMPNASFSTLKIQPSEP RDSAVYFCASSL TCRβV12-4 Cynomolgus DAGVTQTPRHKVTEMGQEVTMRCQPIL 105Monkey GHNTVFWYRQTVMQGLELLVYLRNKASLDDSGMPKDRFSAEMPDASLATLKIQPSEPRDSAVYLCASGLAttorney Docket No. JANX-004 / 05WO 339516-2027 Target Species Amino Acid Sequence SEQ ID NO TCRβV12-4 Rhesus DAGVTQTPRHKVTEMGQEVTMRCQPI 106Monkey LGHNTVFWYRQTVMQGLELLVYLRNK ASLDDSGMPKDRFSAEMPDASLATLKIQ PSEP RDSAVYLC ASGL TCRβV20-1 Human GAVVSQHPSWVICKSGTSVKIECRSLDF 107QATTMFWYRQFPKQSLMLMATSNEGSK ATYEQGVEKDKFLINHASLTLSTLTVTS AHPEDSSFYICSAR TCRβV20-1 Cynomolgus AAVVSQYPSRVICKRGTSVKIECRCLDF 108Monkey QATTMFWYRQFQTQSLILMATSNEGSG VTYEQGVKQDKFPINHI’NLITS TLTVTN AHPEDSSFYICSAR TCRβV20-1 Rhesus AAVVSQYPSRVICKRGTSVKIECRCLDF 109Monkey QATTMFWYRQFQTQSI1I. A4ATSNEGSGVTYEQGVKQDKFPINHPNI. TFSTI> TVTNAHP EDSSFYICS AR

[0377] In some embodiments, TCRPV comprises or consists of an amino acid sequence of any one of SEQ ID NOs: 93-109. In some embodiments, TCRPV comprises or consists of an amino acid sequence with at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.5% sequence identity to any one of SEQ ID NOs: 93-109. In some embodiments, TCRPV comprises or consists of an amino acid sequence of any one of SEQ ID NOs: 93-109 with one or more mutations therein. In some embodiments, TCRPV comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more mutations in any one of SEQ ID NOs: 93-109. In some embodiments, TCRPV comprises 1-5, 5-10, 11-15, 15- 20, 20-25, 25-30, or more than 30 mutations in any one of SEQ ID NOs: 93-109.

[0378] An exemplary amino acid sequence for TCRαV family members is shown in Table 11 below and can also be found on the ImMunoGeneTics Information System website: http: / / www.imgt.org / , or in a similar resource.Table 11. TCRαVTarget Species Amino Acid Sequence SEQ ID NO TCRαV1-2 Human WGVFLLYVSMKMGGTTGQNIDQPTEMTATE 149GAIVQINCTYQTSGFNGLFWYQQHAGEAPTFL SYNVLDGLEEKGRFSSFLSRSKGYSYLLLKELQMKDSASYLCAAttorney Docket No....

Claims

Attorney Docket No. JANX-004 / 05WO 339516-2027 WHAT IS CLAIMED:1, A multi -specific polypeptide comprising:(a) a first binding domain that specifically binds T cell receptor alpha variable region (TCRαV), or T cell receptor beta variable region (TCRβV); and(b) a second binding domain that specifically binds CD 19.2, A multi -specific polypeptide comprising:(a) a first binding domain that specifically binds CD3; and(b) a second binding domain that specifically binds CD19.

3. The multi- specific polypeptide of claim 1 or 2, further comprising: (c) a half-life extension moiety.

4. The multi-specific polypeptide of any one of claims 1-3, wherein the CD19 comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 151.5, The multi-specific polypeptide of any one of claims 1-4, wherein the second binding domain comprises:(i) an immunoglobulin heavy chain variable (VH) region comprising a heavy chain CDR1 (HCDR1), a heavy chain CDR2 (HCDR2), and a heavy chain CDR3 (HCDR3), and(ii) an immunoglobulin light chain variable (VL) region comprising a light chain CDRl (LCDR1), a light chain CDR2 (LCDR2), and a light chain CDR3 (LCDR3).6, The multi-specific polypeptide of claim 5, wherein the second binding domain is a single chain variable fragment (scFv), a Fab, a CrossFab, a Fab’, or a F(ab’)2.

7. The multi-specific polypeptide of claim 6, wherein the Fab comprises the VH region, the VL region, a first heavy chain constant region (CHI), and a light chain constant region (CL), wherein the C-terminus of the VH region is connected to the N-terminus of the CHI region, and the C-terminus of the VL region is connected to the N-terminus of the CL region.

8. The multi-specific polypeptide of claim 6, wherein the CrossFab comprises the VH region, the VL region, a CHI region, and a CL region, wherein the C-terminus of the VH region is connected toAttorney Docket No. JANX-004 / 05WO 339516-2027 the N-terminus of the CL region, and the C-terminus of the VL region is connected to the N-terminus of the CH1 region.

9. The multi-specific polypeptide of claim 7 or 8, wherein the CHI region and the CL region are connected by a disulfide bond.

10. The multi-specific polypeptide of any one of claims 6-9, wherein the Fab or the CrossFab is a charge steering Fab or a charge steering CrossFab.

11. The multi-specific polypeptide of claim 10, wherein a CHI region of the charge steering Fab or the charge steering CrossFab comprises mutations K147E / K213E according to EU numbering, and a CL region of the charge steering Fab or the charge steering CrossFab comprises mutations El 23R / Q124K according to EU numbering.

12. The multi-specific polypeptide of claim 6, wherein the scFv comprises the VH region and the VL region.

13. The multi-specific polypeptide of claim 12, wherein the C-terminus of the VH region is linked to the N-terminus of the VL region.

14. The multi-specific polypeptide of claim 12, wherein the C-terminus of the VL region is linked to the N-terminus of the VH region.

15. The multi-specific polypeptide of any one of claims 12-14, wherein the VH region and the VL region are linked by a peptide linker (PL2).

16. The multi-specific polypeptide of claim 15, wherein the peptide linker (PL2) comprises the formula of (Gly4Ser)n, wherein n = 1-5.

17. The multi-specific polypeptide of claim 16, wherein the peptide linker (PL2) is (GlyrSeff.

18. The multi-specific polypeptide of claim 16, wherein the peptide linker (PL2) is (Gly4Ser)i.

19. The multi-specific polypeptide of any one of claims 5-18, wherein the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2, and the LCDR3 of the second binding domain are according to one of the combinations of complementarity determining regions (CDRs) of Table 14 or Table 15.Attorney Docket No. JANX-004 / 05WO 339516-2027 20. The multi-specific polypeptide of claim 19, wherein the HCDR1 comprises an amino acid sequence of SYVMH (SEQ ID NO: 303), the HCDR2 comprises an ammo acid sequence of YINPYNDGTKYNEKFQG (SEQ ID NO: 311), the HCDR3 comprises an amino acid sequence of GTYYYGTRVFDY (SEQ ID NO: 317), the LCDR1 comprises an amino acid sequence of RSSKSLQNVNGNTYLY (SEQ ID NO: 323), the LCDR2 comprises an amino acid sequence of RMSNLNS (SEQ ID NO: 329), and the LCDR3 comprises an ammo acid sequence of MQHLEYPIT (SEQ ID NO: 334), wherein the CDRs correspond to the second binding domain and are numbered with reference to the Kabat numbering scheme.

21. The multi-specific polypeptide of claim 19, wherein the HCDR1 comprises an amino acid sequence of TSGMGVG (SEQ ID NO: 304), the HCDR2 comprises an amino acid sequence of HIWWDDDKRYNPALKS (SEQ ID NO: 312), the HCDR3 comprises an amino acid sequence of MELWSYYFDY (SEQ ID NO: 318), the LCDR1 comprises an amino acid sequence of SASSSVSYMH (SEQ ID NO: 324), the LCDR2 comprises an amino acid sequence of DTSKLAS (SEQ ID NO: 328), and the LCDR3 comprises an amino acid sequence of FQGSVYPFT (SEQ ID NO: 335), wherein the CDRs correspond to the second binding domain and are numbered with reference to the Kabat numbering scheme.

22. The multi-specific polypeptide of claim 19, wherein the HCDR1 comprises an amino acid sequence of TSTMGVG (SEQ ID NO: 306), the HCDR2 comprises an amino acid sequence of FIWWDDDKRYNPNLKS (SEQ ID NO: 314), the HCDR3 comprises an amino acid sequence of MELWSYYFDY (SEQ ID NO: 318), the LCDR1 comprises an amino acid sequence of SASSSVGYMH (SEQ ID NO: 326), the LCDR2 comprises an amino acid sequence of DTSKLAS (SEQ ID NO: 328), and the LCDR3 comprises an amino acid sequence of FQGSVYPFT (SEQ ID NO: 335), wherein the CDRs correspond to the second binding domain and are numbered with reference to the Kabat numbering scheme.

23. The multi-specific polypeptide of claim 19, wherein the HCDR1 comprises an amino acid sequence of TSTMGVG (SEQ ID NO: 306), the HCDR2 comprises an amino acid sequence of FIWWDDDKRYNPNLKS (SEQ ID NO: 314), the HCDR3 comprises an amino acid sequence of MELWSYYFDP (SEQ ID NO: 320), the LCDR1 comprises an amino acid sequence of SASSSVGYMH (SEQ ID NO: 326), the LCDR2 comprises an amino acid sequence of DTSKLAF (SEQ ID NO: 331), and the LCDR3 comprises an amino acid sequence of FQGSVYPFT (SEQ ID NO:Attorney Docket No. JANX-004 / 05WO 339516-2027 335), wherein the CDRs correspond to the second binding domain and are numbered with reference to the Kabat numbering scheme.

24. The multi-specific polypeptide of any one of claims 5-23, wherein the VH region of the second binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to any one of SEQ ID NOs: 365, 367, 369, 371, 373, 375, 377, 379, 381, and 383, and wherein the VL region of the second binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 366, 368, 370, 372, 374, 376, 378, 380, 382, and 384.

25. The multi-specific polypeptide of any one of claims 1-6 and 12-24, wherein the second binding domain comprises an scFv comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to any one of SEQ ID NOs: 385-386.

26. The multi-specific polypeptide of any one of claims 1-11 and 19-24, wherein the second binding domain comprises a Fab or CrossFab comprising (i) a heavy chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to any one of SEQ ID NOs: 387, 389, 391, 393, 395, 397, 399, 401, 403, and 405; and (li) a light chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to any one of SEQ ID NOs: 388, 390, 392, 394, 396, 398, 400, 402, 404, and 406.

27. The multi-specific polypeptide of any one of claims 1 and 3-26, wherein the first binding domain specifically binds TCRpV.

28. The multi-specific polypeptide of any one of claims 1 and 3-27, wherein the TCRPV is selected from the group consisting of TCRpV-5-5, TCRpV-5-6, TCRPV6-5, TCRpV-12-3, TCRpV-12-4, and TCRpV-20-1.

29. The multi-specific polypeptide of any one of claims I and 3-28, wherein the TCRpV comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to any one of SEQ ID NOs: 100-116.Attorney Docket No. JANX-004 / 05WO 339516-2027 30. The multi-specific polypeptide of any one of claims 1 and 3-29, wherein the first binding domain comprises complementarity determining regions (CDRs) from a binding molecule selected from the group consisting of: IMMU 546, F1N9, AMKB1-2, ZOE, 3G5, ZIZOU4, IMMU 157, LC4, 3DI I, I CI, W112, MH3-2, 4H11, 36213, BAM13, HI3I, A. H-53, H132, IMMU 222, JU-74, JU74.3, OT145, BL37.2, S511, VER2.32.1, IG125, 56C5, 56C5.2, 16G8, MX-6, JR2, AF-23, AF23, AIIUT7, TAMAYA1.2, BA62, BA62.6, CI, E17.5F3, E17.5F3.15.13, MPB2D5, C21, CAS1.1.3, CH92, 8F10, JOVI-3, WJF24, ELL1.4, JOVI-1, SP305, LG.3A10, 5A8A10, 5D9F1, and KFN; wherein the CDRs are each determined according to the Kabat numbering scheme, the Chothia numbering scheme, or the ImMunoGeneTics Information System (IMGT).

31. The multi-specific polypeptide of any one of claims 1 and 3-26, wherein the first binding domain specifically binds TCRaV.

32. The multi-specific polypeptide of any one of claims 1, 3-26, and 31, wherein the TCRαV is TCRαV 1-2.

33. The multi-specific polypeptide of any one of claims 1, 3-26, 31, and 32, wherein the TCRαV comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 149.

34. The multi-specific polypeptide of any one of claims 1, 3-26, and 31-33, wherein the first binding domain comprises CDRs from a binding molecule selected from the group consisting of: Cl 5, 6B11, SFB280, 3C10, Fl, 6D6.6, and clone 34; wherein the CDRs are each determined according to the Kabat numbering scheme, the Chothia numbering scheme, or the ImMunoGeneTics Information System (IMGT).

35. The multi-specific polypeptide of any one of claims 1-34, wherein the first binding domain comprises:(i) a VII region comprising an IICDRl, an HCDR2, and an HCDR3, and(li) a VL region comprising an LCDRl, an LCDR2, and an LCDR3.

36. The multi-specific polypeptide of claim 35, wherein the first binding domain is a single chain variable fragment (scFv), a Fab, a CrossFab, a Fab’, or a F(ab’)2.Attorney Docket No. JANX-004 / 05WO 339516-2027 37. The multi-specific polypeptide of claim 36, wherein the Fab comprises the VH region, the VL region, a CHI region, and a CL region, wherein the C-terminus of the VH region is connected to the N-terminus of the CHI region, and the C-terminus of the VL region is connected to the N-terminus of the CL region.

38. The multi -specific polypeptide of claim 36, wherein the CrossFab comprises the VH region, the VL region, a CHI region, and a CL region, wherein the C-terminus of the VH region is connected to the N-terminus of the CL region, and the C-terminus of the VL region is connected to the N-terminus of the CHI region.

39. The multi-specific polypeptide of claim 37 or 38, wherein the CHI region and the CL region are connected by a disulfide bond.

40. The multi-specific polypeptide of any one of claims 36-39, wherein the Fab or the CrossFab is a charge steering Fab or a charge steering CrossFab.

41. The multi-specific polypeptide of claim 40, wherein a CHI region of the charge steering Fab or the charge steering CrossFab comprises mutations K147E / K213E according to EU numbering, and a CL region of the charge steering Fab or charge steering CrossFab comprises mutations El 23R / Q124K according to EU numbering.

42. The multi-specific polypeptide of claim 36, wherein the scFv comprises the VH region and the VL region.

43. The multi-specific polypeptide of claim 42, wherein the C-terminus of the VH region is linked to the N-terminus of the VL region,44. The multi-specific polypeptide of claim 42, wherein the C-terminus of the VL region is linked to the N-terminus of the VH region,45. The multi-specific polypeptide of any one of claims 42-44, wherein the VH region and the VL region are linked by one or more engineered disulfide bond(s).

46. The multi-specific polypeptide of claim 45, wherein one cysteine that forms the engineered disulfide bond is located in the VH region, and wherein the other cysteine that forms the engineered disulfide bond is located in the VL region.Attorney Docket No. JANX-004 / 05WO 339516-2027 47. The multi- specific polypeptide of claim 45 or 46, wherein the positions of the one or more engineered disulfide bond(s) are selected from the group consisting of VH44-VL100, VH100B-VL49, VH100-VL50, VH101-VL46, and VH105-VL43.

48. The multi-specific polypeptide of any one of claims 42-47, wherein the VH region and the VL region are linked by a peptide linker (PL1).49, The multi-specific polypeptide of claim 48, wherein the peptide linker (PL1) comprises the formula of (Gly4Ser)n, wherein n = 1-5.50, The multi-specific polypeptide of claim 49, wherein the peptide linker (PL1) is (Gly4Ser)3.

51. The multi-specific polypeptide of claim 49, wherein the peptide linker (PL1) is (Gly4Ser)i.

52. The multi-specific polypeptide of any one of claims 35-51, wherein the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2, and the LCDR3 of the first binding domain are according to one of the combinations of complementarity’ determining regions (CDRs) of Table 1, Table 2, Table 6, or Table 7.

53. The multi-specific polypeptide of any one of claims 35-52, wherein the HCDR1 comprises an amino acid sequence of LYYIH (SEQ ID NO: 1138), the HCDR2 comprises an amino acid sequence of WFFPGSGNIKYNEKFKG (SEQ ID NO: 2), the HCDR3 comprises an amino acid sequence of SYYSFDVLDY (SEQ ID NO: 1139), the LCDR1 comprises an amino acid sequence of KASQNVGIRVV (SEQ ID NO: 1140), the LCDR2 comprises an amino acid sequence of SSSHRYS (SEQ ID NO: 5), and the LCDR3 comprises an amino acid sequence of QQFKSYPIT (SEQ ID NO: 1141), wherein the CDRs correspond to the first binding domain and are numbered with reference to the Kabat numbering scheme.54, The multi -specific polypeptide of any one of claims 35-52, wherein the HCDR1 comprises an amino acid sequence of TYYIH (SEQ ID NO: 1), the HCDR2 comprises an amino acid sequence of WFFPRSGNIKYNEKFKG (SEQ ID NO: 1142), the HCDR3 comprises an amino acid sequence of SYYSFDVLDY (SEQ ID NO: 1139), the LCDR1 comprises an amino acid sequence of KASQNVGIRVV (SEQ ID NO: 1140), the LCDR2 comprises an amino acid sequence of SSSHRYS (SEQ ID NO: 5), and the LCDR3 comprises an amino acid sequence of QQFKSYPIT (SEQ ID NO:Attorney Docket No. JANX-004 / 05WO 339516-2027 1141), wherein the CDRs correspond to the first binding domain and are numbered with reference to the Kabat numbering scheme.

55. The multi-specific polypeptide of any one of claims 35-52, wherein the HCDR1 comprises an amino acid sequence of GYSFTLYY (SEQ ID NO: 1143), the HCDR2 comprises an amino acid sequence of FFPGSGNI (SEQ ID NO: 18), the HCDR3 comprises an amino acid sequence of A / XSYYSFDVLDY (SEQ ID NO: 1144), the LCDR1 comprises an ammo acid sequence of QNVGIR (SEQ ID NO: 1145), the LCDR2 comprises an amino acid sequence of SSS, and the LCDR3 comprises an amino acid sequence of QQFKSYPIT (SEQ ID NO: 1146), wherein the CDRs correspond to the first binding domain and are numbered with reference to the IMGT numbering scheme.

56. The multi-specific polypeptide of any one of claims 35-52, wherein the HCDR1 comprises an amino acid sequence of GYSFTTYY (SEQ ID NO: 17), the HCDR2 comprises an amino acid sequence of FFPRSGNI (SEQ ID NO: 1147), the HCDR3 comprises an amino acid sequence of AASYYSFDVLDY (SEQ ID NO: 1144), the LCDR1 comprises an amino acid sequence of QNVGIR (SEQ ID NO: 1145), the LCDR2 comprises an ammo acid sequence of SSS, and the LCDR3 comprises an ammo acid sequence of QQFKSYPIT (SEQ ID NO: 1146), wherein the CDRs correspond to the first binding domain and are numbered with reference to the IMGT numbering scheme.

57. The multi-specific polypeptide of any one of claims 35-56, wherein the VH region of the first binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to one of SEQ ID NOs listed in the VH column of Table 3 or Table 8, and wherein the VL region of the first binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the corresponding VL SEQ ID NO listed in the same row of Table 3 or Table 8.

58. The multi-specific polypeptide of any one of claims 35-56, wherein the VH region of the first binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1148 or SEQ ID NO: 1190, and wherein the VL region of the first binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1149 or SEQ ID NO: 1192.Attorney Docket No. JANX-004 / 05WO 339516-2027 59. The multi-specific polypeptide of any one of claims 35-56, wherein the VH region of the first binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1150 or SEQ ID NO: 1191, and wherein the VL region of the first binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1149 or SEQ ID NO: 1192.

60. The multi-specific polypeptide of any one of claims 35-51, wherein the HCDRl comprises an amino acid sequence of SEQ ID NO: 201, the HCDR2 comprises an amino acid sequence of SEQ ID NO: 202, the HCDR3 comprises an amino acid sequence of SEQ ID NO: 203, the LCDRI comprises an ammo acid sequence of SEQ ID NO: 204, the LCDR2 comprises an amino acid sequence of SEQ ID NO: 205, and the LCDR3 comprises an amino acid sequence of SEQ ID NO: 206, wherein the CDRs correspond to the first binding domain and are numbered with reference to the Kabat numbering scheme.

61. The multi -specific polypeptide of claim 60, wherein the VH region of the first binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to one of SEQ ID NO: 213, and wherein the VL region of the first binding domain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the corresponding VL SEQ ID NO: 214.

62. The multi-specific polypeptide of any one of claims 1, 3-36, and 42-59, wherein the first binding domain comprises an scFv comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to any one of SEQ ID NOs in Table 4 or Table 9.

63. The multi-specific polypeptide of any one of claims 1, 3-36, and 42-59, wherein the first binding domain comprises an scFv comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1151.

64. The multi-specific polypeptide of any one of claims 1, 3-36, and 42-59, wherein the first binding domain comprises an scFv comprising an amino acid sequence that is at least 80%, at leastAttorney Docket No. JANX-004 / 05WO 339516-2027 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1152.

65. The multi-specific polypeptide of any one of claims 1, 3-36, and 42-59, wherein the first binding domain comprises an scFv comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1153.

66. The multi-specific polypeptide of any one of claims 1, 3-36, and 42-59, wherein the first binding domain comprises an scFv comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1154.

67. The multi-specific polypeptide of any one of claims 1, 3-41, 56, and 57, wherein the first binding domain comprises a Fab or CrossFab comprising (i) a heavy chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to any one of SEQ ID NOs: 243, 245, 1071-1086, 1112- 1123, 1129,1130, 1155, and 1157; and (ii) a light chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to any one of SEQ ID NOs: 244, 246, 1055-1070, 1100-1111, 1127,1128, 1156, and 1158.

68. The multi-specific polypeptide of any one of claims 3-67, wherein the half-life extension moiety is selected from the group consisting of a fragment crystallizable (Fc) region (e.g., a single chain Fc), an albumin (e.g., human serum albumin), transferrin, a binding domain that specifically binds to transferrin or albumin (e.g., an albumin binding domain (ABD)), an unstructured biodegradable proteins (XTEN), a polyethylene glycol (PEG), a glycine-rich homo-ammo-acid polymer (HAP), a hydroxyethyl starch (HES), a polysialic acid (PSA), an immunoglobulin binding polypeptide, and a conformationally disordered polypeptide comprising Proline, Alanine and Serine (PAS), or a derivative or functional fragment thereof.

69. The multi-specific polypeptide of any one of claims 3-68, wherein the half-life extension moiety is a fragment crystallizable (Fc) region.

70. The multi-specific polypeptide of claim 69, wherein the Fc region comprises two polypeptides.Attorney Docket No. JANX-004 / 05WO 339516-2027 71. The multi-specific polypeptide of claim 70, wherein the Fc region has a knobs-into-holes format, wherein the first polypeptide of the Fc region comprises a hole mutation, and wherein second polypeptide of the Fc region comprises a knob mutation.

72. The multi-specific polypeptide of claim 71, wherein the first polypeptide of the Fc region comprises mutations T366S, L368A and Y407V according to EU numbering, and wherein the second polypeptide of the Fc region comprises a mutation T366W according to EU numbering.

73. The multi-specific polypeptide of claim 71 or 72, wherein the first polypeptide of the Fc region comprising the hole mutation further comprises a mutation Y349C according to EU numbering, wherein the second polypeptide of the Fc region comprising the knob mutation further comprises a mutation S354C according to EU numbering, and wherein the Fc region comprises an engineered disulfide bond formed between these two cysteines.

74. The multi-specific polypeptide of any one of claims 69-73, wherein one or both of the polypeptides of the Fc region comprise mutations L234A, L235A, and P329G according to EU numbering.

75. The multi -specific polypeptide of any one of claims 69-74, wherein one or both of the polypeptides of the Fc region comprise the mutation N297G according to EU numbering.

76. The multi -specific polypeptide of any one of claims 69-75, wherein one or both of the polypeptides of the Fc region comprise mutations H435R and Y436F according to EU numbering.

77. The multi-specific polypeptide of any one of claims 69-76, wherein the Fc region lacks one or more effector functions and / or lacks glycosylation.

78. The multi-specific polypeptide of claim 77, wherein the effector function is selected from the group consisting of antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), binding to a Fey receptor (FcyR), or any combination thereof,79. The multi-specific polypeptide of any one of claims 71 -78, wherein the first polypeptide of the Fc region with a peptide linker PLE of DKTHTCPPCP (SEQ ID NO: 161) comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 154, and wherein the second polypeptide of the Fc regionAttorney Docket No. JANX-004 / 05WO 339516-2027 with a peptide linker PLE of DKTHTCPPCP (SEQ ID NO: 161) comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 155.

80. The multi -specific polypeptide of any one of claims 71 -78, wherein the first polypeptide of the Fc region with a peptide linker PLE of DKTHTCPPCP (SEQ ID NO: 161) comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 156, and wherein the second polypeptide of the Fc region with a peptide linker PLE of DKTHTCPPCP (SEQ ID NO: 161) comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 157,81. The multi-specific polypeptide of any one of claims 35-80, wherein the C-terminus of the VH region of the first binding domain is connected to the N-terminus of the VH region of the second binding domain.

82. The multi-specific polypeptide of any one of claims 35-80, wherein the C-terminus of the VH region of the first binding domain is connected to the N-terminus of the VL region of the second binding domain.

83. The multi- specific polypeptide of any one of claims 35-80, wherein the C-terminus of the VL region of the first binding domain is connected to the N-terminus of the VH region of the second binding domain.

84. The multi-specific polypeptide of any one of claims 35-80, wherein the C-terminus of the VL region of the first binding domain is connected to the N-terminus of the VL region of the second binding domain.

85. The multi-specific polypeptide of any one of claims 35-80, wherein the C-terminus of the CH1 region of the first binding domain is connected to the N-terminus of the VH region of the second binding domain.

86. The ulti -specific polypeptide of any one of claims 35-80, wherein the C-terminus of the CHI region of the first binding domain is connected to the N-terminus of the VL region of the second binding domain.Attorney Docket No. JANX-004 / 05WO 339516-2027 87. The multi-specific polypeptide of any one of claims 35-80, wherein the C-terminus of the CL region of the first binding domain is connected to the N-terminus of the VH region of the second binding domain.

88. The multi-specific polypeptide of any one of claims 35-80, wherein the C-terminus of the CL region of the first binding domain is connected to the N-terminus of the VL region of the second binding domain.

89. The multi-specific polypeptide of any one of claims 82, 84, 86, and 88, wherein the C-terminus of the VH region of the second binding domain is connected to the N-terminus of either the first polypeptide or the second polypeptide of the Fc region.

90. The multi-specific polypeptide of any one of claims 81, 83, 85, and 87, wherein the C-terminus of the VL region of the second binding domain is connected to the N-terminus of either the first polypeptide or the second polypeptide of the Fc region.

91. The multi-specific polypeptide of any one of claims 81-88, wherein the C-terminus of the CHI region of the second binding domain is connected to the N-terminus of either the first polypeptide or the second polypeptide of the Fc region.

92. The multi-specific polypeptide of any one of claims 81-88, wherein the C-terminus of the CL region of the second binding domain is connected to the N-terminus of either the first polypeptide or the second polypeptide of the Fc region.

93. The multi-specific polypeptide of any one of claims 35-80, wherein the C-terminus of the VH region of the second binding domain is connected to the N-terminus of the VH region of the first binding domain,94. The multi -specific polypeptide of any one of claims 35-80, wherein the C-terminus of the VH region of the second binding domain is connected to the N-termmus of the VL region of the first binding domain.

95. The multi-specific polypeptide of any one of claims 35-80, wherein the C-terminus of the VL region of the second binding domain is connected to the N-terminus of the VH region of the first binding domain.Attorney Docket No. JANX-004 / 05WO 339516-2027 96. The multi- specific polypeptide of any one of claims 35-80, wherein the C-tenninus of the VL region of the second binding domain is connected to the N-terminus of the VL region of the first binding domain.

97. The multi-specific polypeptide of any one of claims 35-80, wherein the C-terminus of the CHI region of the second binding domain is connected to the N-terminus of the VH region of the first binding domain.

98. The multi-specific polypeptide of any one of claims 35-80, wherein the C-terminus of the CHI region of the second binding domain is connected to the N-terminus of the VL region of the first binding domain.

99. The multi-specific polypeptide of any one of claims 35-80, wherein the C-terminus of the CL region of the second binding domain is connected to the N-terminus of the VH region of the first binding domain.

100. The multi-specific polypeptide of any one of claims 35-80, wherein the C-terminus of the CL region of the second binding domain is connected to the N-terminus of the VL region of the first binding domain,101. The multi -specific polypeptide of any one of claims 94, 96, 98, and 100, wherein the C-terminus of the VH region of the first binding domain is connected to the N-terminus of either the first polypeptide or the second polypeptide of the Fc region.

102. The multi-specific polypeptide of any one of claims 93, 95, 97, and 99, wherein the C-terminus of the VL region of the first binding domain is connected to the N-terminus of either the first polypeptide or the second polypeptide of the Fc region.

103. The multi- specific polypeptide of any one of claims 93-100, wherein the C-terminus of the CHI region of the first binding domain is connected to the N-terminus of either the first polypeptide or the second polypeptide of the Fc region.

104. The multi-specific polypeptide of any one of claims 93-100, wherein the C-terminus of the CL region of the first binding domain is connected to the N-terminus of either the first polypeptide or the second polypeptide of the Fc region.Attorney Docket No. JANX-004 / 05WO 339516-2027 105. The multi-specific polypeptide of any one of claims 81-104, wherein the second binding domain is connected to the second polypeptide of the Fc region comprising the knob mutation.

106. The multi-specific polypeptide of any one of claims 81-104, wherein the second binding domain is connected to the first polypeptide of the Fc region comprising the hole mutation.

107. The multi- specific polypeptide of any one of claims 81-104, wherein the first binding domain is connected to the second polypeptide of the Fc region comprising the knob mutation.

108. The multi-specific polypeptide of any one of claims 81-104, wherein the first binding domain is connected to the first polypeptide of the Fc region comprising the hole mutation,109. The multi-specific polypeptide of any one of claims 105-108, wherein the other polypeptide of the Fc region is not connected to any binding domain.

110. The multi-specific polypeptide of any one of claims 3-80, wherein the first binding domain is an scFv, wherein the second binding domain is a Fab, wherein the C-terminus of the first binding domain is connected to the N-terminus of the VH region of the second binding domain via a peptide linker (PLB), and wherein the C-terminus of the CH1 region of the second binding domain is connected to the N-terminus of the second polypeptide of the Fc region comprising a knob mutation via a peptide linker (PLE).

111. The multi-specific polypeptide of any one of claims 3-80, wherein the first binding domain is an scFv, wherein the second binding domain is a Fab, wherein the C-terminus of the first binding domain is connected to the N-terminus of the VL region of the second binding domain via a peptide linker (PLB), and wherein the C-terminus of the CH1 region of the second binding domain is connected to the N-terminus of the second polypeptide of the Fc region comprising a knob mutation via a peptide linker (PLE).

112. The multi-specific polypeptide of any one of claims 3-80, wherein the first binding domain is an scFv, wherein the second binding domain is a Fab, wherein the N-terminus of the first binding domain is connected to the C-terminus of the CH1 region of the second binding domain via a peptide linker (PLB), and wherein the C-terminus of the first binding domain is connected to the N-terminus of the second polypeptide of the Fc region comprising a knob mutation via a peptide linker (PLE).Attorney Docket No. JANX-004 / 05WO 339516-2027 113. The multi-specific polypeptide of any one of claims 3-80, wherein the first binding domain is a Fab, wherein the second binding domain is an scFv, wherein the C-terminus of the CH1 region of the first binding domain is connected to the N-terminus of the second binding domain via a peptide linker (PLB), and wherein the C-terminus of the second binding domain is connected to the N-terminus of the second polypeptide of the Fc region comprising a knob mutation via a peptide linker (PLE).

114. The multi-specific polypeptide of any one of claims 3-80, wherein the first binding domain is a Fab, wherein the second binding domain is an scFv, wherein the N-terminus of the VH region of the first binding domain is connected to the C-terminus of the second binding domain via a peptide linker (PLB), and wherein the C-terminus of the CH1 region of the first binding domain is connected to the N-terminus of the second polypeptide of the Fc region comprising a knob mutation via a peptide linker (PLE).

115. The multi-specific polypeptide of any one of claims 3-80, wherein the first binding domain is a Fab, wherein the second binding domain is an scFv, wherein the N-terminus of the VL region of the first binding domain is connected to the C-termmus of the second binding domain via a peptide linker (PLB), and wherein the C-termmus of the CHI region of the first binding domain is connected to the N-terminus of the second polypeptide of the Fc region comprising a knob mutation via a peptide linker (PLE).

116. The multi-specific polypeptide of any one of claims 3-80, wherein the first binding domain is a CrossFab, wherein the second binding domain is a charge steering Fab, wherein the N-terminus of the VL region of the first binding domain is connected to the C-terminus of the CH1 region of the second binding domain via a peptide linker (PLB), and wherein the C-terminus of the CHI region of the first binding domain is connected to the N-terminus of the second polypeptide of the Fc region comprising a knob mutation via a peptide linker (PLE).

117. The multi-specific polypeptide of any one of claims 3-80, wherein the first binding domain is a CrossFab, wherein the second binding domain is a charge steering Fab, wherein the C-terminus of the CH1 region of the first binding domain is connected to the N-terminus of the VL region of the second binding domain via a peptide linker (PLB), and wherein the C-terminus of the CH1 region of the second binding domain is connected to the N-terminus of the second polypeptide of the Fc region comprising a knob mutation via a peptide linker (PLE).Attorney Docket No. JANX-004 / 05WO 339516-2027 118. The multi-specific polypeptide of any one of claims 1-109, wherein the first binding domain and the second binding domain are connected via a peptide linker (PLB).

119. The multi-specific polypeptide of any one of claims 110-118, wherein the peptide linker (PLB) is at least 5 amino acids in length,120. The multi-specific polypeptide of claim 119, wherein the peptide linker (PLB) comprises the formula of (Gly4Ser)n, wherein n = 1-5.

121. The multi-specific polypeptide of claim 120, wherein the peptide linker (PLB) is (Gly4Ser)3.

122. The multi-specific polypeptide of claim 120, wherein the peptide linker (PLB) is (Gly4Ser)2.

123. The multi-specific polypeptide of claim 120, wherein the peptide linker (PLB) is (Gly4Ser)i.

124. The multi-specific polypeptide of any one of claims 70-80, wherein the first binding domain is linked to either the first polypeptide or the second polypeptide of the Fc region, and wherein the second binding domain is linked to the other polypeptide of the Fc region.

125. The multi- specific polypeptide of claim 124, wherein the first binding domain is linked to the second polypeptide of the Fc region comprising a knob mutation, and wherein the second binding domain is linked to the first polypeptide of the Fc region comprising a hole mutation.

126. The multi-specific polypeptide of claim 124 or 125, wherein the first binding domain is a Fab or CrossFab, and wherein the second binding domain is an scFv.

127. The multi-specific polypeptide of claim 124 or 125, wherein the first binding domain is a CrossFab connecting to the Fc region via the C -terminus of its CHI region, and wherein the second binding domain is a Fab connecting to the Fc region via the C-terminus of its CHI region.

128. The multi-specific polypeptide of claim 124 or 125, wherein the first binding domain is a CrossFab connecting to the Fc region via the C-terminus of its CHI region, and wherein the second binding domain is a charge steering Fab connecting to the Fc region via the C-terminus of its CHI region.Attorney Docket No. JANX-004 / 05WO 339516-2027 129. The multi-specific polypeptide of claim 124 or 125, wherein the first binding domain is a CrossFab connecting to the Fc region via the C-terminus of its CL region, and wherein the second binding domain is a Fab connecting to the Fc region via the C-terminus of its CH 1 region.

130. The multi-specific polypeptide of any one of claims 124-129, wherein the C-terminus of the scFv or the CHI region of the binding domain is linked to the N-terminus of the first or the second polypeptide of the Fc region.

131. The multi -specific polypeptide of any one of claims 124-129, wherein the CL region of the binding domain is l inked to the N-terminus of the first or the second polypeptide of the Fc region.

132. The multi -specific polypeptide of any one of claims 3-131, wherein the binding domain and the half-life extension moiety are connected via a peptide linker (PLE).

133. The multi-specific polypeptide of claim 132, wherein the peptide linker (PLE) is at least 5 amino acids in length.

134. The multi-specific polypeptide of claim 133, wherein the peptide linker (PLE) is between 5-10 amino acids, between 11-15 amino acids, between 16-20 amino acids, between 21-25 amino acids, or between 26-30 amino acids, in length.

135. The multi-specific polypeptide of any one of claims 132-134, wherein the peptide linker (PLE) comprises an amino acid sequence having the formula of (GlyrSer);,, wherein n = 1-5.

136. The multi-specific polypeptide of claim 135, wherein the peptide linker (PLE) comprises (Gly4Ser)3.

137. The multi-specific polypeptide of any one of claims 132-134, wherein the peptide linker (PLE) comprises or consists of the amino acid sequence KTHTCP (SEQ ID NO: 158).

138. The multi-specific polypeptide of any one of claims 132-134, wherein the peptide linker (PLE) comprises or consists of the ammo acid sequence DKTHTCP (SEQ ID NO: 160).

139. The multi-specific polypeptide of any one of claims 132-134, wherein the peptide linker (PLE) comprises or consists of the amino acid sequence GGGGSGGGGSKTHTCP (SEQ ID NO: 159).Attorney Docket No. JANX-004 / 05WO 339516-2027 140. The multi-specific polypeptide of any one of claims I -139, wherein the multi-specific polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to any one of SEQ I D NOs: 407-991 and 1159-1179.

141. The multi-specific polypeptide of any one of claims 1-139, wherein the multi-specific polypeptide comprises three non-identical polypeptides.

142. The multi-specific polypeptide of claim 141, wherein the first polypeptide comprises: (i) a I’Ll, linker; and (ii) an Fc heavy chain comprising a hole mutation; the second polypeptide comprises: (i) an anti-TCRP scFv; (ii) a PLB linker; (lii) an anti-CD19 Fab light chain; and the third polypeptide comprises: (i) an anti-CDl 9 Fab heavy chain; (ii) a PLE linker; and (lii) an Fc heavy chain comprising a knob mutation.

143. The multi-specific polypeptide of claim 141, wherein the first polypeptide comprises: (i) a PLE linker; and (ii) an Fc heavy chain comprising a hole mutation; the second polypeptide comprises: (i) an anti-CD19 Fab light chain; and the third polypeptide comprises: (i) an anti-TCRp scFv; (ii) a PLB linker; (iii) an anti-CDl 9 Fab heavy chain; (iv) a PLE linker; and (iii) an Fc heavy chain comprising a knob mutation.

144. The multi-specific polypeptide of claim 141, wherein the first polypeptide comprises: (i) a PLE linker; and (ii) an Fc heavy chain comprising a hole mutation; the second polypeptide comprises: (i) an anti-CD19 Fab heavy chain; (ii) a PLE linker; and (iii) an Fc heavy chain comprising a knob mutation; and the third polypeptide comprises: (i) an anti-TCRp scFv; (ii) a PLB linker; (iii) an anti¬ CDF Fab light chain.

145. The multi-specific polypeptide of claim 141, wherein the first polypeptide comprises: (i) a PLE linker; and (ii) an Fc heavy chain comprising a hole mutation; the second polypeptide comprises: (i) an anti-TCRp scFv; (ii) a PLB linker; (hi) an anti-CD19 Fab heavy chain; (iv) a PLE linker; and (v) an Fc heavy chain comprising a knob mutation; and the third polypeptide comprises an anti-CDl 9 Fab light chain.

146. The multi- specific polypeptide of claim 141, wherein the first polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1159; the second polypeptide comprises an amino acidAttorney Docket No. JANX-004 / 05WO 339516-2027 sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1166; and the third polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1173.

147. The multi- specific polypeptide of claim 141, wherein the first polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1160; the second polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1167; and the third polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1174.

148. The multi-specific polypeptide of claim 141, wherein the first polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1161; the second polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1168; and the third polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1175.

149. The multi-specific polypeptide of claim 141, wherein the first polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1162; the second polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1169; and the third polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1176.

150. The multi- specific polypeptide of claim 141, wherein the first polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1163; the second polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1170; and the third polypeptide comprises an amino acidAttorney Docket No. JANX-004 / 05WO 339516-2027 sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1177.

151. The multi-specific polypeptide of claim 141, wherein the first polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1164; the second polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1171; and the third polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1178.

152. The multi-specific polypeptide of claim 141, wherein the first polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1165; the second polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1172; and the third polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 1179.

153. The multi -specific polypeptide of any one of claims 5-152, wherein the VH and VL regions are numbered with reference to the Rabat numbering scheme.

154. A recombinant nucleic acid molecule encoding the multi-specific polypeptide of any one of claims I -153.

155. A vector comprising the recombinant nucleic acid molecule of claim 154.

156. A pharmaceutical composition comprising (i) the multi-specific polypeptide of any one of claims 1-153, the recombinant nucleic acid molecule of claim 154, or the vector of claim 155, and (ii) a pharmaceutically acceptable carrier, diluent, or excipient.

157. A method of producing a multi-specific polypeptide, comprising introducing the recombinant nucleic acid molecule of claim 154, or the vector of claim 155 into a host cell under conditions to express the multi -specific polypeptide complex in the cell, wherein the method is ex vivo.Attorney Docket No. JANX-004 / 05WO 339516-2027 158. A method of expanding a T cell population, wherein the method comprises contacting an initial T cell population with the multi-specific polypeptide of any one of claims 1-153 or the pharmaceutical composition of claim 156, thereby producing an expanded population of T cells; wherein the initial T cell population expresses TCRPV or TCRaV on the cell surface, and wherein the first binding domain of the multi -specific polypeptide specifically binds the TCRpV or TCRaV.

159. The method of claim 158, wherein the method expands T cells in vitro or ex vivo.

160. The method of claim 158, wherein the method expands T cells in vivo in a subject.

161. The method of any one of claims 158-160, wherein the initial population of T cells comprises a plurality of effector T cells and / or memory T cells.

162. The method of any one of claims 158-161, wherein the expanded population of T cells has an increased expansion of the effector T cells and / or memory T cells compared to a control T cell population that was contacted with a control multi -specific polypeptide comprising a first binding domain that specifically binds to CD3 instead of TCRpV or TCRaV.

163. The method of claim 162, wherein the effector T cells are selected from the group consisting of effector memory T cells (TEM), T effector cells (TEFF), T effector cells re-expressing CD45RA (TEMRA), and a combination thereof,164. The method of claim 162, wherein the memory T cells are selected from the group consisting of central memory T cells (Tcm), T memory stem cells (Tscm), and a combination thereof.

165. The method of any one of claims 158-164, wherein the expanded population of T ceils has an increased percentage of effector T cells and / or memory T cells compared to that of a control T cell population contacted with a control multi-specific polypeptide comprising a first binding domain that specifically binds to CD3 instead of TCRPV or TCRaV.

166. The method of claim 165, wherein the effector T cells are effector memory T cells (TEM).

167. The method of claim 165, wherein the memory T cells are central memory T cells (Tcm).

168. The method of any one of claims 158-167, wherein the expanded population of T cells has an increased and / or prolonged cytotoxicity compared to that of a control T cell population contacted withAttorney Docket No. JANX-004 / 05WO 339516-2027 a control multi-specific polypeptide comprising a first binding domain that specifically binds to CD3 instead of TCRPV or TCRaV.

169. The method of any one of claims 158-168, wherein the comparison between the expanded population of T cells expanded by the multi -specific polypeptide and control T cell population contacted with the control multi-specific polypeptide is performed 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 days after an initial contact of the T cells.

170. The method of any one of claims 158-169, wherein the method depletes B cells,171. A method of depleting B cells in a subject having a disease or disorder related to the B cells, comprising administering to the subject an effective amount of the multi -specific polypeptide of any one of claims 1-153 or the pharmaceutical composition of claim 156.

172. The method of claim 171, wherein the method decreases the number of B cells by at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, at least 99.5%, at least 99.8%, at least 99.9%, or 100%, in the subject.

173. The method of claim 171 or 172, wherein the B cells are autoreactive B cells.

174. The method of claim 173, wherein the B cells are autoreactive B memory cells.

175. The method of any one of claims 171-174, wherein the method reduces the production of autoantibodies.

176. A method of repopulating naive B cells in a subject, comprising administering to the subject an effective amount of the multi-specific polypeptide of any one of claims 1 - 153 or the pharmaceutical composition of claim 156.

177. The method of claim 176, wherein the subject has a disease or disorder related to B cells.

178. The method of claim 176 or 177, wherein the method increases the number of naive B cells by at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100%, in the subject.Attorney Docket No. JANX-004 / 05WO 339516-2027 179. A method of treating a disease or disorder in a subject in need thereof comprising administering to the subject an effective amount of the multi-specific polypeptide of any one of claims 1-153 or the pharmaceutical composition of claim 156.

180. The method of claim 179, wherein the disease or disorder is a cancer.

181. The method of claim 180, wherein the cancer is a blood cancer.

182. The method of claim 181, wherein the blood cancer is chronic lymphocytic leukemia or non¬ Hodgkin lymphoma.

183. The method of claim 179, wherein the disease or disorder is an autoimmune disease.

184. The method of claim 183, wherein the autoimmune disease is rheumatoid arthritis or Systemic lupus erythematosus.

185. The method of any one of claims 179-184, wherein the subject has previously been treated with a multi-specific polypeptide comprising a first binding domain specifically binds to CD3 instead ofTCRpV or TCRaV.

186. The method of any one of claims 179-185, wherein the subject is relapsing or refractory to a treatment comprising a multi-specific polypeptide comprising a first binding domain specifically binds to CD3 instead of TCR0V or TCRaV.

187. The method of any one of claims 179-186, wherein the subject is administered between about 0.07 mg / kg and 0.17 mg / kg of the multi-specific polypeptide.

188. The method of any one of claims 179-187, wherein the administration is intravenous, intraperitoneal, or subcutaneous.

Images